id	sid	tid	token	lemma	pos
dpc-5683	1	1	dermatology	dermatology	NOUN
dpc-5683	1	2	:	:	PUNCT
dpc-5683	1	3	practical	practical	ADJ
dpc-5683	1	4	and	and	CCONJ
dpc-5683	1	5	conceptual	conceptual	ADJ
dpc-5683	1	6	original	original	ADJ
dpc-5683	1	7	article	article	NOUN
dpc-5683	1	8	|	|	ADV
dpc-5683	1	9	dermatol	dermatol	ADJ
dpc-5683	1	10	pract	pract	NOUN
dpc-5683	1	11	concept	concept	NOUN
dpc-5683	1	12	.	.	PUNCT
dpc-5683	2	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	2	2	1	1	NUM
dpc-5683	2	3	retrospective	retrospective	ADJ
dpc-5683	2	4	analysis	analysis	NOUN
dpc-5683	2	5	of	of	ADP
dpc-5683	2	6	second	second	ADJ
dpc-5683	2	7	primary	primary	ADJ
dpc-5683	2	8	malignancies	malignancy	NOUN
dpc-5683	2	9	in	in	ADP
dpc-5683	2	10	patients	patient	NOUN
dpc-5683	2	11	with	with	ADP
dpc-5683	2	12	mycosis	mycosis	NOUN
dpc-5683	2	13	fungoides	fungoide	NOUN
dpc-5683	2	14	and	and	CCONJ
dpc-5683	2	15	sézary	sézary	ADJ
dpc-5683	2	16	syndrome	syndrome	NOUN
dpc-5683	2	17	in	in	ADP
dpc-5683	2	18	croatia	croatia	PROPN
dpc-5683	2	19	mikela	mikela	PROPN
dpc-5683	2	20	petkovic1	petkovic1	PROPN
dpc-5683	2	21	,	,	PUNCT
dpc-5683	2	22	ivana	ivana	PROPN
dpc-5683	2	23	ilic2,3	ilic2,3	PROPN
dpc-5683	2	24	,	,	PUNCT
dpc-5683	2	25	romana	romana	PROPN
dpc-5683	2	26	ceovic1,3	ceovic1,3	PROPN
dpc-5683	2	27	1	1	NUM
dpc-5683	2	28	department	department	NOUN
dpc-5683	2	29	of	of	ADP
dpc-5683	2	30	dermatology	dermatology	NOUN
dpc-5683	2	31	and	and	CCONJ
dpc-5683	2	32	venereology	venereology	NOUN
dpc-5683	2	33	,	,	PUNCT
dpc-5683	2	34	university	university	NOUN
dpc-5683	2	35	hospital	hospital	NOUN
dpc-5683	2	36	centre	centre	PROPN
dpc-5683	2	37	zagreb	zagreb	PROPN
dpc-5683	2	38	,	,	PUNCT
dpc-5683	2	39	zagreb	zagreb	PROPN
dpc-5683	2	40	,	,	PUNCT
dpc-5683	2	41	croatia	croatia	PROPN
dpc-5683	2	42	2	2	NUM
dpc-5683	2	43	department	department	NOUN
dpc-5683	2	44	of	of	ADP
dpc-5683	2	45	pathology	pathology	PROPN
dpc-5683	2	46	and	and	CCONJ
dpc-5683	2	47	cytology	cytology	NOUN
dpc-5683	2	48	,	,	PUNCT
dpc-5683	2	49	university	university	NOUN
dpc-5683	2	50	hospital	hospital	PROPN
dpc-5683	2	51	centre	centre	PROPN
dpc-5683	2	52	zagreb	zagreb	PROPN
dpc-5683	2	53	,	,	PUNCT
dpc-5683	2	54	zagreb	zagreb	PROPN
dpc-5683	2	55	,	,	PUNCT
dpc-5683	2	56	croatia	croatia	PROPN
dpc-5683	2	57	3	3	NUM
dpc-5683	2	58	university	university	PROPN
dpc-5683	2	59	of	of	ADP
dpc-5683	2	60	zagreb	zagreb	PROPN
dpc-5683	2	61	school	school	PROPN
dpc-5683	2	62	of	of	ADP
dpc-5683	2	63	medicine	medicine	NOUN
dpc-5683	2	64	,	,	PUNCT
dpc-5683	2	65	zagreb	zagreb	PROPN
dpc-5683	2	66	,	,	PUNCT
dpc-5683	2	67	croatia	croatia	PROPN
dpc-5683	2	68	key	key	ADJ
dpc-5683	2	69	words	word	NOUN
dpc-5683	2	70	:	:	PUNCT
dpc-5683	2	71	mycosis	mycosis	NOUN
dpc-5683	2	72	fungoides	fungoide	NOUN
dpc-5683	2	73	,	,	PUNCT
dpc-5683	2	74	sézary	sézary	ADJ
dpc-5683	2	75	syndrome	syndrome	NOUN
dpc-5683	2	76	,	,	PUNCT
dpc-5683	2	77	primary	primary	ADJ
dpc-5683	2	78	cutaneous	cutaneous	ADJ
dpc-5683	2	79	t	t	PROPN
dpc-5683	2	80	-	-	PUNCT
dpc-5683	2	81	cell	cell	NOUN
dpc-5683	2	82	lymphoma	lymphoma	NOUN
dpc-5683	2	83	,	,	PUNCT
dpc-5683	2	84	primary	primary	ADJ
dpc-5683	2	85	malignancy	malignancy	NOUN
dpc-5683	2	86	,	,	PUNCT
dpc-5683	2	87	breast	breast	NOUN
dpc-5683	2	88	cancer	cancer	NOUN
dpc-5683	2	89	citation	citation	NOUN
dpc-5683	2	90	:	:	PUNCT
dpc-5683	2	91	petkovic	petkovic	PROPN
dpc-5683	2	92	m	m	PROPN
dpc-5683	2	93	,	,	PUNCT
dpc-5683	2	94	ilic	ilic	PROPN
dpc-5683	2	95	i	i	PROPN
dpc-5683	2	96	,	,	PUNCT
dpc-5683	2	97	ceovic	ceovic	PROPN
dpc-5683	2	98	r.	r.	PROPN
dpc-5683	2	99	retrospective	retrospective	ADJ
dpc-5683	2	100	analysis	analysis	NOUN
dpc-5683	2	101	of	of	ADP
dpc-5683	2	102	second	second	ADJ
dpc-5683	2	103	primary	primary	ADJ
dpc-5683	2	104	malignancies	malignancy	NOUN
dpc-5683	2	105	in	in	ADP
dpc-5683	2	106	patients	patient	NOUN
dpc-5683	2	107	with	with	ADP
dpc-5683	2	108	mycosis	mycosis	NOUN
dpc-5683	2	109	fungoides	fungoide	NOUN
dpc-5683	2	110	and	and	CCONJ
dpc-5683	2	111	sézary	sézary	ADJ
dpc-5683	2	112	syndrome	syndrome	NOUN
dpc-5683	2	113	in	in	ADP
dpc-5683	2	114	croatia	croatia	PROPN
dpc-5683	2	115	.	.	PUNCT
dpc-5683	3	1	dermatol	dermatol	NOUN
dpc-5683	3	2	pract	pract	PROPN
dpc-5683	3	3	concept	concept	NOUN
dpc-5683	3	4	.	.	PUNCT
dpc-5683	4	1	2025;15(4):5683	2025;15(4):5683	X
dpc-5683	4	2	.	.	PUNCT
dpc-5683	5	1	doi	doi	NOUN
dpc-5683	5	2	:	:	PUNCT
dpc-5683	5	3	https://doi.org/10.5826/dpc.1504a5683	https://doi.org/10.5826/dpc.1504a5683	PRON
dpc-5683	5	4	accepted	accept	VERB
dpc-5683	5	5	:	:	PUNCT
dpc-5683	5	6	august	august	PROPN
dpc-5683	5	7	24	24	NUM
dpc-5683	5	8	,	,	PUNCT
dpc-5683	5	9	2025	2025	NUM
dpc-5683	5	10	;	;	PUNCT
dpc-5683	5	11	published	publish	VERB
dpc-5683	5	12	:	:	PUNCT
dpc-5683	6	1	october	october	PROPN
dpc-5683	6	2	2025	2025	NUM
dpc-5683	6	3	copyright	copyright	NOUN
dpc-5683	6	4	:	:	PUNCT
dpc-5683	6	5	©	©	PROPN
dpc-5683	6	6	2025	2025	NUM
dpc-5683	6	7	marzola	marzola	NOUN
dpc-5683	6	8	et	et	PROPN
dpc-5683	6	9	al	al	PROPN
dpc-5683	6	10	.	.	PUNCT
dpc-5683	7	1	this	this	PRON
dpc-5683	7	2	is	be	AUX
dpc-5683	7	3	an	an	DET
dpc-5683	7	4	open	open	ADJ
dpc-5683	7	5	-	-	PUNCT
dpc-5683	7	6	access	access	NOUN
dpc-5683	7	7	article	article	NOUN
dpc-5683	7	8	distributed	distribute	VERB
dpc-5683	7	9	under	under	ADP
dpc-5683	7	10	the	the	DET
dpc-5683	7	11	terms	term	NOUN
dpc-5683	7	12	of	of	ADP
dpc-5683	7	13	the	the	DET
dpc-5683	7	14	creative	creative	ADJ
dpc-5683	7	15	commons	common	NOUN
dpc-5683	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5683	7	17	license	license	NOUN
dpc-5683	7	18	(	(	PUNCT
dpc-5683	7	19	by	by	ADP
dpc-5683	7	20	-	-	PUNCT
dpc-5683	7	21	nc-4.0	nc-4.0	NOUN
dpc-5683	7	22	)	)	PUNCT
dpc-5683	7	23	,	,	PUNCT
dpc-5683	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5683	7	25	,	,	PUNCT
dpc-5683	7	26	which	which	PRON
dpc-5683	7	27	permits	permit	VERB
dpc-5683	7	28	unrestricted	unrestricted	ADJ
dpc-5683	7	29	noncommercial	noncommercial	ADJ
dpc-5683	7	30	use	use	NOUN
dpc-5683	7	31	,	,	PUNCT
dpc-5683	7	32	distribution	distribution	NOUN
dpc-5683	7	33	,	,	PUNCT
dpc-5683	7	34	and	and	CCONJ
dpc-5683	7	35	reproduction	reproduction	NOUN
dpc-5683	7	36	in	in	ADP
dpc-5683	7	37	any	any	DET
dpc-5683	7	38	medium	medium	NOUN
dpc-5683	7	39	,	,	PUNCT
dpc-5683	7	40	provided	provide	VERB
dpc-5683	7	41	the	the	DET
dpc-5683	7	42	original	original	ADJ
dpc-5683	7	43	authors	author	NOUN
dpc-5683	7	44	and	and	CCONJ
dpc-5683	7	45	source	source	NOUN
dpc-5683	7	46	are	be	AUX
dpc-5683	7	47	credited	credit	VERB
dpc-5683	7	48	.	.	PUNCT
dpc-5683	8	1	funding	funding	NOUN
dpc-5683	8	2	:	:	PUNCT
dpc-5683	8	3	none	none	NOUN
dpc-5683	8	4	.	.	PUNCT
dpc-5683	9	1	competing	compete	VERB
dpc-5683	9	2	interests	interest	NOUN
dpc-5683	9	3	:	:	PUNCT
dpc-5683	9	4	none	none	NOUN
dpc-5683	9	5	.	.	PUNCT
dpc-5683	10	1	authorship	authorship	NOUN
dpc-5683	10	2	:	:	PUNCT
dpc-5683	10	3	all	all	DET
dpc-5683	10	4	authors	author	NOUN
dpc-5683	10	5	have	have	AUX
dpc-5683	10	6	contributed	contribute	VERB
dpc-5683	10	7	significantly	significantly	ADV
dpc-5683	10	8	to	to	ADP
dpc-5683	10	9	this	this	DET
dpc-5683	10	10	publication	publication	NOUN
dpc-5683	10	11	.	.	PUNCT
dpc-5683	11	1	corresponding	correspond	VERB
dpc-5683	11	2	author	author	NOUN
dpc-5683	11	3	:	:	PUNCT
dpc-5683	11	4	mikela	mikela	PROPN
dpc-5683	11	5	petkovic	petkovic	PROPN
dpc-5683	11	6	,	,	PUNCT
dpc-5683	11	7	md	md	PROPN
dpc-5683	11	8	,	,	PUNCT
dpc-5683	11	9	department	department	NOUN
dpc-5683	11	10	of	of	ADP
dpc-5683	11	11	dermatology	dermatology	NOUN
dpc-5683	11	12	and	and	CCONJ
dpc-5683	11	13	venereology	venereology	NOUN
dpc-5683	11	14	,	,	PUNCT
dpc-5683	11	15	university	university	NOUN
dpc-5683	11	16	hospital	hospital	NOUN
dpc-5683	11	17	centre	centre	PROPN
dpc-5683	11	18	zagreb	zagreb	PROPN
dpc-5683	11	19	,	,	PUNCT
dpc-5683	11	20	ulica	ulica	PROPN
dpc-5683	11	21	mije	mije	PROPN
dpc-5683	11	22	kispatica	kispatica	PROPN
dpc-5683	11	23	12	12	NUM
dpc-5683	11	24	,	,	PUNCT
dpc-5683	11	25	10000	10000	NUM
dpc-5683	11	26	zagreb	zagreb	PROPN
dpc-5683	11	27	,	,	PUNCT
dpc-5683	11	28	croatia	croatia	PROPN
dpc-5683	11	29	.	.	PUNCT
dpc-5683	12	1	orcid	orcid	NOUN
dpc-5683	12	2	:	:	PUNCT
dpc-5683	12	3	0000	0000	NUM
dpc-5683	12	4	-	-	PUNCT
dpc-5683	12	5	0001	0001	NUM
dpc-5683	12	6	-	-	PUNCT
dpc-5683	12	7	7499	7499	NUM
dpc-5683	12	8	-	-	SYM
dpc-5683	12	9	1650	1650	NUM
dpc-5683	12	10	.	.	PUNCT
dpc-5683	13	1	e	e	X
dpc-5683	13	2	-	-	NOUN
dpc-5683	13	3	mail	mail	NOUN
dpc-5683	13	4	:	:	PUNCT
dpc-5683	14	1	dr.mikela@gmail.com	dr.mikela@gmail.com	PROPN
dpc-5683	14	2	introduction	introduction	NOUN
dpc-5683	14	3	:	:	PUNCT
dpc-5683	14	4	patients	patient	NOUN
dpc-5683	14	5	with	with	ADP
dpc-5683	14	6	mycosis	mycosis	NOUN
dpc-5683	14	7	fungoides	fungoide	NOUN
dpc-5683	14	8	(	(	PUNCT
dpc-5683	14	9	mf	mf	X
dpc-5683	14	10	)	)	PUNCT
dpc-5683	14	11	have	have	VERB
dpc-5683	14	12	a	a	DET
dpc-5683	14	13	higher	high	ADJ
dpc-5683	14	14	risk	risk	NOUN
dpc-5683	14	15	of	of	ADP
dpc-5683	14	16	developing	develop	VERB
dpc-5683	14	17	second	second	ADJ
dpc-5683	14	18	primary	primary	ADJ
dpc-5683	14	19	malignancy	malignancy	NOUN
dpc-5683	14	20	.	.	PUNCT
dpc-5683	15	1	the	the	DET
dpc-5683	15	2	type	type	NOUN
dpc-5683	15	3	of	of	ADP
dpc-5683	15	4	second	second	ADJ
dpc-5683	15	5	malignancy	malignancy	NOUN
dpc-5683	15	6	varies	vary	VERB
dpc-5683	15	7	across	across	ADP
dpc-5683	15	8	the	the	DET
dpc-5683	15	9	studies	study	NOUN
dpc-5683	15	10	,	,	PUNCT
dpc-5683	15	11	and	and	CCONJ
dpc-5683	15	12	no	no	DET
dpc-5683	15	13	established	establish	VERB
dpc-5683	15	14	guidelines	guideline	NOUN
dpc-5683	15	15	currently	currently	ADV
dpc-5683	15	16	exist	exist	VERB
dpc-5683	15	17	for	for	ADP
dpc-5683	15	18	screening	screen	VERB
dpc-5683	15	19	mf	mf	NOUN
dpc-5683	15	20	patients	patient	NOUN
dpc-5683	15	21	.	.	PUNCT
dpc-5683	16	1	objective	objective	ADJ
dpc-5683	16	2	:	:	PUNCT
dpc-5683	16	3	to	to	PART
dpc-5683	16	4	identify	identify	VERB
dpc-5683	16	5	mf	mf	NOUN
dpc-5683	16	6	and	and	CCONJ
dpc-5683	16	7	sézary	sézary	ADJ
dpc-5683	16	8	syndrome	syndrome	NOUN
dpc-5683	16	9	(	(	PUNCT
dpc-5683	16	10	ss	ss	NOUN
dpc-5683	16	11	)	)	PUNCT
dpc-5683	16	12	patients	patient	NOUN
dpc-5683	16	13	at	at	ADP
dpc-5683	16	14	a	a	DET
dpc-5683	16	15	potentially	potentially	ADV
dpc-5683	16	16	higher	high	ADJ
dpc-5683	16	17	risk	risk	NOUN
dpc-5683	16	18	of	of	ADP
dpc-5683	16	19	developing	develop	VERB
dpc-5683	16	20	a	a	DET
dpc-5683	16	21	secondary	secondary	ADJ
dpc-5683	16	22	primary	primary	ADJ
dpc-5683	16	23	malignancy	malignancy	NOUN
dpc-5683	16	24	,	,	PUNCT
dpc-5683	16	25	assess	assess	VERB
dpc-5683	16	26	the	the	DET
dpc-5683	16	27	prevalence	prevalence	NOUN
dpc-5683	16	28	of	of	ADP
dpc-5683	16	29	other	other	ADJ
dpc-5683	16	30	secondary	secondary	ADJ
dpc-5683	16	31	malignancies	malignancy	NOUN
dpc-5683	16	32	,	,	PUNCT
dpc-5683	16	33	and	and	CCONJ
dpc-5683	16	34	evaluate	evaluate	VERB
dpc-5683	16	35	whether	whether	SCONJ
dpc-5683	16	36	mf	mf	NOUN
dpc-5683	16	37	with	with	ADP
dpc-5683	16	38	other	other	ADJ
dpc-5683	16	39	primary	primary	ADJ
dpc-5683	16	40	malignancies	malignancy	NOUN
dpc-5683	16	41	leads	lead	VERB
dpc-5683	16	42	to	to	ADP
dpc-5683	16	43	a	a	DET
dpc-5683	16	44	worse	bad	ADJ
dpc-5683	16	45	prognosis	prognosis	NOUN
dpc-5683	16	46	based	base	VERB
dpc-5683	16	47	on	on	ADP
dpc-5683	16	48	mf	mf	NOUN
dpc-5683	16	49	variants	variant	NOUN
dpc-5683	16	50	.	.	PUNCT
dpc-5683	17	1	methods	method	NOUN
dpc-5683	17	2	:	:	PUNCT
dpc-5683	17	3	this	this	DET
dpc-5683	17	4	observational	observational	ADJ
dpc-5683	17	5	single	single	ADJ
dpc-5683	17	6	-	-	PUNCT
dpc-5683	17	7	center	center	NOUN
dpc-5683	17	8	retrospective	retrospective	ADJ
dpc-5683	17	9	study	study	NOUN
dpc-5683	17	10	followed	follow	VERB
dpc-5683	17	11	84	84	NUM
dpc-5683	17	12	patients	patient	NOUN
dpc-5683	17	13	for	for	ADP
dpc-5683	17	14	a	a	DET
dpc-5683	17	15	minimum	minimum	NOUN
dpc-5683	17	16	of	of	ADP
dpc-5683	17	17	five	five	NUM
dpc-5683	17	18	years	year	NOUN
dpc-5683	17	19	.	.	PUNCT
dpc-5683	18	1	results	result	NOUN
dpc-5683	18	2	:	:	PUNCT
dpc-5683	18	3	we	we	PRON
dpc-5683	18	4	identified	identify	VERB
dpc-5683	18	5	16	16	NUM
dpc-5683	18	6	patients	patient	NOUN
dpc-5683	18	7	(	(	PUNCT
dpc-5683	18	8	19	19	NUM
dpc-5683	18	9	%	%	NOUN
dpc-5683	18	10	)	)	PUNCT
dpc-5683	18	11	with	with	ADP
dpc-5683	18	12	second	second	ADJ
dpc-5683	18	13	malignancy	malignancy	NOUN
dpc-5683	18	14	,	,	PUNCT
dpc-5683	18	15	of	of	ADP
dpc-5683	18	16	whom	whom	PRON
dpc-5683	18	17	eight	eight	NUM
dpc-5683	18	18	(	(	PUNCT
dpc-5683	18	19	50	50	NUM
dpc-5683	18	20	%	%	NOUN
dpc-5683	18	21	)	)	PUNCT
dpc-5683	18	22	had	have	VERB
dpc-5683	18	23	hematological	hematological	ADJ
dpc-5683	18	24	neoplasms	neoplasm	NOUN
dpc-5683	18	25	.	.	PUNCT
dpc-5683	19	1	among	among	ADP
dpc-5683	19	2	other	other	ADJ
dpc-5683	19	3	malignancies	malignancy	NOUN
dpc-5683	19	4	,	,	PUNCT
dpc-5683	19	5	breast	breast	NOUN
dpc-5683	19	6	cancer	cancer	NOUN
dpc-5683	19	7	was	be	AUX
dpc-5683	19	8	the	the	DET
dpc-5683	19	9	most	most	ADV
dpc-5683	19	10	common	common	ADJ
dpc-5683	19	11	(	(	PUNCT
dpc-5683	19	12	n=5	n=5	NUM
dpc-5683	19	13	)	)	PUNCT
dpc-5683	19	14	,	,	PUNCT
dpc-5683	19	15	followed	follow	VERB
dpc-5683	19	16	by	by	ADP
dpc-5683	19	17	other	other	ADJ
dpc-5683	19	18	malignancies	malignancy	NOUN
dpc-5683	19	19	,	,	PUNCT
dpc-5683	19	20	including	include	VERB
dpc-5683	19	21	lung	lung	NOUN
dpc-5683	19	22	cancer	cancer	NOUN
dpc-5683	19	23	,	,	PUNCT
dpc-5683	19	24	prostate	prostate	NOUN
dpc-5683	19	25	cancer	cancer	NOUN
dpc-5683	19	26	,	,	PUNCT
dpc-5683	19	27	kidney	kidney	NOUN
dpc-5683	19	28	cancer	cancer	NOUN
dpc-5683	19	29	,	,	PUNCT
dpc-5683	19	30	and	and	CCONJ
dpc-5683	19	31	so	so	ADV
dpc-5683	19	32	on	on	ADV
dpc-5683	19	33	.	.	PUNCT
dpc-5683	20	1	the	the	DET
dpc-5683	20	2	median	median	ADJ
dpc-5683	20	3	age	age	NOUN
dpc-5683	20	4	at	at	ADP
dpc-5683	20	5	disease	disease	NOUN
dpc-5683	20	6	onset	onset	NOUN
dpc-5683	20	7	was	be	AUX
dpc-5683	20	8	53.0	53.0	NUM
dpc-5683	20	9	years	year	NOUN
dpc-5683	20	10	,	,	PUNCT
dpc-5683	20	11	while	while	SCONJ
dpc-5683	20	12	median	median	ADJ
dpc-5683	20	13	age	age	NOUN
dpc-5683	20	14	at	at	ADP
dpc-5683	20	15	second	second	ADJ
dpc-5683	20	16	malignancy	malignancy	NOUN
dpc-5683	20	17	diagnosis	diagnosis	NOUN
dpc-5683	20	18	was	be	AUX
dpc-5683	20	19	60.5	60.5	NUM
dpc-5683	20	20	years	year	NOUN
dpc-5683	20	21	.	.	PUNCT
dpc-5683	21	1	no	no	DET
dpc-5683	21	2	sex	sex	NOUN
dpc-5683	21	3	predominance	predominance	NOUN
dpc-5683	21	4	was	be	AUX
dpc-5683	21	5	observed	observe	VERB
dpc-5683	21	6	.	.	PUNCT
dpc-5683	22	1	although	although	SCONJ
dpc-5683	22	2	not	not	PART
dpc-5683	22	3	statistically	statistically	ADV
dpc-5683	22	4	significant	significant	ADJ
dpc-5683	22	5	,	,	PUNCT
dpc-5683	22	6	seven	seven	NUM
dpc-5683	22	7	of	of	ADP
dpc-5683	22	8	sixteen	sixteen	NUM
dpc-5683	22	9	patients	patient	NOUN
dpc-5683	22	10	(	(	PUNCT
dpc-5683	22	11	43.75	43.75	NUM
dpc-5683	22	12	%	%	NOUN
dpc-5683	22	13	)	)	PUNCT
dpc-5683	22	14	who	who	PRON
dpc-5683	22	15	developed	develop	VERB
dpc-5683	22	16	second	second	ADJ
dpc-5683	22	17	malignancy	malignancy	NOUN
dpc-5683	22	18	had	have	VERB
dpc-5683	22	19	mf	mf	PRON
dpc-5683	22	20	variant	variant	NOUN
dpc-5683	22	21	(	(	PUNCT
dpc-5683	22	22	such	such	ADJ
dpc-5683	22	23	as	as	ADP
dpc-5683	22	24	folliculotropic	folliculotropic	ADJ
dpc-5683	22	25	mf	mf	NOUN
dpc-5683	22	26	)	)	PUNCT
dpc-5683	22	27	or	or	CCONJ
dpc-5683	22	28	sezary	sezary	ADJ
dpc-5683	22	29	syndrome	syndrome	NOUN
dpc-5683	22	30	.	.	PUNCT
dpc-5683	23	1	disease	disease	NOUN
dpc-5683	23	2	progression	progression	NOUN
dpc-5683	23	3	was	be	AUX
dpc-5683	23	4	more	more	ADV
dpc-5683	23	5	common	common	ADJ
dpc-5683	23	6	in	in	ADP
dpc-5683	23	7	patients	patient	NOUN
dpc-5683	23	8	with	with	ADP
dpc-5683	23	9	mf	mf	NOUN
dpc-5683	23	10	variant	variant	NOUN
dpc-5683	23	11	.	.	PUNCT
dpc-5683	24	1	abstract	abstract	ADJ
dpc-5683	24	2	2	2	NUM
dpc-5683	24	3	original	original	ADJ
dpc-5683	24	4	article	article	NOUN
dpc-5683	24	5	|	|	ADV
dpc-5683	24	6	dermatol	dermatol	ADJ
dpc-5683	24	7	pract	pract	NOUN
dpc-5683	24	8	concept	concept	NOUN
dpc-5683	24	9	.	.	PUNCT
dpc-5683	25	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	25	2	introduction	introduction	NOUN
dpc-5683	25	3	primary	primary	ADJ
dpc-5683	25	4	cutaneous	cutaneous	ADJ
dpc-5683	25	5	t	t	PROPN
dpc-5683	25	6	-	-	PUNCT
dpc-5683	25	7	cell	cell	NOUN
dpc-5683	25	8	lymphomas	lymphoma	NOUN
dpc-5683	25	9	(	(	PUNCT
dpc-5683	25	10	ctcl	ctcl	NOUN
dpc-5683	25	11	)	)	PUNCT
dpc-5683	25	12	belong	belong	VERB
dpc-5683	25	13	to	to	ADP
dpc-5683	25	14	a	a	DET
dpc-5683	25	15	heterogeneous	heterogeneous	ADJ
dpc-5683	25	16	group	group	NOUN
dpc-5683	25	17	of	of	ADP
dpc-5683	25	18	non	non	ADJ
dpc-5683	25	19	-	-	ADJ
dpc-5683	25	20	hodgkin	hodgkin	ADJ
dpc-5683	25	21	lymphomas	lymphoma	NOUN
dpc-5683	25	22	(	(	PUNCT
dpc-5683	25	23	nhl	nhl	PROPN
dpc-5683	25	24	)	)	PUNCT
dpc-5683	25	25	,	,	PUNCT
dpc-5683	25	26	primarily	primarily	ADV
dpc-5683	25	27	affecting	affect	VERB
dpc-5683	25	28	the	the	DET
dpc-5683	25	29	skin	skin	NOUN
dpc-5683	25	30	and	and	CCONJ
dpc-5683	25	31	not	not	PART
dpc-5683	25	32	having	have	VERB
dpc-5683	25	33	extracutaneous	extracutaneous	ADJ
dpc-5683	25	34	manifestations	manifestation	NOUN
dpc-5683	25	35	at	at	ADP
dpc-5683	25	36	the	the	DET
dpc-5683	25	37	time	time	NOUN
dpc-5683	25	38	of	of	ADP
dpc-5683	25	39	diagnosis	diagnosis	NOUN
dpc-5683	25	40	.	.	PUNCT
dpc-5683	26	1	nhl	nhl	PROPN
dpc-5683	26	2	primarily	primarily	ADV
dpc-5683	26	3	appear	appear	VERB
dpc-5683	26	4	in	in	ADP
dpc-5683	26	5	the	the	DET
dpc-5683	26	6	lymph	lymph	NOUN
dpc-5683	26	7	nodes	node	NOUN
dpc-5683	26	8	,	,	PUNCT
dpc-5683	26	9	and	and	CCONJ
dpc-5683	26	10	in	in	ADP
dpc-5683	26	11	the	the	DET
dpc-5683	26	12	case	case	NOUN
dpc-5683	26	13	of	of	ADP
dpc-5683	26	14	extranodal	extranodal	NOUN
dpc-5683	26	15	occurrence	occurrence	NOUN
dpc-5683	26	16	,	,	PUNCT
dpc-5683	26	17	they	they	PRON
dpc-5683	26	18	most	most	ADV
dpc-5683	26	19	often	often	ADV
dpc-5683	26	20	affect	affect	VERB
dpc-5683	26	21	the	the	DET
dpc-5683	26	22	gastrointestinal	gastrointestinal	ADJ
dpc-5683	26	23	system	system	NOUN
dpc-5683	26	24	,	,	PUNCT
dpc-5683	26	25	and	and	CCONJ
dpc-5683	26	26	then	then	ADV
dpc-5683	26	27	the	the	DET
dpc-5683	26	28	skin	skin	NOUN
dpc-5683	26	29	elsewhere	elsewhere	ADV
dpc-5683	26	30	.	.	PUNCT
dpc-5683	27	1	mf	mf	NOUN
dpc-5683	27	2	presents	present	VERB
dpc-5683	27	3	with	with	ADP
dpc-5683	27	4	clinical	clinical	ADJ
dpc-5683	27	5	variants	variant	NOUN
dpc-5683	27	6	such	such	ADJ
dpc-5683	27	7	as	as	ADP
dpc-5683	27	8	folliculotropic	folliculotropic	ADJ
dpc-5683	27	9	(	(	PUNCT
dpc-5683	27	10	fmf	fmf	NOUN
dpc-5683	27	11	)	)	PUNCT
dpc-5683	27	12	,	,	PUNCT
dpc-5683	27	13	pagetoid	pagetoid	NOUN
dpc-5683	27	14	reticulosis	reticulosis	NOUN
dpc-5683	27	15	,	,	PUNCT
dpc-5683	27	16	and	and	CCONJ
dpc-5683	27	17	granulomatous	granulomatous	ADJ
dpc-5683	27	18	slack	slack	NOUN
dpc-5683	27	19	skin	skin	NOUN
dpc-5683	27	20	,	,	PUNCT
dpc-5683	27	21	and	and	CCONJ
dpc-5683	27	22	rare	rare	ADJ
dpc-5683	27	23	variants	variant	NOUN
dpc-5683	27	24	such	such	ADJ
dpc-5683	27	25	as	as	ADP
dpc-5683	27	26	hypopigmented	hypopigmented	ADJ
dpc-5683	27	27	,	,	PUNCT
dpc-5683	27	28	hyperpigmented	hyperpigmented	ADJ
dpc-5683	27	29	,	,	PUNCT
dpc-5683	27	30	ichthyosiform	ichthyosiform	NOUN
dpc-5683	27	31	,	,	PUNCT
dpc-5683	27	32	palmar	palmar	NOUN
dpc-5683	27	33	and	and	CCONJ
dpc-5683	27	34	plantar	plantar	NOUN
dpc-5683	27	35	,	,	PUNCT
dpc-5683	27	36	poikilodermatic	poikilodermatic	ADJ
dpc-5683	27	37	form	form	NOUN
dpc-5683	27	38	,	,	PUNCT
dpc-5683	27	39	et	et	NOUN
dpc-5683	27	40	cetera	cetera	NOUN
dpc-5683	28	1	[	[	X
dpc-5683	28	2	1	1	NUM
dpc-5683	28	3	]	]	PUNCT
dpc-5683	28	4	.	.	PUNCT
dpc-5683	29	1	a	a	DET
dpc-5683	29	2	second	second	ADJ
dpc-5683	29	3	primary	primary	ADJ
dpc-5683	29	4	malignancy	malignancy	NOUN
dpc-5683	29	5	(	(	PUNCT
dpc-5683	29	6	spm	spm	PROPN
dpc-5683	29	7	)	)	PUNCT
dpc-5683	29	8	is	be	AUX
dpc-5683	29	9	a	a	DET
dpc-5683	29	10	new	new	ADJ
dpc-5683	29	11	,	,	PUNCT
dpc-5683	29	12	unrelated	unrelated	ADJ
dpc-5683	29	13	cancer	cancer	NOUN
dpc-5683	29	14	that	that	PRON
dpc-5683	29	15	arises	arise	VERB
dpc-5683	29	16	in	in	ADP
dpc-5683	29	17	an	an	DET
dpc-5683	29	18	individual	individual	NOUN
dpc-5683	29	19	with	with	ADP
dpc-5683	29	20	a	a	DET
dpc-5683	29	21	history	history	NOUN
dpc-5683	29	22	of	of	ADP
dpc-5683	29	23	cancer	cancer	NOUN
dpc-5683	29	24	,	,	PUNCT
dpc-5683	29	25	separate	separate	ADJ
dpc-5683	29	26	from	from	ADP
dpc-5683	29	27	a	a	DET
dpc-5683	29	28	recurrence	recurrence	NOUN
dpc-5683	29	29	or	or	CCONJ
dpc-5683	29	30	metastasis	metastasis	NOUN
dpc-5683	29	31	of	of	ADP
dpc-5683	29	32	the	the	DET
dpc-5683	29	33	original	original	ADJ
dpc-5683	29	34	disease	disease	NOUN
dpc-5683	29	35	.	.	PUNCT
dpc-5683	30	1	patients	patient	NOUN
dpc-5683	30	2	with	with	ADP
dpc-5683	30	3	mf	mf	NOUN
dpc-5683	30	4	and	and	CCONJ
dpc-5683	30	5	sézary	sézary	ADJ
dpc-5683	30	6	syndrome	syndrome	NOUN
dpc-5683	30	7	(	(	PUNCT
dpc-5683	30	8	ss	ss	NOUN
dpc-5683	30	9	)	)	PUNCT
dpc-5683	30	10	have	have	VERB
dpc-5683	30	11	a	a	DET
dpc-5683	30	12	higher	high	ADJ
dpc-5683	30	13	risk	risk	NOUN
dpc-5683	30	14	of	of	ADP
dpc-5683	30	15	developing	develop	VERB
dpc-5683	30	16	other	other	ADJ
dpc-5683	30	17	second	second	ADJ
dpc-5683	30	18	primary	primary	ADJ
dpc-5683	30	19	malignancies	malignancy	NOUN
dpc-5683	30	20	,	,	PUNCT
dpc-5683	30	21	most	most	ADV
dpc-5683	30	22	commonly	commonly	ADV
dpc-5683	30	23	hematological	hematological	ADJ
dpc-5683	30	24	cancers	cancer	NOUN
dpc-5683	30	25	(	(	PUNCT
dpc-5683	30	26	non	non	ADJ
dpc-5683	30	27	-	-	ADJ
dpc-5683	30	28	hodgkin	hodgkin	ADJ
dpc-5683	30	29	lymphoma	lymphoma	NOUN
dpc-5683	30	30	,	,	PUNCT
dpc-5683	30	31	hodgkin	hodgkin	NOUN
dpc-5683	30	32	lymphoma	lymphoma	NOUN
dpc-5683	30	33	,	,	PUNCT
dpc-5683	30	34	lymphomatoid	lymphomatoid	ADJ
dpc-5683	30	35	papulosis	papulosis	NOUN
dpc-5683	30	36	,	,	PUNCT
dpc-5683	30	37	leukemia	leukemia	NOUN
dpc-5683	30	38	,	,	PUNCT
dpc-5683	30	39	multiple	multiple	ADJ
dpc-5683	30	40	myeloma	myeloma	NOUN
dpc-5683	30	41	)	)	PUNCT
dpc-5683	30	42	and	and	CCONJ
dpc-5683	30	43	solid	solid	ADJ
dpc-5683	30	44	tumors	tumor	NOUN
dpc-5683	30	45	such	such	ADJ
dpc-5683	30	46	as	as	ADP
dpc-5683	30	47	skin	skin	NOUN
dpc-5683	30	48	cancer	cancer	NOUN
dpc-5683	30	49	,	,	PUNCT
dpc-5683	30	50	lung	lung	NOUN
dpc-5683	30	51	cancer	cancer	NOUN
dpc-5683	30	52	,	,	PUNCT
dpc-5683	30	53	breast	breast	NOUN
dpc-5683	30	54	cancer	cancer	NOUN
dpc-5683	30	55	,	,	PUNCT
dpc-5683	30	56	prostate	prostate	NOUN
dpc-5683	30	57	cancer	cancer	NOUN
dpc-5683	30	58	,	,	PUNCT
dpc-5683	30	59	kidney	kidney	NOUN
dpc-5683	30	60	cancer	cancer	NOUN
dpc-5683	30	61	,	,	PUNCT
dpc-5683	30	62	colorectal	colorectal	ADJ
dpc-5683	30	63	cancer	cancer	NOUN
dpc-5683	30	64	,	,	PUNCT
dpc-5683	30	65	and	and	CCONJ
dpc-5683	30	66	bladder	bladder	NOUN
dpc-5683	30	67	cancer	cancer	NOUN
dpc-5683	30	68	,	,	PUNCT
dpc-5683	30	69	likely	likely	ADJ
dpc-5683	30	70	due	due	ADJ
dpc-5683	30	71	to	to	ADP
dpc-5683	30	72	chronic	chronic	ADJ
dpc-5683	30	73	immune	immune	ADJ
dpc-5683	30	74	dysregulation	dysregulation	NOUN
dpc-5683	30	75	,	,	PUNCT
dpc-5683	30	76	prolonged	prolong	VERB
dpc-5683	30	77	inflammation	inflammation	NOUN
dpc-5683	30	78	,	,	PUNCT
dpc-5683	30	79	and	and	CCONJ
dpc-5683	30	80	prior	prior	ADJ
dpc-5683	30	81	treatments	treatment	NOUN
dpc-5683	30	82	[	[	PUNCT
dpc-5683	30	83	2	2	NUM
dpc-5683	30	84	-	-	SYM
dpc-5683	30	85	8	8	NUM
dpc-5683	30	86	]	]	PUNCT
dpc-5683	30	87	.	.	PUNCT
dpc-5683	31	1	the	the	DET
dpc-5683	31	2	objectives	objective	NOUN
dpc-5683	31	3	of	of	ADP
dpc-5683	31	4	our	our	PRON
dpc-5683	31	5	study	study	NOUN
dpc-5683	31	6	were	be	AUX
dpc-5683	31	7	to	to	PART
dpc-5683	31	8	identify	identify	VERB
dpc-5683	31	9	mf	mf	NOUN
dpc-5683	31	10	and	and	CCONJ
dpc-5683	31	11	sézary	sézary	ADJ
dpc-5683	31	12	syndrome	syndrome	NOUN
dpc-5683	31	13	(	(	PUNCT
dpc-5683	31	14	ss	ss	NOUN
dpc-5683	31	15	)	)	PUNCT
dpc-5683	31	16	patients	patient	NOUN
dpc-5683	31	17	at	at	ADP
dpc-5683	31	18	a	a	DET
dpc-5683	31	19	potentially	potentially	ADV
dpc-5683	31	20	higher	high	ADJ
dpc-5683	31	21	risk	risk	NOUN
dpc-5683	31	22	of	of	ADP
dpc-5683	31	23	developing	develop	VERB
dpc-5683	31	24	a	a	DET
dpc-5683	31	25	secondary	secondary	ADJ
dpc-5683	31	26	primary	primary	ADJ
dpc-5683	31	27	malignancy	malignancy	NOUN
dpc-5683	31	28	,	,	PUNCT
dpc-5683	31	29	to	to	PART
dpc-5683	31	30	assess	assess	VERB
dpc-5683	31	31	the	the	DET
dpc-5683	31	32	prevalence	prevalence	NOUN
dpc-5683	31	33	of	of	ADP
dpc-5683	31	34	other	other	ADJ
dpc-5683	31	35	secondary	secondary	ADJ
dpc-5683	31	36	malignancies	malignancy	NOUN
dpc-5683	31	37	,	,	PUNCT
dpc-5683	31	38	and	and	CCONJ
dpc-5683	31	39	to	to	PART
dpc-5683	31	40	evaluate	evaluate	VERB
dpc-5683	31	41	whether	whether	SCONJ
dpc-5683	31	42	mf	mf	NOUN
dpc-5683	31	43	with	with	ADP
dpc-5683	31	44	other	other	ADJ
dpc-5683	31	45	primary	primary	ADJ
dpc-5683	31	46	malignancies	malignancy	NOUN
dpc-5683	31	47	leads	lead	VERB
dpc-5683	31	48	to	to	ADP
dpc-5683	31	49	a	a	DET
dpc-5683	31	50	worse	bad	ADJ
dpc-5683	31	51	prognosis	prognosis	NOUN
dpc-5683	31	52	based	base	VERB
dpc-5683	31	53	on	on	ADP
dpc-5683	31	54	mf	mf	NOUN
dpc-5683	31	55	variants	variant	NOUN
dpc-5683	31	56	.	.	PUNCT
dpc-5683	32	1	patients	patient	NOUN
dpc-5683	32	2	and	and	CCONJ
dpc-5683	32	3	methods	method	NOUN
dpc-5683	32	4	this	this	DET
dpc-5683	32	5	observational	observational	ADJ
dpc-5683	32	6	single	single	ADJ
dpc-5683	32	7	-	-	PUNCT
dpc-5683	32	8	center	center	NOUN
dpc-5683	32	9	retrospective	retrospective	ADJ
dpc-5683	32	10	study	study	NOUN
dpc-5683	32	11	included	include	VERB
dpc-5683	32	12	patients	patient	NOUN
dpc-5683	32	13	diagnosed	diagnose	VERB
dpc-5683	32	14	with	with	ADP
dpc-5683	32	15	ctcl	ctcl	NOUN
dpc-5683	32	16	at	at	ADP
dpc-5683	32	17	the	the	DET
dpc-5683	32	18	department	department	NOUN
dpc-5683	32	19	of	of	ADP
dpc-5683	32	20	pathology	pathology	PROPN
dpc-5683	32	21	and	and	CCONJ
dpc-5683	32	22	cytology	cytology	NOUN
dpc-5683	32	23	and	and	CCONJ
dpc-5683	32	24	the	the	DET
dpc-5683	32	25	department	department	NOUN
dpc-5683	32	26	of	of	ADP
dpc-5683	32	27	dermatology	dermatology	NOUN
dpc-5683	32	28	and	and	CCONJ
dpc-5683	32	29	venereology	venereology	NOUN
dpc-5683	32	30	at	at	ADP
dpc-5683	32	31	the	the	DET
dpc-5683	32	32	clinical	clinical	ADJ
dpc-5683	32	33	hospital	hospital	NOUN
dpc-5683	32	34	centre	centre	NOUN
dpc-5683	32	35	zagreb	zagreb	PROPN
dpc-5683	32	36	and	and	CCONJ
dpc-5683	32	37	university	university	PROPN
dpc-5683	32	38	of	of	ADP
dpc-5683	32	39	zagreb	zagreb	PROPN
dpc-5683	32	40	,	,	PUNCT
dpc-5683	32	41	a	a	DET
dpc-5683	32	42	tertiary	tertiary	ADJ
dpc-5683	32	43	center	center	NOUN
dpc-5683	32	44	with	with	ADP
dpc-5683	32	45	referral	referral	ADJ
dpc-5683	32	46	center	center	NOUN
dpc-5683	32	47	for	for	ADP
dpc-5683	32	48	dermatological	dermatological	ADJ
dpc-5683	32	49	oncology	oncology	NOUN
dpc-5683	32	50	.	.	PUNCT
dpc-5683	33	1	the	the	DET
dpc-5683	33	2	diagnosis	diagnosis	NOUN
dpc-5683	33	3	of	of	ADP
dpc-5683	33	4	ctcl	ctcl	NOUN
dpc-5683	33	5	was	be	AUX
dpc-5683	33	6	confirmed	confirm	VERB
dpc-5683	33	7	based	base	VERB
dpc-5683	33	8	on	on	ADP
dpc-5683	33	9	immunohistopathology	immunohistopathology	NOUN
dpc-5683	33	10	analysis	analysis	NOUN
dpc-5683	33	11	in	in	ADP
dpc-5683	33	12	conjunction	conjunction	NOUN
dpc-5683	33	13	with	with	ADP
dpc-5683	33	14	the	the	DET
dpc-5683	33	15	clinical	clinical	ADJ
dpc-5683	33	16	findings	finding	NOUN
dpc-5683	33	17	.	.	PUNCT
dpc-5683	34	1	all	all	DET
dpc-5683	34	2	patients	patient	NOUN
dpc-5683	34	3	diagnosed	diagnose	VERB
dpc-5683	34	4	with	with	ADP
dpc-5683	34	5	ctcl	ctcl	NOUN
dpc-5683	34	6	between	between	ADP
dpc-5683	34	7	1	1	NUM
dpc-5683	34	8	february	february	NOUN
dpc-5683	34	9	2003	2003	NUM
dpc-5683	34	10	and	and	CCONJ
dpc-5683	34	11	31	31	NUM
dpc-5683	34	12	december	december	PROPN
dpc-5683	34	13	2017	2017	NUM
dpc-5683	34	14	and	and	CCONJ
dpc-5683	34	15	followed	follow	VERB
dpc-5683	34	16	for	for	ADP
dpc-5683	34	17	at	at	ADV
dpc-5683	34	18	least	least	ADV
dpc-5683	34	19	five	five	NUM
dpc-5683	34	20	years	year	NOUN
dpc-5683	34	21	,	,	PUNCT
dpc-5683	34	22	were	be	AUX
dpc-5683	34	23	included	include	VERB
dpc-5683	34	24	in	in	ADP
dpc-5683	34	25	the	the	DET
dpc-5683	34	26	study	study	NOUN
dpc-5683	34	27	.	.	PUNCT
dpc-5683	35	1	a	a	DET
dpc-5683	35	2	total	total	NOUN
dpc-5683	35	3	of	of	ADP
dpc-5683	35	4	84	84	NUM
dpc-5683	35	5	patients	patient	NOUN
dpc-5683	35	6	(	(	PUNCT
dpc-5683	35	7	n=84	n=84	NOUN
dpc-5683	35	8	)	)	PUNCT
dpc-5683	35	9	met	meet	VERB
dpc-5683	35	10	the	the	DET
dpc-5683	35	11	inclusion	inclusion	NOUN
dpc-5683	35	12	criteria	criterion	NOUN
dpc-5683	35	13	and	and	CCONJ
dpc-5683	35	14	were	be	AUX
dpc-5683	35	15	followed	follow	VERB
dpc-5683	35	16	up	up	ADP
dpc-5683	35	17	until	until	ADP
dpc-5683	35	18	31	31	NUM
dpc-5683	35	19	december	december	PROPN
dpc-5683	35	20	2022	2022	NUM
dpc-5683	35	21	.	.	PUNCT
dpc-5683	36	1	the	the	DET
dpc-5683	36	2	following	follow	VERB
dpc-5683	36	3	data	datum	NOUN
dpc-5683	36	4	were	be	AUX
dpc-5683	36	5	analyzed	analyze	VERB
dpc-5683	36	6	for	for	ADP
dpc-5683	36	7	mf	mf	NOUN
dpc-5683	36	8	patients	patient	NOUN
dpc-5683	36	9	:	:	PUNCT
dpc-5683	36	10	age	age	NOUN
dpc-5683	36	11	at	at	ADP
dpc-5683	36	12	onset	onset	NOUN
dpc-5683	36	13	of	of	ADP
dpc-5683	36	14	lesions	lesion	NOUN
dpc-5683	36	15	,	,	PUNCT
dpc-5683	36	16	age	age	NOUN
dpc-5683	36	17	at	at	ADP
dpc-5683	36	18	diagnosis	diagnosis	NOUN
dpc-5683	36	19	,	,	PUNCT
dpc-5683	36	20	staging	stage	VERB
dpc-5683	36	21	at	at	ADP
dpc-5683	36	22	diagnosis	diagnosis	NOUN
dpc-5683	36	23	,	,	PUNCT
dpc-5683	36	24	sex	sex	NOUN
dpc-5683	36	25	,	,	PUNCT
dpc-5683	36	26	disease	disease	NOUN
dpc-5683	36	27	progression	progression	NOUN
dpc-5683	36	28	,	,	PUNCT
dpc-5683	36	29	high	high	ADJ
dpc-5683	36	30	-	-	PUNCT
dpc-5683	36	31	grade	grade	NOUN
dpc-5683	36	32	transformation	transformation	NOUN
dpc-5683	36	33	,	,	PUNCT
dpc-5683	36	34	type	type	NOUN
dpc-5683	36	35	of	of	ADP
dpc-5683	36	36	mf	mf	NOUN
dpc-5683	36	37	and	and	CCONJ
dpc-5683	36	38	mf	mf	NOUN
dpc-5683	36	39	variants	variant	NOUN
dpc-5683	36	40	,	,	PUNCT
dpc-5683	36	41	development	development	NOUN
dpc-5683	36	42	of	of	ADP
dpc-5683	36	43	secondary	secondary	ADJ
dpc-5683	36	44	primary	primary	ADJ
dpc-5683	36	45	malignancy	malignancy	NOUN
dpc-5683	36	46	,	,	PUNCT
dpc-5683	36	47	age	age	NOUN
dpc-5683	36	48	at	at	ADP
dpc-5683	36	49	diagnosis	diagnosis	NOUN
dpc-5683	36	50	of	of	ADP
dpc-5683	36	51	secondary	secondary	ADJ
dpc-5683	36	52	primary	primary	ADJ
dpc-5683	36	53	malignancies	malignancy	NOUN
dpc-5683	36	54	,	,	PUNCT
dpc-5683	36	55	and	and	CCONJ
dpc-5683	36	56	development	development	NOUN
dpc-5683	36	57	of	of	ADP
dpc-5683	36	58	non	non	ADJ
dpc-5683	36	59	-	-	ADJ
dpc-5683	36	60	melanoma	melanoma	ADJ
dpc-5683	36	61	skin	skin	NOUN
dpc-5683	36	62	cancer	cancer	NOUN
dpc-5683	36	63	(	(	PUNCT
dpc-5683	36	64	nmsc	nmsc	NOUN
dpc-5683	36	65	)	)	PUNCT
dpc-5683	36	66	and	and	CCONJ
dpc-5683	36	67	melanoma	melanoma	NOUN
dpc-5683	36	68	.	.	PUNCT
dpc-5683	37	1	staging	staging	NOUN
dpc-5683	37	2	of	of	ADP
dpc-5683	37	3	the	the	DET
dpc-5683	37	4	disease	disease	NOUN
dpc-5683	37	5	was	be	AUX
dpc-5683	37	6	determined	determine	VERB
dpc-5683	37	7	according	accord	VERB
dpc-5683	37	8	to	to	ADP
dpc-5683	37	9	tnmb	tnmb	VERB
dpc-5683	37	10	classification	classification	NOUN
dpc-5683	37	11	[	[	X
dpc-5683	37	12	9	9	NUM
dpc-5683	37	13	]	]	PUNCT
dpc-5683	37	14	.	.	PUNCT
dpc-5683	38	1	statistical	statistical	ADJ
dpc-5683	38	2	analysis	analysis	NOUN
dpc-5683	38	3	the	the	DET
dpc-5683	38	4	data	datum	NOUN
dpc-5683	38	5	are	be	AUX
dpc-5683	38	6	presented	present	VERB
dpc-5683	38	7	in	in	ADP
dpc-5683	38	8	tables	table	NOUN
dpc-5683	38	9	and	and	CCONJ
dpc-5683	38	10	graphs	graph	NOUN
dpc-5683	38	11	.	.	PUNCT
dpc-5683	39	1	the	the	DET
dpc-5683	39	2	normality	normality	NOUN
dpc-5683	39	3	of	of	ADP
dpc-5683	39	4	the	the	DET
dpc-5683	39	5	distribution	distribution	NOUN
dpc-5683	39	6	of	of	ADP
dpc-5683	39	7	numerical	numerical	ADJ
dpc-5683	39	8	data	datum	NOUN
dpc-5683	39	9	was	be	AUX
dpc-5683	39	10	assessed	assess	VERB
dpc-5683	39	11	using	use	VERB
dpc-5683	39	12	smirnov	smirnov	ADJ
dpc-5683	39	13	-	-	PUNCT
dpc-5683	39	14	kolmogorov	kolmogorov	ADJ
dpc-5683	39	15	test	test	NOUN
dpc-5683	39	16	,	,	PUNCT
dpc-5683	39	17	and	and	CCONJ
dpc-5683	39	18	corresponding	correspond	VERB
dpc-5683	39	19	non	non	ADJ
dpc-5683	39	20	parametric	parametric	ADJ
dpc-5683	39	21	statistical	statistical	ADJ
dpc-5683	39	22	tests	test	NOUN
dpc-5683	39	23	were	be	AUX
dpc-5683	39	24	applied	apply	VERB
dpc-5683	39	25	based	base	VERB
dpc-5683	39	26	on	on	ADP
dpc-5683	39	27	the	the	DET
dpc-5683	39	28	results	result	NOUN
dpc-5683	39	29	.	.	PUNCT
dpc-5683	40	1	quantitative	quantitative	ADJ
dpc-5683	40	2	data	datum	NOUN
dpc-5683	40	3	are	be	AUX
dpc-5683	40	4	presented	present	VERB
dpc-5683	40	5	as	as	ADP
dpc-5683	40	6	medians	median	NOUN
dpc-5683	40	7	with	with	ADP
dpc-5683	40	8	interquartile	interquartile	NOUN
dpc-5683	40	9	ranges	range	NOUN
dpc-5683	40	10	,	,	PUNCT
dpc-5683	40	11	while	while	SCONJ
dpc-5683	40	12	categorical	categorical	ADJ
dpc-5683	40	13	data	datum	NOUN
dpc-5683	40	14	are	be	AUX
dpc-5683	40	15	reported	report	VERB
dpc-5683	40	16	as	as	ADP
dpc-5683	40	17	absolute	absolute	ADJ
dpc-5683	40	18	frequencies	frequency	NOUN
dpc-5683	40	19	with	with	ADP
dpc-5683	40	20	corresponding	correspond	VERB
dpc-5683	40	21	proportions	proportion	NOUN
dpc-5683	40	22	or	or	CCONJ
dpc-5683	40	23	95	95	NUM
dpc-5683	40	24	%	%	NOUN
dpc-5683	40	25	confidence	confidence	NOUN
dpc-5683	40	26	intervals	interval	NOUN
dpc-5683	40	27	(	(	PUNCT
dpc-5683	40	28	cis	cis	NOUN
dpc-5683	40	29	)	)	PUNCT
dpc-5683	40	30	.	.	PUNCT
dpc-5683	41	1	differences	difference	NOUN
dpc-5683	41	2	in	in	ADP
dpc-5683	41	3	quantitative	quantitative	ADJ
dpc-5683	41	4	values	value	NOUN
dpc-5683	41	5	were	be	AUX
dpc-5683	41	6	analyzed	analyze	VERB
dpc-5683	41	7	using	use	VERB
dpc-5683	41	8	the	the	DET
dpc-5683	41	9	mann	mann	PROPN
dpc-5683	41	10	-	-	PUNCT
dpc-5683	41	11	whitney	whitney	PROPN
dpc-5683	41	12	u	u	PROPN
dpc-5683	41	13	test	test	NOUN
dpc-5683	41	14	.	.	PUNCT
dpc-5683	42	1	differences	difference	NOUN
dpc-5683	42	2	in	in	ADP
dpc-5683	42	3	categorical	categorical	ADJ
dpc-5683	42	4	variables	variable	NOUN
dpc-5683	42	5	were	be	AUX
dpc-5683	42	6	analyzed	analyze	VERB
dpc-5683	42	7	by	by	ADP
dpc-5683	42	8	fisher	fisher	PROPN
dpc-5683	42	9	's	's	PART
dpc-5683	42	10	exact	exact	ADJ
dpc-5683	42	11	test	test	NOUN
dpc-5683	42	12	,	,	PUNCT
dpc-5683	42	13	or	or	CCONJ
dpc-5683	42	14	fisher	fisher	PROPN
dpc-5683	42	15	-	-	PUNCT
dpc-5683	42	16	freeman	freeman	PROPN
dpc-5683	42	17	-	-	PUNCT
dpc-5683	42	18	halton	halton	PROPN
dpc-5683	42	19	's	's	PART
dpc-5683	42	20	exact	exact	ADJ
dpc-5683	42	21	test	test	NOUN
dpc-5683	42	22	in	in	ADP
dpc-5683	42	23	the	the	DET
dpc-5683	42	24	case	case	NOUN
dpc-5683	42	25	of	of	ADP
dpc-5683	42	26	contingency	contingency	NOUN
dpc-5683	42	27	tables	table	NOUN
dpc-5683	42	28	that	that	PRON
dpc-5683	42	29	were	be	AUX
dpc-5683	42	30	larger	large	ADJ
dpc-5683	42	31	than	than	ADP
dpc-5683	42	32	the	the	DET
dpc-5683	42	33	2	2	NUM
dpc-5683	42	34	x	x	SYM
dpc-5683	42	35	2	2	NUM
dpc-5683	42	36	format	format	NOUN
dpc-5683	42	37	.	.	PUNCT
dpc-5683	43	1	the	the	DET
dpc-5683	43	2	kaplan	kaplan	PROPN
dpc-5683	43	3	-	-	PUNCT
dpc-5683	43	4	meier	meier	PROPN
dpc-5683	43	5	curve	curve	NOUN
dpc-5683	43	6	with	with	ADP
dpc-5683	43	7	the	the	DET
dpc-5683	43	8	associated	associate	VERB
dpc-5683	43	9	log	log	NOUN
dpc-5683	43	10	-	-	PUNCT
dpc-5683	43	11	rank	rank	NOUN
dpc-5683	43	12	test	test	NOUN
dpc-5683	43	13	was	be	AUX
dpc-5683	43	14	used	use	VERB
dpc-5683	43	15	to	to	PART
dpc-5683	43	16	analyze	analyze	VERB
dpc-5683	43	17	survival	survival	NOUN
dpc-5683	43	18	until	until	ADP
dpc-5683	43	19	disease	disease	NOUN
dpc-5683	43	20	progression	progression	NOUN
dpc-5683	43	21	.	.	PUNCT
dpc-5683	44	1	all	all	DET
dpc-5683	44	2	p	p	NOUN
dpc-5683	44	3	-	-	PUNCT
dpc-5683	44	4	values	value	NOUN
dpc-5683	44	5	less	less	ADJ
dpc-5683	44	6	than	than	ADP
dpc-5683	44	7	0.05	0.05	NUM
dpc-5683	44	8	were	be	AUX
dpc-5683	44	9	considered	consider	VERB
dpc-5683	44	10	statistically	statistically	ADV
dpc-5683	44	11	significant	significant	ADJ
dpc-5683	44	12	.	.	PUNCT
dpc-5683	45	1	in	in	ADP
dpc-5683	45	2	the	the	DET
dpc-5683	45	3	analysis	analysis	NOUN
dpc-5683	45	4	and	and	CCONJ
dpc-5683	45	5	graphic	graphic	ADJ
dpc-5683	45	6	displays	display	NOUN
dpc-5683	45	7	,	,	PUNCT
dpc-5683	45	8	the	the	DET
dpc-5683	45	9	licensed	licensed	ADJ
dpc-5683	45	10	program	program	NOUN
dpc-5683	45	11	support	support	NOUN
dpc-5683	45	12	ibm	ibm	PROPN
dpc-5683	45	13	spss	spss	PROPN
dpc-5683	45	14	statistics	statistic	NOUN
dpc-5683	45	15	for	for	ADP
dpc-5683	45	16	windows	window	NOUN
dpc-5683	45	17	,	,	PUNCT
dpc-5683	45	18	version	version	NOUN
dpc-5683	45	19	29.0.1	29.0.1	NOUN
dpc-5683	45	20	,	,	PUNCT
dpc-5683	45	21	was	be	AUX
dpc-5683	45	22	used	use	VERB
dpc-5683	45	23	.	.	PUNCT
dpc-5683	46	1	results	result	VERB
dpc-5683	46	2	the	the	DET
dpc-5683	46	3	study	study	NOUN
dpc-5683	46	4	included	include	VERB
dpc-5683	46	5	total	total	NOUN
dpc-5683	46	6	of	of	ADP
dpc-5683	46	7	84	84	NUM
dpc-5683	46	8	patients	patient	NOUN
dpc-5683	46	9	:	:	PUNCT
dpc-5683	46	10	50	50	NUM
dpc-5683	46	11	males	male	NOUN
dpc-5683	46	12	and	and	CCONJ
dpc-5683	46	13	34	34	NUM
dpc-5683	46	14	females	female	NOUN
dpc-5683	46	15	.	.	PUNCT
dpc-5683	47	1	the	the	DET
dpc-5683	47	2	majority	majority	NOUN
dpc-5683	47	3	of	of	ADP
dpc-5683	47	4	patients	patient	NOUN
dpc-5683	47	5	(	(	PUNCT
dpc-5683	47	6	n=48	n=48	NOUN
dpc-5683	47	7	,	,	PUNCT
dpc-5683	47	8	57.1	57.1	NUM
dpc-5683	47	9	%	%	NOUN
dpc-5683	47	10	)	)	PUNCT
dpc-5683	47	11	had	have	VERB
dpc-5683	47	12	early	early	ADJ
dpc-5683	47	13	-	-	PUNCT
dpc-5683	47	14	stage	stage	NOUN
dpc-5683	47	15	disease	disease	NOUN
dpc-5683	47	16	(	(	PUNCT
dpc-5683	47	17	ia	ia	PROPN
dpc-5683	47	18	+	+	CCONJ
dpc-5683	47	19	ib	ib	NOUN
dpc-5683	47	20	)	)	PUNCT
dpc-5683	47	21	.	.	PUNCT
dpc-5683	48	1	disease	disease	NOUN
dpc-5683	48	2	progression	progression	NOUN
dpc-5683	48	3	was	be	AUX
dpc-5683	48	4	observed	observe	VERB
dpc-5683	48	5	in	in	ADP
dpc-5683	48	6	19	19	NUM
dpc-5683	48	7	patients	patient	NOUN
dpc-5683	48	8	(	(	PUNCT
dpc-5683	48	9	22.6	22.6	NUM
dpc-5683	48	10	%	%	NOUN
dpc-5683	48	11	)	)	PUNCT
dpc-5683	48	12	,	,	PUNCT
dpc-5683	48	13	and	and	CCONJ
dpc-5683	48	14	14.3	14.3	NUM
dpc-5683	48	15	%	%	NOUN
dpc-5683	48	16	of	of	ADP
dpc-5683	48	17	the	the	DET
dpc-5683	48	18	patients	patient	NOUN
dpc-5683	48	19	had	have	VERB
dpc-5683	48	20	fatal	fatal	ADJ
dpc-5683	48	21	outcome	outcome	NOUN
dpc-5683	48	22	.	.	PUNCT
dpc-5683	49	1	among	among	ADP
dpc-5683	49	2	our	our	PRON
dpc-5683	49	3	cohort	cohort	NOUN
dpc-5683	49	4	,	,	PUNCT
dpc-5683	49	5	33.3	33.3	NUM
dpc-5683	49	6	%	%	NOUN
dpc-5683	49	7	(	(	PUNCT
dpc-5683	49	8	28	28	NUM
dpc-5683	49	9	patients	patient	NOUN
dpc-5683	49	10	)	)	PUNCT
dpc-5683	49	11	had	have	VERB
dpc-5683	49	12	some	some	PRON
dpc-5683	49	13	of	of	ADP
dpc-5683	49	14	the	the	DET
dpc-5683	49	15	variants	variant	NOUN
dpc-5683	49	16	of	of	ADP
dpc-5683	49	17	mf	mf	NOUN
dpc-5683	49	18	or	or	CCONJ
dpc-5683	49	19	ss	ss	NOUN
dpc-5683	49	20	.	.	PUNCT
dpc-5683	50	1	the	the	DET
dpc-5683	50	2	mf	mf	NOUN
dpc-5683	50	3	variants	variant	NOUN
dpc-5683	50	4	of	of	ADP
dpc-5683	50	5	mf	mf	NOUN
dpc-5683	50	6	included	include	VERB
dpc-5683	50	7	nine	nine	NUM
dpc-5683	50	8	patients	patient	NOUN
dpc-5683	50	9	with	with	ADP
dpc-5683	50	10	large	large	ADJ
dpc-5683	50	11	cell	cell	NOUN
dpc-5683	50	12	transformation	transformation	NOUN
dpc-5683	50	13	(	(	PUNCT
dpc-5683	50	14	eight	eight	NUM
dpc-5683	50	15	patients	patient	NOUN
dpc-5683	50	16	had	have	AUX
dpc-5683	50	17	cd30	cd30	PROPN
dpc-5683	50	18	+	+	CCONJ
dpc-5683	50	19	large	large	ADJ
dpc-5683	50	20	cell	cell	NOUN
dpc-5683	50	21	transformation	transformation	NOUN
dpc-5683	50	22	,	,	PUNCT
dpc-5683	50	23	while	while	SCONJ
dpc-5683	50	24	one	one	NUM
dpc-5683	50	25	patient	patient	NOUN
dpc-5683	50	26	had	have	VERB
dpc-5683	50	27	cd30large	cd30large	ADJ
dpc-5683	50	28	cell	cell	NOUN
dpc-5683	50	29	transformation	transformation	NOUN
dpc-5683	50	30	)	)	PUNCT
dpc-5683	50	31	,	,	PUNCT
dpc-5683	50	32	two	two	NUM
dpc-5683	50	33	with	with	ADP
dpc-5683	50	34	hypopigmented	hypopigmented	ADJ
dpc-5683	50	35	mf	mf	NOUN
dpc-5683	50	36	,	,	PUNCT
dpc-5683	50	37	three	three	NUM
dpc-5683	50	38	with	with	ADP
dpc-5683	50	39	erythroderma	erythroderma	NOUN
dpc-5683	50	40	,	,	PUNCT
dpc-5683	50	41	six	six	NUM
dpc-5683	50	42	with	with	ADP
dpc-5683	50	43	folliculotropic	folliculotropic	ADJ
dpc-5683	50	44	mf	mf	NOUN
dpc-5683	50	45	(	(	PUNCT
dpc-5683	50	46	fmf	fmf	NOUN
dpc-5683	50	47	)	)	PUNCT
dpc-5683	50	48	,	,	PUNCT
dpc-5683	50	49	two	two	NUM
dpc-5683	50	50	with	with	ADP
dpc-5683	50	51	syringotropic	syringotropic	ADJ
dpc-5683	50	52	mf	mf	NOUN
dpc-5683	50	53	,	,	PUNCT
dpc-5683	50	54	1	1	NUM
dpc-5683	50	55	with	with	ADP
dpc-5683	50	56	conclusion	conclusion	NOUN
dpc-5683	50	57	:	:	PUNCT
dpc-5683	50	58	a	a	DET
dpc-5683	50	59	higher	high	ADJ
dpc-5683	50	60	risk	risk	NOUN
dpc-5683	50	61	for	for	ADP
dpc-5683	50	62	developing	develop	VERB
dpc-5683	50	63	a	a	DET
dpc-5683	50	64	second	second	ADJ
dpc-5683	50	65	primary	primary	ADJ
dpc-5683	50	66	neoplasm	neoplasm	NOUN
dpc-5683	50	67	was	be	AUX
dpc-5683	50	68	observed	observe	VERB
dpc-5683	50	69	.	.	PUNCT
dpc-5683	51	1	however	however	ADV
dpc-5683	51	2	,	,	PUNCT
dpc-5683	51	3	additional	additional	ADJ
dpc-5683	51	4	cancer	cancer	NOUN
dpc-5683	51	5	screening	screening	NOUN
dpc-5683	51	6	beyond	beyond	ADP
dpc-5683	51	7	routine	routine	ADJ
dpc-5683	51	8	ageand	ageand	NOUN
dpc-5683	51	9	sex	sex	NOUN
dpc-5683	51	10	-	-	PUNCT
dpc-5683	51	11	appropriate	appropriate	ADJ
dpc-5683	51	12	examinations	examination	NOUN
dpc-5683	51	13	is	be	AUX
dpc-5683	51	14	not	not	PART
dpc-5683	51	15	yet	yet	ADV
dpc-5683	51	16	included	include	VERB
dpc-5683	51	17	in	in	ADP
dpc-5683	51	18	the	the	DET
dpc-5683	51	19	current	current	ADJ
dpc-5683	51	20	guidelines	guideline	NOUN
dpc-5683	51	21	.	.	PUNCT
dpc-5683	52	1	based	base	VERB
dpc-5683	52	2	on	on	ADP
dpc-5683	52	3	our	our	PRON
dpc-5683	52	4	findings	finding	NOUN
dpc-5683	52	5	,	,	PUNCT
dpc-5683	52	6	we	we	PRON
dpc-5683	52	7	recommend	recommend	VERB
dpc-5683	52	8	that	that	SCONJ
dpc-5683	52	9	mf	mf	NOUN
dpc-5683	52	10	patients	patient	NOUN
dpc-5683	52	11	undergo	undergo	VERB
dpc-5683	52	12	regular	regular	ADJ
dpc-5683	52	13	preventive	preventive	ADJ
dpc-5683	52	14	screenings	screening	NOUN
dpc-5683	52	15	for	for	ADP
dpc-5683	52	16	the	the	DET
dpc-5683	52	17	early	early	ADJ
dpc-5683	52	18	detection	detection	NOUN
dpc-5683	52	19	of	of	ADP
dpc-5683	52	20	other	other	ADJ
dpc-5683	52	21	primary	primary	ADJ
dpc-5683	52	22	malignancies	malignancy	NOUN
dpc-5683	52	23	.	.	PUNCT
dpc-5683	53	1	original	original	ADJ
dpc-5683	53	2	article	article	NOUN
dpc-5683	53	3	|	|	ADV
dpc-5683	53	4	dermatol	dermatol	ADJ
dpc-5683	53	5	pract	pract	NOUN
dpc-5683	53	6	concept	concept	NOUN
dpc-5683	53	7	.	.	PUNCT
dpc-5683	54	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	54	2	3	3	NUM
dpc-5683	54	3	poikilodermatous	poikilodermatous	ADJ
dpc-5683	54	4	form	form	NOUN
dpc-5683	54	5	,	,	PUNCT
dpc-5683	54	6	and	and	CCONJ
dpc-5683	54	7	one	one	NUM
dpc-5683	54	8	with	with	ADP
dpc-5683	54	9	cd4+cd8	cd4+cd8	PROPN
dpc-5683	54	10	+	+	X
dpc-5683	54	11	mf	mf	X
dpc-5683	54	12	.	.	PUNCT
dpc-5683	54	13	additionally	additionally	ADV
dpc-5683	54	14	,	,	PUNCT
dpc-5683	54	15	five	five	NUM
dpc-5683	54	16	patients	patient	NOUN
dpc-5683	54	17	had	have	VERB
dpc-5683	54	18	ss	ss	NOUN
dpc-5683	54	19	.	.	PUNCT
dpc-5683	55	1	all	all	PRON
dpc-5683	55	2	patient	patient	ADJ
dpc-5683	55	3	with	with	ADP
dpc-5683	55	4	ss	ss	NOUN
dpc-5683	55	5	had	have	VERB
dpc-5683	55	6	stage	stage	NOUN
dpc-5683	55	7	4a	4a	NOUN
dpc-5683	55	8	according	accord	VERB
dpc-5683	55	9	to	to	ADP
dpc-5683	55	10	tnmb	tnmb	VERB
dpc-5683	55	11	classification	classification	NOUN
dpc-5683	55	12	.	.	PUNCT
dpc-5683	56	1	disease	disease	NOUN
dpc-5683	56	2	progression	progression	NOUN
dpc-5683	56	3	was	be	AUX
dpc-5683	56	4	significantly	significantly	ADV
dpc-5683	56	5	more	more	ADV
dpc-5683	56	6	common	common	ADJ
dpc-5683	56	7	in	in	ADP
dpc-5683	56	8	this	this	DET
dpc-5683	56	9	subgroup	subgroup	NOUN
dpc-5683	56	10	(	(	PUNCT
dpc-5683	56	11	p<0.001	p<0.001	PROPN
dpc-5683	56	12	)	)	PUNCT
dpc-5683	56	13	.	.	PUNCT
dpc-5683	57	1	a	a	DET
dpc-5683	57	2	significant	significant	ADJ
dpc-5683	57	3	association	association	NOUN
dpc-5683	57	4	was	be	AUX
dpc-5683	57	5	found	find	VERB
dpc-5683	57	6	between	between	ADP
dpc-5683	57	7	advanced	advanced	ADJ
dpc-5683	57	8	disease	disease	NOUN
dpc-5683	57	9	stages	stage	NOUN
dpc-5683	57	10	and	and	CCONJ
dpc-5683	57	11	the	the	DET
dpc-5683	57	12	presence	presence	NOUN
dpc-5683	57	13	of	of	ADP
dpc-5683	57	14	mf	mf	NOUN
dpc-5683	57	15	or	or	CCONJ
dpc-5683	57	16	ss	ss	NOUN
dpc-5683	57	17	variants	variant	NOUN
dpc-5683	57	18	,	,	PUNCT
dpc-5683	57	19	with	with	ADP
dpc-5683	57	20	higher	high	ADJ
dpc-5683	57	21	stages	stage	NOUN
dpc-5683	57	22	more	more	ADV
dpc-5683	57	23	prevalent	prevalent	ADJ
dpc-5683	57	24	in	in	ADP
dpc-5683	57	25	these	these	DET
dpc-5683	57	26	patients	patient	NOUN
dpc-5683	57	27	(	(	PUNCT
dpc-5683	57	28	p<0.001	p<0.001	PROPN
dpc-5683	57	29	)	)	PUNCT
dpc-5683	57	30	.	.	PUNCT
dpc-5683	58	1	these	these	DET
dpc-5683	58	2	patients	patient	NOUN
dpc-5683	58	3	also	also	ADV
dpc-5683	58	4	had	have	VERB
dpc-5683	58	5	a	a	DET
dpc-5683	58	6	significantly	significantly	ADV
dpc-5683	58	7	shorter	short	ADJ
dpc-5683	58	8	survival	survival	NOUN
dpc-5683	58	9	time	time	NOUN
dpc-5683	58	10	to	to	ADP
dpc-5683	58	11	disease	disease	NOUN
dpc-5683	58	12	progression	progression	NOUN
dpc-5683	58	13	(	(	PUNCT
dpc-5683	58	14	p<0.001	p<0.001	X
dpc-5683	58	15	)	)	PUNCT
dpc-5683	58	16	(	(	PUNCT
dpc-5683	58	17	table	table	NOUN
dpc-5683	58	18	1	1	NUM
dpc-5683	58	19	)	)	PUNCT
dpc-5683	58	20	.	.	PUNCT
dpc-5683	59	1	within	within	ADP
dpc-5683	59	2	our	our	PRON
dpc-5683	59	3	cohort	cohort	NOUN
dpc-5683	59	4	,	,	PUNCT
dpc-5683	59	5	16	16	NUM
dpc-5683	59	6	patients	patient	NOUN
dpc-5683	59	7	(	(	PUNCT
dpc-5683	59	8	19.0	19.0	NUM
dpc-5683	59	9	%	%	NOUN
dpc-5683	59	10	)	)	PUNCT
dpc-5683	59	11	developed	develop	VERB
dpc-5683	59	12	a	a	DET
dpc-5683	59	13	second	second	ADJ
dpc-5683	59	14	primary	primary	ADJ
dpc-5683	59	15	malignancy	malignancy	NOUN
dpc-5683	59	16	,	,	PUNCT
dpc-5683	59	17	with	with	ADP
dpc-5683	59	18	eight	eight	NUM
dpc-5683	59	19	(	(	PUNCT
dpc-5683	59	20	50.0	50.0	NUM
dpc-5683	59	21	%	%	NOUN
dpc-5683	59	22	)	)	PUNCT
dpc-5683	59	23	of	of	ADP
dpc-5683	59	24	these	these	PRON
dpc-5683	59	25	with	with	ADP
dpc-5683	59	26	hematological	hematological	ADJ
dpc-5683	59	27	neoplasms	neoplasm	NOUN
dpc-5683	59	28	.	.	PUNCT
dpc-5683	60	1	no	no	DET
dpc-5683	60	2	case	case	NOUN
dpc-5683	60	3	of	of	ADP
dpc-5683	60	4	melanoma	melanoma	NOUN
dpc-5683	60	5	was	be	AUX
dpc-5683	60	6	diagnosed	diagnose	VERB
dpc-5683	60	7	;	;	PUNCT
dpc-5683	60	8	however	however	ADV
dpc-5683	60	9	,	,	PUNCT
dpc-5683	60	10	five	five	NUM
dpc-5683	60	11	patients	patient	NOUN
dpc-5683	60	12	developed	develop	VERB
dpc-5683	60	13	nmsc	nmsc	NOUN
dpc-5683	60	14	during	during	ADP
dpc-5683	60	15	follow	follow	NOUN
dpc-5683	60	16	-	-	PUNCT
dpc-5683	60	17	up	up	NOUN
dpc-5683	60	18	.	.	PUNCT
dpc-5683	61	1	all	all	DET
dpc-5683	61	2	patients	patient	NOUN
dpc-5683	61	3	who	who	PRON
dpc-5683	61	4	developed	develop	VERB
dpc-5683	61	5	nmsc	nmsc	NOUN
dpc-5683	61	6	had	have	AUX
dpc-5683	61	7	been	be	AUX
dpc-5683	61	8	previously	previously	ADV
dpc-5683	61	9	treated	treat	VERB
dpc-5683	61	10	with	with	ADP
dpc-5683	61	11	puva	puva	PROPN
dpc-5683	61	12	therapy	therapy	NOUN
dpc-5683	61	13	.	.	PUNCT
dpc-5683	62	1	the	the	DET
dpc-5683	62	2	most	most	ADV
dpc-5683	62	3	common	common	ADJ
dpc-5683	62	4	solid	solid	ADJ
dpc-5683	62	5	organ	organ	NOUN
dpc-5683	62	6	malignancy	malignancy	NOUN
dpc-5683	62	7	was	be	AUX
dpc-5683	62	8	breast	breast	NOUN
dpc-5683	62	9	cancer	cancer	NOUN
dpc-5683	62	10	(	(	PUNCT
dpc-5683	62	11	five	five	NUM
dpc-5683	62	12	patients	patient	NOUN
dpc-5683	62	13	)	)	PUNCT
dpc-5683	62	14	.	.	PUNCT
dpc-5683	63	1	other	other	ADJ
dpc-5683	63	2	primary	primary	ADJ
dpc-5683	63	3	malignancies	malignancy	NOUN
dpc-5683	63	4	included	include	VERB
dpc-5683	63	5	papillary	papillary	ADJ
dpc-5683	63	6	thyroid	thyroid	NOUN
dpc-5683	63	7	cancer	cancer	NOUN
dpc-5683	63	8	,	,	PUNCT
dpc-5683	63	9	endometrial	endometrial	ADJ
dpc-5683	63	10	cancer	cancer	NOUN
dpc-5683	63	11	,	,	PUNCT
dpc-5683	63	12	prostate	prostate	NOUN
dpc-5683	63	13	cancer	cancer	NOUN
dpc-5683	63	14	(	(	PUNCT
dpc-5683	63	15	two	two	NUM
dpc-5683	63	16	patients	patient	NOUN
dpc-5683	63	17	)	)	PUNCT
dpc-5683	63	18	,	,	PUNCT
dpc-5683	63	19	sublingual	sublingual	ADJ
dpc-5683	63	20	squamous	squamous	ADJ
dpc-5683	63	21	cell	cell	NOUN
dpc-5683	63	22	carcinoma	carcinoma	NOUN
dpc-5683	63	23	,	,	PUNCT
dpc-5683	63	24	lung	lung	NOUN
dpc-5683	63	25	cancer	cancer	NOUN
dpc-5683	63	26	,	,	PUNCT
dpc-5683	63	27	and	and	CCONJ
dpc-5683	63	28	kidney	kidney	NOUN
dpc-5683	63	29	cancer	cancer	NOUN
dpc-5683	63	30	,	,	PUNCT
dpc-5683	63	31	together	together	ADV
dpc-5683	63	32	accounting	account	VERB
dpc-5683	63	33	for	for	ADP
dpc-5683	63	34	8	8	NUM
dpc-5683	63	35	%	%	NOUN
dpc-5683	63	36	(	(	PUNCT
dpc-5683	63	37	9.52	9.52	NUM
dpc-5683	63	38	%	%	NOUN
dpc-5683	63	39	)	)	PUNCT
dpc-5683	63	40	of	of	ADP
dpc-5683	63	41	study	study	NOUN
dpc-5683	63	42	population	population	NOUN
dpc-5683	63	43	(	(	PUNCT
dpc-5683	63	44	table	table	NOUN
dpc-5683	63	45	2	2	NUM
dpc-5683	63	46	)	)	PUNCT
dpc-5683	63	47	.	.	PUNCT
dpc-5683	64	1	among	among	ADP
dpc-5683	64	2	these	these	DET
dpc-5683	64	3	16	16	NUM
dpc-5683	64	4	patients	patient	NOUN
dpc-5683	64	5	,	,	PUNCT
dpc-5683	64	6	four	four	NUM
dpc-5683	64	7	(	(	PUNCT
dpc-5683	64	8	25	25	NUM
dpc-5683	64	9	%	%	NOUN
dpc-5683	64	10	)	)	PUNCT
dpc-5683	64	11	had	have	VERB
dpc-5683	64	12	two	two	NUM
dpc-5683	64	13	or	or	CCONJ
dpc-5683	64	14	more	more	ADJ
dpc-5683	64	15	other	other	ADJ
dpc-5683	64	16	primary	primary	ADJ
dpc-5683	64	17	malignancies	malignancy	NOUN
dpc-5683	64	18	in	in	ADP
dpc-5683	64	19	addition	addition	NOUN
dpc-5683	64	20	to	to	ADP
dpc-5683	64	21	ctcl	ctcl	NOUN
dpc-5683	64	22	.	.	PUNCT
dpc-5683	65	1	of	of	ADP
dpc-5683	65	2	these	these	DET
dpc-5683	65	3	four	four	NUM
dpc-5683	65	4	patients	patient	NOUN
dpc-5683	65	5	,	,	PUNCT
dpc-5683	65	6	three	three	NUM
dpc-5683	65	7	were	be	AUX
dpc-5683	65	8	female	female	ADJ
dpc-5683	65	9	,	,	PUNCT
dpc-5683	65	10	and	and	CCONJ
dpc-5683	65	11	all	all	DET
dpc-5683	65	12	three	three	NUM
dpc-5683	65	13	had	have	VERB
dpc-5683	65	14	breast	breast	NOUN
dpc-5683	65	15	cancer	cancer	NOUN
dpc-5683	65	16	as	as	ADP
dpc-5683	65	17	one	one	NUM
dpc-5683	65	18	of	of	ADP
dpc-5683	65	19	the	the	DET
dpc-5683	65	20	other	other	ADJ
dpc-5683	65	21	primary	primary	ADJ
dpc-5683	65	22	malignancies	malignancy	NOUN
dpc-5683	65	23	.	.	PUNCT
dpc-5683	66	1	one	one	NUM
dpc-5683	66	2	patient	patient	NOUN
dpc-5683	66	3	had	have	VERB
dpc-5683	66	4	mf	mf	NOUN
dpc-5683	66	5	,	,	PUNCT
dpc-5683	66	6	breast	breast	NOUN
dpc-5683	66	7	cancer	cancer	NOUN
dpc-5683	66	8	,	,	PUNCT
dpc-5683	66	9	and	and	CCONJ
dpc-5683	66	10	endometrial	endometrial	ADJ
dpc-5683	66	11	cancer	cancer	NOUN
dpc-5683	66	12	.	.	PUNCT
dpc-5683	67	1	the	the	DET
dpc-5683	67	2	second	second	ADJ
dpc-5683	67	3	patient	patient	NOUN
dpc-5683	67	4	had	have	VERB
dpc-5683	67	5	ss	ss	NOUN
dpc-5683	67	6	,	,	PUNCT
dpc-5683	67	7	breast	breast	NOUN
dpc-5683	67	8	cancer	cancer	NOUN
dpc-5683	67	9	,	,	PUNCT
dpc-5683	67	10	and	and	CCONJ
dpc-5683	67	11	squamous	squamous	ADJ
dpc-5683	67	12	cell	cell	NOUN
dpc-5683	67	13	sublingual	sublingual	ADJ
dpc-5683	67	14	cancer	cancer	NOUN
dpc-5683	67	15	.	.	PUNCT
dpc-5683	68	1	the	the	DET
dpc-5683	68	2	third	third	ADJ
dpc-5683	68	3	patient	patient	NOUN
dpc-5683	68	4	had	have	VERB
dpc-5683	68	5	mf	mf	NOUN
dpc-5683	68	6	,	,	PUNCT
dpc-5683	68	7	breast	breast	NOUN
dpc-5683	68	8	cancer	cancer	NOUN
dpc-5683	68	9	,	,	PUNCT
dpc-5683	68	10	papillary	papillary	ADJ
dpc-5683	68	11	thyroid	thyroid	NOUN
dpc-5683	68	12	cancer	cancer	NOUN
dpc-5683	68	13	,	,	PUNCT
dpc-5683	68	14	and	and	CCONJ
dpc-5683	68	15	monoclonal	monoclonal	NOUN
dpc-5683	68	16	gammopathy	gammopathy	ADJ
dpc-5683	68	17	of	of	ADP
dpc-5683	68	18	table	table	NOUN
dpc-5683	68	19	1	1	NUM
dpc-5683	68	20	.	.	PUNCT
dpc-5683	69	1	average	average	ADJ
dpc-5683	69	2	survival	survival	NOUN
dpc-5683	69	3	to	to	ADP
dpc-5683	69	4	progression	progression	NOUN
dpc-5683	69	5	according	accord	VERB
dpc-5683	69	6	to	to	ADP
dpc-5683	69	7	the	the	DET
dpc-5683	69	8	specific	specific	ADJ
dpc-5683	69	9	form	form	NOUN
dpc-5683	69	10	of	of	ADP
dpc-5683	69	11	mf	mf	NOUN
dpc-5683	69	12	or	or	CCONJ
dpc-5683	69	13	ss	ss	NOUN
dpc-5683	69	14	.	.	PUNCT
dpc-5683	70	1	patients	patient	NOUN
dpc-5683	70	2	with	with	ADP
dpc-5683	70	3	specific	specific	ADJ
dpc-5683	70	4	form	form	NOUN
dpc-5683	70	5	of	of	ADP
dpc-5683	70	6	mf	mf	NOUN
dpc-5683	70	7	or	or	CCONJ
dpc-5683	70	8	ss	ss	PROPN
dpc-5683	70	9	had	have	VERB
dpc-5683	70	10	a	a	DET
dpc-5683	70	11	significantly	significantly	ADV
dpc-5683	70	12	shorter	short	ADJ
dpc-5683	70	13	survival	survival	NOUN
dpc-5683	70	14	to	to	ADP
dpc-5683	70	15	progression	progression	NOUN
dpc-5683	70	16	(	(	PUNCT
dpc-5683	70	17	p<0.001	p<0.001	PROPN
dpc-5683	70	18	)	)	PUNCT
dpc-5683	70	19	.	.	PUNCT
dpc-5683	71	1	variant	variant	NOUN
dpc-5683	71	2	of	of	ADP
dpc-5683	71	3	mf	mf	NOUN
dpc-5683	71	4	or	or	CCONJ
dpc-5683	71	5	ss	ss	PRON
dpc-5683	71	6	median	median	ADJ
dpc-5683	71	7	survival	survival	NOUN
dpc-5683	71	8	to	to	ADP
dpc-5683	71	9	progression	progression	NOUN
dpc-5683	71	10	time	time	NOUN
dpc-5683	71	11	(	(	PUNCT
dpc-5683	71	12	months	month	NOUN
dpc-5683	71	13	)	)	PUNCT
dpc-5683	71	14	standard	standard	ADJ
dpc-5683	71	15	error	error	NOUN
dpc-5683	71	16	95	95	NUM
dpc-5683	71	17	%	%	NOUN
dpc-5683	71	18	ci	ci	NOUN
dpc-5683	71	19	lower	low	ADJ
dpc-5683	71	20	upper	upper	ADJ
dpc-5683	72	1	no	no	PRON
dpc-5683	72	2	47.81	47.81	NUM
dpc-5683	72	3	2.25	2.25	NUM
dpc-5683	72	4	43.40	43.40	NUM
dpc-5683	72	5	52.23	52.23	NUM
dpc-5683	73	1	yes	yes	INTJ
dpc-5683	73	2	7.46	7.46	NUM
dpc-5683	73	3	1.39	1.39	NUM
dpc-5683	73	4	4.74	4.74	NUM
dpc-5683	73	5	10.18	10.18	NUM
dpc-5683	73	6	total	total	NOUN
dpc-5683	73	7	34.09	34.09	NUM
dpc-5683	73	8	3.89	3.89	NUM
dpc-5683	73	9	26.47	26.47	NUM
dpc-5683	73	10	41.71	41.71	NUM
dpc-5683	73	11	table	table	NOUN
dpc-5683	73	12	2	2	NUM
dpc-5683	73	13	.	.	PUNCT
dpc-5683	73	14	type	type	NOUN
dpc-5683	73	15	of	of	ADP
dpc-5683	73	16	second	second	ADJ
dpc-5683	73	17	primary	primary	ADJ
dpc-5683	73	18	malignancy	malignancy	NOUN
dpc-5683	73	19	.	.	PUNCT
dpc-5683	74	1	second	second	ADJ
dpc-5683	74	2	primary	primary	ADJ
dpc-5683	74	3	malignancy	malignancy	NOUN
dpc-5683	74	4	n=16	n=16	NOUN
dpc-5683	74	5	(	(	PUNCT
dpc-5683	74	6	19	19	NUM
dpc-5683	74	7	%	%	NOUN
dpc-5683	74	8	)	)	PUNCT
dpc-5683	74	9	hematologic	hematologic	NOUN
dpc-5683	74	10	neoplasms	neoplasm	NOUN
dpc-5683	74	11	chronic	chronic	VERB
dpc-5683	74	12	lymphatic	lymphatic	ADJ
dpc-5683	74	13	leukemia	leukemia	NOUN
dpc-5683	74	14	(	(	PUNCT
dpc-5683	74	15	n=2	n=2	NOUN
dpc-5683	74	16	)	)	PUNCT
dpc-5683	74	17	hodgkin	hodgkin	PROPN
dpc-5683	74	18	lymphoma	lymphoma	PROPN
dpc-5683	74	19	b	b	NOUN
dpc-5683	74	20	-	-	PUNCT
dpc-5683	74	21	cell	cell	NOUN
dpc-5683	74	22	large	large	ADJ
dpc-5683	74	23	cell	cell	NOUN
dpc-5683	74	24	nhl	nhl	PROPN
dpc-5683	74	25	tonsillar	tonsillar	PROPN
dpc-5683	74	26	nhl	nhl	PROPN
dpc-5683	74	27	monoclonal	monoclonal	NOUN
dpc-5683	74	28	gammopathy	gammopathy	ADJ
dpc-5683	74	29	mgus	mgus	ADJ
dpc-5683	74	30	(	(	PUNCT
dpc-5683	74	31	monoclonal	monoclonal	NOUN
dpc-5683	74	32	gammopathy	gammopathy	ADJ
dpc-5683	74	33	of	of	ADP
dpc-5683	74	34	undetermined	undetermined	ADJ
dpc-5683	74	35	significance	significance	NOUN
dpc-5683	74	36	)	)	PUNCT
dpc-5683	74	37	smm	smm	NOUN
dpc-5683	74	38	(	(	PUNCT
dpc-5683	74	39	smoldering	smoldering	NOUN
dpc-5683	74	40	,	,	PUNCT
dpc-5683	74	41	multiple	multiple	ADJ
dpc-5683	74	42	myeloma	myeloma	NOUN
dpc-5683	74	43	)	)	PUNCT
dpc-5683	74	44	n=8	n=8	ADP
dpc-5683	74	45	(	(	PUNCT
dpc-5683	74	46	50	50	NUM
dpc-5683	74	47	%	%	NOUN
dpc-5683	74	48	)	)	PUNCT
dpc-5683	74	49	non	non	ADJ
dpc-5683	74	50	-	-	ADJ
dpc-5683	74	51	hematologic	hematologic	ADJ
dpc-5683	74	52	neoplasms	neoplasm	NOUN
dpc-5683	74	53	breast	breast	NOUN
dpc-5683	74	54	cancer	cancer	NOUN
dpc-5683	74	55	(	(	PUNCT
dpc-5683	74	56	n=5	n=5	ADJ
dpc-5683	74	57	)	)	PUNCT
dpc-5683	74	58	prostate	prostate	NOUN
dpc-5683	74	59	cancer	cancer	NOUN
dpc-5683	74	60	(	(	PUNCT
dpc-5683	74	61	n=2	n=2	NOUN
dpc-5683	74	62	)	)	PUNCT
dpc-5683	74	63	kidney	kidney	NOUN
dpc-5683	74	64	cancer	cancer	NOUN
dpc-5683	74	65	(	(	PUNCT
dpc-5683	74	66	n=2	n=2	NOUN
dpc-5683	74	67	)	)	PUNCT
dpc-5683	74	68	thyroid	thyroid	NOUN
dpc-5683	74	69	papillary	papillary	NOUN
dpc-5683	74	70	cancer	cancer	NOUN
dpc-5683	74	71	endometrial	endometrial	ADJ
dpc-5683	74	72	cancer	cancer	NOUN
dpc-5683	74	73	sublingual	sublingual	ADJ
dpc-5683	74	74	squamous	squamous	ADJ
dpc-5683	74	75	-	-	PUNCT
dpc-5683	74	76	cell	cell	NOUN
dpc-5683	74	77	cancer	cancer	NOUN
dpc-5683	74	78	lung	lung	NOUN
dpc-5683	74	79	cancer	cancer	NOUN
dpc-5683	74	80	n=8	n=8	PROPN
dpc-5683	74	81	(	(	PUNCT
dpc-5683	74	82	50	50	NUM
dpc-5683	74	83	%	%	NOUN
dpc-5683	74	84	)	)	PUNCT
dpc-5683	74	85	non	non	ADJ
dpc-5683	74	86	-	-	ADJ
dpc-5683	74	87	melanoma	melanoma	ADJ
dpc-5683	74	88	skin	skin	NOUN
dpc-5683	74	89	cancer	cancer	NOUN
dpc-5683	74	90	bcc	bcc	PROPN
dpc-5683	74	91	(	(	PUNCT
dpc-5683	74	92	n=4	n=4	NOUN
dpc-5683	74	93	)	)	PUNCT
dpc-5683	74	94	scc	scc	NOUN
dpc-5683	74	95	n=5	n=5	X
dpc-5683	74	96	(	(	PUNCT
dpc-5683	74	97	5.95	5.95	NUM
dpc-5683	74	98	%	%	NOUN
dpc-5683	74	99	)	)	PUNCT
dpc-5683	74	100	melanoma	melanoma	NOUN
dpc-5683	74	101	none	none	NOUN
dpc-5683	74	102	4	4	NUM
dpc-5683	74	103	original	original	ADJ
dpc-5683	74	104	article	article	NOUN
dpc-5683	74	105	|	|	ADV
dpc-5683	74	106	dermatol	dermatol	ADJ
dpc-5683	74	107	pract	pract	NOUN
dpc-5683	74	108	concept	concept	NOUN
dpc-5683	74	109	.	.	PUNCT
dpc-5683	75	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	75	2	primary	primary	ADJ
dpc-5683	75	3	cancer	cancer	NOUN
dpc-5683	75	4	,	,	PUNCT
dpc-5683	75	5	with	with	ADP
dpc-5683	75	6	an	an	DET
dpc-5683	75	7	average	average	ADJ
dpc-5683	75	8	time	time	NOUN
dpc-5683	75	9	of	of	ADP
dpc-5683	75	10	7.5	7.5	NUM
dpc-5683	75	11	years	year	NOUN
dpc-5683	75	12	between	between	ADP
dpc-5683	75	13	the	the	DET
dpc-5683	75	14	two	two	NUM
dpc-5683	75	15	diagnoses	diagnosis	NOUN
dpc-5683	75	16	(	(	PUNCT
dpc-5683	75	17	table	table	NOUN
dpc-5683	75	18	4	4	NUM
dpc-5683	75	19	)	)	PUNCT
dpc-5683	75	20	.	.	PUNCT
dpc-5683	76	1	discussion	discussion	NOUN
dpc-5683	76	2	our	our	PRON
dpc-5683	76	3	study	study	NOUN
dpc-5683	76	4	supports	support	VERB
dpc-5683	76	5	the	the	DET
dpc-5683	76	6	evidence	evidence	NOUN
dpc-5683	76	7	of	of	ADP
dpc-5683	76	8	an	an	DET
dpc-5683	76	9	increased	increase	VERB
dpc-5683	76	10	risk	risk	NOUN
dpc-5683	76	11	of	of	ADP
dpc-5683	76	12	second	second	ADJ
dpc-5683	76	13	primary	primary	ADJ
dpc-5683	76	14	malignancies	malignancy	NOUN
dpc-5683	76	15	in	in	ADP
dpc-5683	76	16	patients	patient	NOUN
dpc-5683	76	17	with	with	ADP
dpc-5683	76	18	mf	mf	NOUN
dpc-5683	76	19	.	.	PUNCT
dpc-5683	77	1	we	we	PRON
dpc-5683	77	2	examined	examine	VERB
dpc-5683	77	3	the	the	DET
dpc-5683	77	4	percentage	percentage	NOUN
dpc-5683	77	5	of	of	ADP
dpc-5683	77	6	patients	patient	NOUN
dpc-5683	77	7	who	who	PRON
dpc-5683	77	8	developed	develop	VERB
dpc-5683	77	9	a	a	DET
dpc-5683	77	10	second	second	ADJ
dpc-5683	77	11	primary	primary	ADJ
dpc-5683	77	12	malignancy	malignancy	NOUN
dpc-5683	77	13	,	,	PUNCT
dpc-5683	77	14	considering	consider	VERB
dpc-5683	77	15	that	that	SCONJ
dpc-5683	77	16	previous	previous	ADJ
dpc-5683	77	17	literature	literature	NOUN
dpc-5683	77	18	has	have	AUX
dpc-5683	77	19	reported	report	VERB
dpc-5683	77	20	an	an	DET
dpc-5683	77	21	increased	increase	VERB
dpc-5683	77	22	incidence	incidence	NOUN
dpc-5683	77	23	of	of	ADP
dpc-5683	77	24	a	a	DET
dpc-5683	77	25	second	second	ADJ
dpc-5683	77	26	primary	primary	ADJ
dpc-5683	77	27	malignancy	malignancy	NOUN
dpc-5683	77	28	in	in	ADP
dpc-5683	77	29	patients	patient	NOUN
dpc-5683	77	30	with	with	ADP
dpc-5683	77	31	ctcl	ctcl	NOUN
dpc-5683	77	32	[	[	X
dpc-5683	77	33	2	2	NUM
dpc-5683	77	34	-	-	NUM
dpc-5683	77	35	8,10	8,10	NUM
dpc-5683	77	36	-	-	NUM
dpc-5683	77	37	13	13	NUM
dpc-5683	77	38	]	]	PUNCT
dpc-5683	77	39	.	.	PUNCT
dpc-5683	78	1	in	in	ADP
dpc-5683	78	2	our	our	PRON
dpc-5683	78	3	cohort	cohort	NOUN
dpc-5683	78	4	of	of	ADP
dpc-5683	78	5	84	84	NUM
dpc-5683	78	6	patients	patient	NOUN
dpc-5683	78	7	19	19	NUM
dpc-5683	78	8	%	%	NOUN
dpc-5683	78	9	(	(	PUNCT
dpc-5683	78	10	n=16	n=16	NOUN
dpc-5683	78	11	)	)	PUNCT
dpc-5683	78	12	developed	develop	VERB
dpc-5683	78	13	another	another	DET
dpc-5683	78	14	primary	primary	ADJ
dpc-5683	78	15	malignant	malignant	ADJ
dpc-5683	78	16	disease	disease	NOUN
dpc-5683	78	17	.	.	PUNCT
dpc-5683	79	1	among	among	ADP
dpc-5683	79	2	these	these	DET
dpc-5683	79	3	second	second	ADJ
dpc-5683	79	4	primary	primary	ADJ
dpc-5683	79	5	malignancies	malignancy	NOUN
dpc-5683	79	6	,	,	PUNCT
dpc-5683	79	7	hematological	hematological	ADJ
dpc-5683	79	8	neoplasm	neoplasm	NOUN
dpc-5683	79	9	were	be	AUX
dpc-5683	79	10	the	the	DET
dpc-5683	79	11	most	most	ADV
dpc-5683	79	12	frequent	frequent	ADJ
dpc-5683	79	13	,	,	PUNCT
dpc-5683	79	14	occurring	occur	VERB
dpc-5683	79	15	in	in	ADP
dpc-5683	79	16	50	50	NUM
dpc-5683	79	17	%	%	NOUN
dpc-5683	79	18	(	(	PUNCT
dpc-5683	79	19	n=8	n=8	NUM
dpc-5683	79	20	)	)	PUNCT
dpc-5683	79	21	of	of	ADP
dpc-5683	79	22	patients	patient	NOUN
dpc-5683	79	23	,	,	PUNCT
dpc-5683	79	24	which	which	PRON
dpc-5683	79	25	is	be	AUX
dpc-5683	79	26	in	in	ADP
dpc-5683	79	27	concordance	concordance	NOUN
dpc-5683	79	28	to	to	ADP
dpc-5683	79	29	previous	previous	ADJ
dpc-5683	79	30	undetermined	undetermined	ADJ
dpc-5683	79	31	significance	significance	NOUN
dpc-5683	79	32	(	(	PUNCT
dpc-5683	79	33	mgus	mgus	ADJ
dpc-5683	79	34	)	)	PUNCT
dpc-5683	79	35	.	.	PUNCT
dpc-5683	80	1	the	the	DET
dpc-5683	80	2	only	only	ADJ
dpc-5683	80	3	male	male	ADJ
dpc-5683	80	4	subject	subject	NOUN
dpc-5683	80	5	in	in	ADP
dpc-5683	80	6	this	this	DET
dpc-5683	80	7	subgroup	subgroup	NOUN
dpc-5683	80	8	,	,	PUNCT
dpc-5683	80	9	in	in	ADP
dpc-5683	80	10	addition	addition	NOUN
dpc-5683	80	11	to	to	ADP
dpc-5683	80	12	mf	mf	X
dpc-5683	80	13	,	,	PUNCT
dpc-5683	80	14	had	have	VERB
dpc-5683	80	15	chronic	chronic	ADJ
dpc-5683	80	16	lymphocytic	lymphocytic	ADJ
dpc-5683	80	17	leukemia	leukemia	NOUN
dpc-5683	80	18	(	(	PUNCT
dpc-5683	80	19	cll	cll	PROPN
dpc-5683	80	20	)	)	PUNCT
dpc-5683	80	21	and	and	CCONJ
dpc-5683	80	22	kidney	kidney	NOUN
dpc-5683	80	23	cancer	cancer	NOUN
dpc-5683	80	24	.	.	PUNCT
dpc-5683	81	1	of	of	ADP
dpc-5683	81	2	these	these	DET
dpc-5683	81	3	16	16	NUM
dpc-5683	81	4	patients	patient	NOUN
dpc-5683	81	5	who	who	PRON
dpc-5683	81	6	developed	develop	VERB
dpc-5683	81	7	a	a	DET
dpc-5683	81	8	second	second	ADJ
dpc-5683	81	9	primary	primary	ADJ
dpc-5683	81	10	malignancy	malignancy	NOUN
dpc-5683	81	11	,	,	PUNCT
dpc-5683	81	12	seven	seven	NUM
dpc-5683	81	13	(	(	PUNCT
dpc-5683	81	14	43.75	43.75	NUM
dpc-5683	81	15	%	%	NOUN
dpc-5683	81	16	)	)	PUNCT
dpc-5683	81	17	had	have	VERB
dpc-5683	81	18	an	an	DET
dpc-5683	81	19	mf	mf	NOUN
dpc-5683	81	20	variant	variant	NOUN
dpc-5683	81	21	.	.	PUNCT
dpc-5683	82	1	among	among	ADP
dpc-5683	82	2	these	these	DET
dpc-5683	82	3	seven	seven	NUM
dpc-5683	82	4	patients	patient	NOUN
dpc-5683	82	5	,	,	PUNCT
dpc-5683	82	6	five	five	NUM
dpc-5683	82	7	(	(	PUNCT
dpc-5683	82	8	31.25	31.25	NUM
dpc-5683	82	9	%	%	NOUN
dpc-5683	82	10	)	)	PUNCT
dpc-5683	82	11	experienced	experienced	ADJ
dpc-5683	82	12	disease	disease	NOUN
dpc-5683	82	13	progression	progression	NOUN
dpc-5683	82	14	,	,	PUNCT
dpc-5683	82	15	although	although	SCONJ
dpc-5683	82	16	these	these	DET
dpc-5683	82	17	findings	finding	NOUN
dpc-5683	82	18	were	be	AUX
dpc-5683	82	19	not	not	PART
dpc-5683	82	20	statistically	statistically	ADV
dpc-5683	82	21	significant	significant	ADJ
dpc-5683	82	22	(	(	PUNCT
dpc-5683	82	23	table	table	NOUN
dpc-5683	82	24	3	3	NUM
dpc-5683	82	25	)	)	PUNCT
dpc-5683	82	26	.	.	PUNCT
dpc-5683	83	1	in	in	ADP
dpc-5683	83	2	the	the	DET
dpc-5683	83	3	group	group	NOUN
dpc-5683	83	4	of	of	ADP
dpc-5683	83	5	patients	patient	NOUN
dpc-5683	83	6	who	who	PRON
dpc-5683	83	7	developed	develop	VERB
dpc-5683	83	8	second	second	ADJ
dpc-5683	83	9	primary	primary	ADJ
dpc-5683	83	10	malignancy	malignancy	NOUN
dpc-5683	83	11	,	,	PUNCT
dpc-5683	83	12	the	the	DET
dpc-5683	83	13	distribution	distribution	NOUN
dpc-5683	83	14	by	by	ADP
dpc-5683	83	15	sex	sex	NOUN
dpc-5683	83	16	was	be	AUX
dpc-5683	83	17	the	the	DET
dpc-5683	83	18	same	same	ADJ
dpc-5683	83	19	:	:	PUNCT
dpc-5683	83	20	50	50	NUM
dpc-5683	83	21	%	%	NOUN
dpc-5683	83	22	were	be	AUX
dpc-5683	83	23	female	female	ADJ
dpc-5683	83	24	(	(	PUNCT
dpc-5683	83	25	n=8	n=8	NUM
dpc-5683	83	26	)	)	PUNCT
dpc-5683	83	27	and	and	CCONJ
dpc-5683	83	28	50	50	NUM
dpc-5683	83	29	%	%	NOUN
dpc-5683	83	30	were	be	AUX
dpc-5683	83	31	male	male	ADJ
dpc-5683	83	32	(	(	PUNCT
dpc-5683	83	33	n=8	n=8	NUM
dpc-5683	83	34	)	)	PUNCT
dpc-5683	83	35	.	.	PUNCT
dpc-5683	84	1	the	the	DET
dpc-5683	84	2	median	median	ADJ
dpc-5683	84	3	age	age	NOUN
dpc-5683	84	4	at	at	ADP
dpc-5683	84	5	onset	onset	NOUN
dpc-5683	84	6	of	of	ADP
dpc-5683	84	7	ctcl	ctcl	NOUN
dpc-5683	84	8	was	be	AUX
dpc-5683	84	9	53.0	53.0	NUM
dpc-5683	84	10	years	year	NOUN
dpc-5683	84	11	(	(	PUNCT
dpc-5683	84	12	interquartile	interquartile	NOUN
dpc-5683	84	13	range	range	NOUN
dpc-5683	84	14	,	,	PUNCT
dpc-5683	84	15	40.5–62.8	40.5–62.8	DET
dpc-5683	84	16	years	year	NOUN
dpc-5683	84	17	)	)	PUNCT
dpc-5683	84	18	,	,	PUNCT
dpc-5683	84	19	and	and	CCONJ
dpc-5683	84	20	the	the	DET
dpc-5683	84	21	median	median	ADJ
dpc-5683	84	22	time	time	NOUN
dpc-5683	84	23	to	to	ADP
dpc-5683	84	24	diagnosis	diagnosis	NOUN
dpc-5683	84	25	was	be	AUX
dpc-5683	84	26	3.0	3.0	NUM
dpc-5683	84	27	years	year	NOUN
dpc-5683	84	28	(	(	PUNCT
dpc-5683	84	29	interquartile	interquartile	NOUN
dpc-5683	84	30	range	range	NOUN
dpc-5683	84	31	,	,	PUNCT
dpc-5683	84	32	1.0	1.0	NUM
dpc-5683	84	33	-	-	SYM
dpc-5683	84	34	10.0	10.0	NUM
dpc-5683	84	35	years	year	NOUN
dpc-5683	84	36	)	)	PUNCT
dpc-5683	84	37	.	.	PUNCT
dpc-5683	85	1	the	the	DET
dpc-5683	85	2	median	median	ADJ
dpc-5683	85	3	age	age	NOUN
dpc-5683	85	4	at	at	ADP
dpc-5683	85	5	diagnosis	diagnosis	NOUN
dpc-5683	85	6	of	of	ADP
dpc-5683	85	7	the	the	DET
dpc-5683	85	8	second	second	ADJ
dpc-5683	85	9	malignancy	malignancy	NOUN
dpc-5683	85	10	was	be	AUX
dpc-5683	85	11	60.5	60.5	NUM
dpc-5683	85	12	years	year	NOUN
dpc-5683	85	13	.	.	PUNCT
dpc-5683	86	1	in	in	ADP
dpc-5683	86	2	this	this	DET
dpc-5683	86	3	cohort	cohort	NOUN
dpc-5683	86	4	,	,	PUNCT
dpc-5683	86	5	ctcl	ctcl	NOUN
dpc-5683	86	6	preceded	precede	VERB
dpc-5683	86	7	the	the	DET
dpc-5683	86	8	appearance	appearance	NOUN
dpc-5683	86	9	of	of	ADP
dpc-5683	86	10	the	the	DET
dpc-5683	86	11	second	second	ADJ
dpc-5683	86	12	table	table	NOUN
dpc-5683	86	13	3	3	NUM
dpc-5683	86	14	.	.	PUNCT
dpc-5683	86	15	differences	difference	NOUN
dpc-5683	86	16	in	in	ADP
dpc-5683	86	17	categorical	categorical	ADJ
dpc-5683	86	18	clinical	clinical	ADJ
dpc-5683	86	19	indicators	indicator	NOUN
dpc-5683	86	20	in	in	ADP
dpc-5683	86	21	relation	relation	NOUN
dpc-5683	86	22	to	to	ADP
dpc-5683	86	23	the	the	DET
dpc-5683	86	24	specificity	specificity	NOUN
dpc-5683	86	25	of	of	ADP
dpc-5683	86	26	the	the	DET
dpc-5683	86	27	disease	disease	NOUN
dpc-5683	86	28	.	.	PUNCT
dpc-5683	87	1	mf	mf	NOUN
dpc-5683	87	2	variant	variant	NOUN
dpc-5683	87	3	or	or	CCONJ
dpc-5683	87	4	ss	ss	PRON
dpc-5683	87	5	p	p	NOUN
dpc-5683	87	6	-	-	PUNCT
dpc-5683	87	7	value	value	NOUN
dpc-5683	88	1	no	no	INTJ
dpc-5683	88	2	yes	yes	INTJ
dpc-5683	88	3	n=55	n=55	ADV
dpc-5683	88	4	n=28	n=28	PROPN
dpc-5683	88	5	n	n	PRON
dpc-5683	88	6	%	%	NOUN
dpc-5683	88	7	n	n	PRON
dpc-5683	88	8	%	%	NOUN
dpc-5683	88	9	sex	sex	NOUN
dpc-5683	88	10	male	male	NOUN
dpc-5683	88	11	34	34	NUM
dpc-5683	88	12	61.80	61.80	NUM
dpc-5683	88	13	%	%	NOUN
dpc-5683	88	14	16	16	NUM
dpc-5683	88	15	55.20	55.20	NUM
dpc-5683	88	16	%	%	NOUN
dpc-5683	88	17	0.642	0.642	NUM
dpc-5683	88	18	female	female	ADJ
dpc-5683	88	19	22	22	NUM
dpc-5683	88	20	38.20	38.20	NUM
dpc-5683	88	21	%	%	NOUN
dpc-5683	88	22	12	12	NUM
dpc-5683	88	23	44.80	44.80	NUM
dpc-5683	88	24	%	%	NOUN
dpc-5683	88	25	stage	stage	NOUN
dpc-5683	88	26	*	*	PUNCT
dpc-5683	88	27	ia	ia	PROPN
dpc-5683	88	28	ib	ib	NOUN
dpc-5683	88	29	18	18	NUM
dpc-5683	88	30	25	25	NUM
dpc-5683	88	31	21.40	21.40	NUM
dpc-5683	88	32	%	%	NOUN
dpc-5683	88	33	29.8	29.8	NUM
dpc-5683	88	34	%	%	NOUN
dpc-5683	88	35	0	0	NUM
dpc-5683	88	36	5	5	NUM
dpc-5683	88	37	0.00	0.00	NUM
dpc-5683	88	38	%	%	NOUN
dpc-5683	88	39	5.96	5.96	NUM
dpc-5683	88	40	%	%	NOUN
dpc-5683	88	41	<	<	X
dpc-5683	88	42	0.001	0.001	NUM
dpc-5683	88	43	iia	iia	PROPN
dpc-5683	88	44	iib	iib	NOUN
dpc-5683	88	45	2	2	NUM
dpc-5683	88	46	6	6	NUM
dpc-5683	88	47	2.40	2.40	NUM
dpc-5683	88	48	%	%	NOUN
dpc-5683	88	49	7.14	7.14	NUM
dpc-5683	88	50	%	%	NOUN
dpc-5683	88	51	1	1	NUM
dpc-5683	88	52	12	12	NUM
dpc-5683	88	53	1.19	1.19	NUM
dpc-5683	88	54	%	%	NOUN
dpc-5683	88	55	14.29	14.29	NUM
dpc-5683	88	56	%	%	NOUN
dpc-5683	88	57	iiia	iiia	PROPN
dpc-5683	88	58	iiib	iiib	NOUN
dpc-5683	88	59	0	0	NUM
dpc-5683	88	60	0	0	NUM
dpc-5683	88	61	0.00	0.00	NUM
dpc-5683	88	62	%	%	NOUN
dpc-5683	88	63	0.00	0.00	NUM
dpc-5683	88	64	%	%	NOUN
dpc-5683	88	65	4	4	NUM
dpc-5683	88	66	1	1	NUM
dpc-5683	88	67	14.80	14.80	NUM
dpc-5683	88	68	%	%	NOUN
dpc-5683	88	69	1.19	1.19	NUM
dpc-5683	88	70	%	%	NOUN
dpc-5683	88	71	iva	iva	NOUN
dpc-5683	88	72	ivb	ivb	NOUN
dpc-5683	88	73	1	1	NUM
dpc-5683	88	74	0	0	NUM
dpc-5683	88	75	1.19	1.19	NUM
dpc-5683	88	76	%	%	NOUN
dpc-5683	88	77	0.00	0.00	NUM
dpc-5683	88	78	%	%	NOUN
dpc-5683	88	79	5	5	NUM
dpc-5683	88	80	0	0	NUM
dpc-5683	88	81	18.50	18.50	NUM
dpc-5683	88	82	%	%	NOUN
dpc-5683	88	83	0.00	0.00	NUM
dpc-5683	88	84	%	%	NOUN
dpc-5683	88	85	second	second	ADJ
dpc-5683	88	86	primary	primary	ADJ
dpc-5683	88	87	malignancy	malignancy	NOUN
dpc-5683	89	1	no	no	DET
dpc-5683	89	2	47	47	NUM
dpc-5683	89	3	83.93	83.93	NUM
dpc-5683	89	4	%	%	NOUN
dpc-5683	89	5	21	21	NUM
dpc-5683	89	6	75.0	75.0	NUM
dpc-5683	89	7	%	%	NOUN
dpc-5683	89	8	0.158	0.158	NUM
dpc-5683	89	9	yes	yes	NOUN
dpc-5683	89	10	9	9	NUM
dpc-5683	89	11	16.07	16.07	NUM
dpc-5683	89	12	%	%	NOUN
dpc-5683	89	13	7	7	NUM
dpc-5683	89	14	25.0	25.0	NUM
dpc-5683	89	15	%	%	NOUN
dpc-5683	89	16	hematological	hematological	ADJ
dpc-5683	89	17	neoplasms	neoplasm	NOUN
dpc-5683	89	18	no	no	DET
dpc-5683	89	19	52	52	NUM
dpc-5683	89	20	92.86	92.86	NUM
dpc-5683	89	21	%	%	NOUN
dpc-5683	89	22	24	24	NUM
dpc-5683	89	23	85.7	85.7	NUM
dpc-5683	89	24	%	%	NOUN
dpc-5683	89	25	0.118	0.118	NUM
dpc-5683	89	26	yes	yes	INTJ
dpc-5683	89	27	4	4	NUM
dpc-5683	89	28	7.14	7.14	NUM
dpc-5683	89	29	%	%	NOUN
dpc-5683	89	30	4	4	NUM
dpc-5683	89	31	14.3	14.3	NUM
dpc-5683	89	32	%	%	NOUN
dpc-5683	89	33	breast	breast	NOUN
dpc-5683	89	34	cancer	cancer	NOUN
dpc-5683	89	35	no	no	DET
dpc-5683	89	36	52	52	NUM
dpc-5683	89	37	94.5	94.5	NUM
dpc-5683	89	38	%	%	NOUN
dpc-5683	89	39	27	27	NUM
dpc-5683	89	40	93.1	93.1	NUM
dpc-5683	89	41	%	%	NOUN
dpc-5683	89	42	1.000	1.000	NUM
dpc-5683	89	43	yes	yes	NOUN
dpc-5683	89	44	3	3	NUM
dpc-5683	89	45	5.5	5.5	NUM
dpc-5683	89	46	%	%	NOUN
dpc-5683	89	47	2	2	NUM
dpc-5683	89	48	6.9	6.9	NUM
dpc-5683	89	49	%	%	NOUN
dpc-5683	89	50	other	other	ADJ
dpc-5683	89	51	non	non	ADJ
dpc-5683	89	52	-	-	ADJ
dpc-5683	89	53	hematological	hematological	ADJ
dpc-5683	89	54	malignancies	malignancy	NOUN
dpc-5683	89	55	no	no	DET
dpc-5683	89	56	48	48	NUM
dpc-5683	89	57	87.3	87.3	NUM
dpc-5683	89	58	%	%	NOUN
dpc-5683	89	59	28	28	NUM
dpc-5683	89	60	96.6	96.6	NUM
dpc-5683	89	61	%	%	NOUN
dpc-5683	89	62	0.253	0.253	NUM
dpc-5683	90	1	yes	yes	INTJ
dpc-5683	90	2	7	7	NUM
dpc-5683	90	3	12.7	12.7	NUM
dpc-5683	90	4	%	%	NOUN
dpc-5683	90	5	1	1	NUM
dpc-5683	90	6	3.4	3.4	NUM
dpc-5683	90	7	%	%	NOUN
dpc-5683	90	8	folliculotropic	folliculotropic	ADJ
dpc-5683	90	9	mf	mf	NOUN
dpc-5683	90	10	no	no	DET
dpc-5683	90	11	55	55	NUM
dpc-5683	90	12	100.0	100.0	NUM
dpc-5683	90	13	%	%	NOUN
dpc-5683	90	14	23	23	NUM
dpc-5683	90	15	79.3	79.3	NUM
dpc-5683	90	16	%	%	NOUN
dpc-5683	90	17	0.001	0.001	NUM
dpc-5683	90	18	yes	yes	NOUN
dpc-5683	90	19	0	0	NUM
dpc-5683	90	20	0.0	0.0	NUM
dpc-5683	90	21	%	%	NOUN
dpc-5683	90	22	6	6	NUM
dpc-5683	90	23	20.7	20.7	NUM
dpc-5683	90	24	%	%	NOUN
dpc-5683	90	25	table	table	NOUN
dpc-5683	90	26	4	4	NUM
dpc-5683	90	27	.	.	PUNCT
dpc-5683	91	1	descriptive	descriptive	ADJ
dpc-5683	91	2	statistics	statistic	NOUN
dpc-5683	91	3	of	of	ADP
dpc-5683	91	4	sociodemographic	sociodemographic	ADJ
dpc-5683	91	5	values	value	NOUN
dpc-5683	91	6	.	.	PUNCT
dpc-5683	91	7	  	  	SPACE
dpc-5683	92	1	n	n	PRON
dpc-5683	92	2	min	min	NOUN
dpc-5683	92	3	max	max	PROPN
dpc-5683	92	4	centile	centile	VERB
dpc-5683	92	5	25	25	NUM
dpc-5683	92	6	.	.	PUNCT
dpc-5683	93	1	median	median	PROPN
dpc-5683	93	2	75	75	NUM
dpc-5683	93	3	.	.	PUNCT
dpc-5683	94	1	the	the	DET
dpc-5683	94	2	median	median	ADJ
dpc-5683	94	3	age	age	NOUN
dpc-5683	94	4	at	at	ADP
dpc-5683	94	5	the	the	DET
dpc-5683	94	6	onset	onset	NOUN
dpc-5683	94	7	of	of	ADP
dpc-5683	94	8	disease	disease	NOUN
dpc-5683	94	9	80	80	NUM
dpc-5683	94	10	8.00	8.00	NUM
dpc-5683	94	11	83.00	83.00	NUM
dpc-5683	94	12	40.50	40.50	NUM
dpc-5683	94	13	53.00	53.00	NUM
dpc-5683	94	14	62.75	62.75	NUM
dpc-5683	94	15	median	median	ADJ
dpc-5683	94	16	time	time	NOUN
dpc-5683	94	17	to	to	PART
dpc-5683	94	18	diagnosis	diagnosis	VERB
dpc-5683	94	19	ctcl	ctcl	NOUN
dpc-5683	94	20	71	71	NUM
dpc-5683	94	21	1.00	1.00	NUM
dpc-5683	94	22	51.00	51.00	NUM
dpc-5683	94	23	1.00	1.00	NUM
dpc-5683	94	24	3.00	3.00	NUM
dpc-5683	94	25	10.00	10.00	NUM
dpc-5683	94	26	the	the	DET
dpc-5683	94	27	median	median	ADJ
dpc-5683	94	28	age	age	NOUN
dpc-5683	94	29	at	at	ADP
dpc-5683	94	30	the	the	DET
dpc-5683	94	31	second	second	ADJ
dpc-5683	94	32	primary	primary	ADJ
dpc-5683	94	33	malignancy	malignancy	NOUN
dpc-5683	94	34	16	16	NUM
dpc-5683	94	35	34.00	34.00	NUM
dpc-5683	94	36	82.00	82.00	NUM
dpc-5683	94	37	52.25	52.25	NUM
dpc-5683	94	38	60.50	60.50	NUM
dpc-5683	94	39	70.50	70.50	NUM
dpc-5683	94	40	original	original	ADJ
dpc-5683	94	41	article	article	NOUN
dpc-5683	94	42	|	|	ADV
dpc-5683	94	43	dermatol	dermatol	ADJ
dpc-5683	94	44	pract	pract	NOUN
dpc-5683	94	45	concept	concept	NOUN
dpc-5683	94	46	.	.	PUNCT
dpc-5683	95	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	95	2	5	5	NUM
dpc-5683	95	3	therapy	therapy	NOUN
dpc-5683	95	4	.	.	PUNCT
dpc-5683	96	1	we	we	PRON
dpc-5683	96	2	also	also	ADV
dpc-5683	96	3	considered	consider	VERB
dpc-5683	96	4	an	an	DET
dpc-5683	96	5	mf	mf	NOUN
dpc-5683	96	6	variant	variant	NOUN
dpc-5683	96	7	as	as	ADP
dpc-5683	96	8	a	a	DET
dpc-5683	96	9	potential	potential	ADJ
dpc-5683	96	10	risk	risk	NOUN
dpc-5683	96	11	factor	factor	NOUN
dpc-5683	96	12	for	for	ADP
dpc-5683	96	13	developing	develop	VERB
dpc-5683	96	14	second	second	ADJ
dpc-5683	96	15	primary	primary	ADJ
dpc-5683	96	16	malignancies	malignancy	NOUN
dpc-5683	96	17	.	.	PUNCT
dpc-5683	97	1	although	although	SCONJ
dpc-5683	97	2	statistical	statistical	ADJ
dpc-5683	97	3	significance	significance	NOUN
dpc-5683	97	4	was	be	AUX
dpc-5683	97	5	not	not	PART
dpc-5683	97	6	reached	reach	VERB
dpc-5683	97	7	,	,	PUNCT
dpc-5683	97	8	43.75	43.75	NUM
dpc-5683	97	9	%	%	NOUN
dpc-5683	97	10	(	(	PUNCT
dpc-5683	97	11	7/16	7/16	NUM
dpc-5683	97	12	)	)	PUNCT
dpc-5683	97	13	patients	patient	NOUN
dpc-5683	97	14	who	who	PRON
dpc-5683	97	15	developed	develop	VERB
dpc-5683	97	16	another	another	DET
dpc-5683	97	17	malignancy	malignancy	NOUN
dpc-5683	97	18	had	have	VERB
dpc-5683	97	19	mf	mf	NOUN
dpc-5683	97	20	variant	variant	NOUN
dpc-5683	97	21	or	or	CCONJ
dpc-5683	97	22	ss	ss	NOUN
dpc-5683	97	23	.	.	PUNCT
dpc-5683	98	1	in	in	ADP
dpc-5683	98	2	our	our	PRON
dpc-5683	98	3	study	study	NOUN
dpc-5683	98	4	group	group	NOUN
dpc-5683	98	5	,	,	PUNCT
dpc-5683	98	6	patients	patient	NOUN
dpc-5683	98	7	with	with	ADP
dpc-5683	98	8	fmf	fmf	PROPN
dpc-5683	98	9	more	more	ADV
dpc-5683	98	10	often	often	ADV
dpc-5683	98	11	had	have	VERB
dpc-5683	98	12	disease	disease	NOUN
dpc-5683	98	13	progression	progression	NOUN
dpc-5683	98	14	,	,	PUNCT
dpc-5683	98	15	consistent	consistent	ADJ
dpc-5683	98	16	with	with	ADP
dpc-5683	98	17	the	the	DET
dpc-5683	98	18	findings	finding	NOUN
dpc-5683	98	19	of	of	ADP
dpc-5683	98	20	agar	agar	NOUN
dpc-5683	98	21	et	et	PROPN
dpc-5683	98	22	al	al	PROPN
dpc-5683	98	23	.	.	PUNCT
dpc-5683	99	1	[	[	X
dpc-5683	99	2	16	16	NUM
dpc-5683	99	3	]	]	PUNCT
dpc-5683	99	4	.	.	PUNCT
dpc-5683	100	1	their	their	PRON
dpc-5683	100	2	study	study	NOUN
dpc-5683	100	3	demonstrated	demonstrate	VERB
dpc-5683	100	4	that	that	SCONJ
dpc-5683	100	5	fmf	fmf	PROPN
dpc-5683	100	6	is	be	AUX
dpc-5683	100	7	associated	associate	VERB
dpc-5683	100	8	with	with	ADP
dpc-5683	100	9	an	an	DET
dpc-5683	100	10	increased	increase	VERB
dpc-5683	100	11	risk	risk	NOUN
dpc-5683	100	12	of	of	ADP
dpc-5683	100	13	disease	disease	NOUN
dpc-5683	100	14	progression	progression	NOUN
dpc-5683	100	15	,	,	PUNCT
dpc-5683	100	16	and	and	CCONJ
dpc-5683	100	17	multivariate	multivariate	VERB
dpc-5683	100	18	analysis	analysis	NOUN
dpc-5683	100	19	identified	identify	VERB
dpc-5683	100	20	advanced	advanced	ADJ
dpc-5683	100	21	skin	skin	NOUN
dpc-5683	100	22	stage	stage	NOUN
dpc-5683	100	23	(	(	PUNCT
dpc-5683	100	24	t	t	PROPN
dpc-5683	100	25	)	)	PUNCT
dpc-5683	100	26	,	,	PUNCT
dpc-5683	100	27	the	the	DET
dpc-5683	100	28	presence	presence	NOUN
dpc-5683	100	29	of	of	ADP
dpc-5683	100	30	tumor	tumor	NOUN
dpc-5683	100	31	clone	clone	NOUN
dpc-5683	100	32	without	without	ADP
dpc-5683	100	33	sézary	sézary	ADJ
dpc-5683	100	34	cells	cell	NOUN
dpc-5683	100	35	in	in	ADP
dpc-5683	100	36	peripheral	peripheral	ADJ
dpc-5683	100	37	blood	blood	NOUN
dpc-5683	100	38	(	(	PUNCT
dpc-5683	100	39	b0	b0	NOUN
dpc-5683	100	40	)	)	PUNCT
dpc-5683	100	41	,	,	PUNCT
dpc-5683	100	42	elevated	elevate	VERB
dpc-5683	100	43	ldh	ldh	PROPN
dpc-5683	100	44	levels	level	NOUN
dpc-5683	100	45	,	,	PUNCT
dpc-5683	100	46	and	and	CCONJ
dpc-5683	100	47	fmf	fmf	NOUN
dpc-5683	100	48	as	as	ADP
dpc-5683	100	49	independent	independent	ADJ
dpc-5683	100	50	predictors	predictor	NOUN
dpc-5683	100	51	of	of	ADP
dpc-5683	100	52	poor	poor	ADJ
dpc-5683	100	53	survival	survival	NOUN
dpc-5683	100	54	and	and	CCONJ
dpc-5683	100	55	increased	increase	VERB
dpc-5683	100	56	risk	risk	NOUN
dpc-5683	100	57	of	of	ADP
dpc-5683	100	58	disease	disease	NOUN
dpc-5683	100	59	progression	progression	NOUN
dpc-5683	100	60	.	.	PUNCT
dpc-5683	101	1	furthermore	furthermore	ADV
dpc-5683	101	2	,	,	PUNCT
dpc-5683	101	3	large	large	ADJ
dpc-5683	101	4	cell	cell	NOUN
dpc-5683	101	5	transformation	transformation	NOUN
dpc-5683	101	6	and	and	CCONJ
dpc-5683	101	7	tumor	tumor	NOUN
dpc-5683	101	8	distribution	distribution	NOUN
dpc-5683	101	9	were	be	AUX
dpc-5683	101	10	independent	independent	ADJ
dpc-5683	101	11	predictors	predictor	NOUN
dpc-5683	101	12	of	of	ADP
dpc-5683	101	13	disease	disease	NOUN
dpc-5683	101	14	progression	progression	NOUN
dpc-5683	101	15	[	[	X
dpc-5683	101	16	16	16	NUM
dpc-5683	101	17	]	]	PUNCT
dpc-5683	101	18	.	.	PUNCT
dpc-5683	102	1	conclusion	conclusion	NOUN
dpc-5683	102	2	we	we	PRON
dpc-5683	102	3	believe	believe	VERB
dpc-5683	102	4	that	that	SCONJ
dpc-5683	102	5	further	further	ADJ
dpc-5683	102	6	research	research	NOUN
dpc-5683	102	7	is	be	AUX
dpc-5683	102	8	needed	need	VERB
dpc-5683	102	9	to	to	PART
dpc-5683	102	10	explore	explore	VERB
dpc-5683	102	11	the	the	DET
dpc-5683	102	12	relationship	relationship	NOUN
dpc-5683	102	13	between	between	ADP
dpc-5683	102	14	primary	primary	ADJ
dpc-5683	102	15	cutaneous	cutaneous	ADJ
dpc-5683	102	16	lymphomas	lymphoma	NOUN
dpc-5683	102	17	and	and	CCONJ
dpc-5683	102	18	other	other	ADJ
dpc-5683	102	19	primary	primary	ADJ
dpc-5683	102	20	malignancies	malignancy	NOUN
dpc-5683	102	21	.	.	PUNCT
dpc-5683	103	1	even	even	ADV
dpc-5683	103	2	though	though	SCONJ
dpc-5683	103	3	the	the	DET
dpc-5683	103	4	association	association	NOUN
dpc-5683	103	5	between	between	ADP
dpc-5683	103	6	ctcl	ctcl	NOUN
dpc-5683	103	7	and	and	CCONJ
dpc-5683	103	8	other	other	ADJ
dpc-5683	103	9	primary	primary	ADJ
dpc-5683	103	10	malignancies	malignancy	NOUN
dpc-5683	103	11	was	be	AUX
dpc-5683	103	12	proven	prove	VERB
dpc-5683	103	13	more	more	ADJ
dpc-5683	103	14	than	than	ADP
dpc-5683	103	15	40	40	NUM
dpc-5683	103	16	years	year	NOUN
dpc-5683	103	17	ago	ago	ADV
dpc-5683	103	18	,	,	PUNCT
dpc-5683	103	19	possible	possible	ADJ
dpc-5683	103	20	risk	risk	NOUN
dpc-5683	103	21	factors	factor	NOUN
dpc-5683	103	22	for	for	ADP
dpc-5683	103	23	their	their	PRON
dpc-5683	103	24	development	development	NOUN
dpc-5683	103	25	have	have	AUX
dpc-5683	103	26	still	still	ADV
dpc-5683	103	27	not	not	PART
dpc-5683	103	28	been	be	AUX
dpc-5683	103	29	discovered	discover	VERB
dpc-5683	103	30	.	.	PUNCT
dpc-5683	104	1	the	the	DET
dpc-5683	104	2	hypothesis	hypothesis	NOUN
dpc-5683	104	3	of	of	ADP
dpc-5683	104	4	a	a	DET
dpc-5683	104	5	single	single	ADJ
dpc-5683	104	6	causative	causative	ADJ
dpc-5683	104	7	factor	factor	NOUN
dpc-5683	104	8	for	for	ADP
dpc-5683	104	9	the	the	DET
dpc-5683	104	10	development	development	NOUN
dpc-5683	104	11	of	of	ADP
dpc-5683	104	12	both	both	DET
dpc-5683	104	13	neoplasms	neoplasm	NOUN
dpc-5683	104	14	is	be	AUX
dpc-5683	104	15	less	less	ADV
dpc-5683	104	16	likely	likely	ADJ
dpc-5683	104	17	due	due	ADP
dpc-5683	104	18	to	to	ADP
dpc-5683	104	19	the	the	DET
dpc-5683	104	20	heterogeneity	heterogeneity	NOUN
dpc-5683	104	21	of	of	ADP
dpc-5683	104	22	the	the	DET
dpc-5683	104	23	second	second	ADJ
dpc-5683	104	24	primary	primary	ADJ
dpc-5683	104	25	malignancies	malignancy	NOUN
dpc-5683	104	26	in	in	ADP
dpc-5683	104	27	relation	relation	NOUN
dpc-5683	104	28	to	to	PART
dpc-5683	104	29	ctcl	ctcl	VERB
dpc-5683	104	30	.	.	PUNCT
dpc-5683	105	1	several	several	ADJ
dpc-5683	105	2	previous	previous	ADJ
dpc-5683	105	3	studies	study	NOUN
dpc-5683	105	4	excluded	exclude	VERB
dpc-5683	105	5	patients	patient	NOUN
dpc-5683	105	6	with	with	ADP
dpc-5683	105	7	a	a	DET
dpc-5683	105	8	second	second	ADJ
dpc-5683	105	9	primary	primary	ADJ
dpc-5683	105	10	malignancy	malignancy	NOUN
dpc-5683	105	11	preceding	precede	VERB
dpc-5683	105	12	ctcl	ctcl	NOUN
dpc-5683	105	13	to	to	PART
dpc-5683	105	14	determine	determine	VERB
dpc-5683	105	15	whether	whether	SCONJ
dpc-5683	105	16	the	the	DET
dpc-5683	105	17	type	type	NOUN
dpc-5683	105	18	of	of	ADP
dpc-5683	105	19	treatment	treatment	NOUN
dpc-5683	105	20	affected	affect	VERB
dpc-5683	105	21	the	the	DET
dpc-5683	105	22	development	development	NOUN
dpc-5683	105	23	of	of	ADP
dpc-5683	105	24	a	a	DET
dpc-5683	105	25	second	second	ADJ
dpc-5683	105	26	primary	primary	ADJ
dpc-5683	105	27	malignancy	malignancy	NOUN
dpc-5683	105	28	,	,	PUNCT
dpc-5683	105	29	but	but	CCONJ
dpc-5683	105	30	the	the	DET
dpc-5683	105	31	heterogeneity	heterogeneity	NOUN
dpc-5683	105	32	of	of	ADP
dpc-5683	105	33	other	other	ADJ
dpc-5683	105	34	primary	primary	ADJ
dpc-5683	105	35	cancers	cancer	NOUN
dpc-5683	105	36	makes	make	VERB
dpc-5683	105	37	this	this	PRON
dpc-5683	105	38	unlikely	unlikely	ADJ
dpc-5683	105	39	.	.	PUNCT
dpc-5683	106	1	it	it	PRON
dpc-5683	106	2	is	be	AUX
dpc-5683	106	3	more	more	ADV
dpc-5683	106	4	likely	likely	ADJ
dpc-5683	106	5	that	that	SCONJ
dpc-5683	106	6	the	the	DET
dpc-5683	106	7	cause	cause	NOUN
dpc-5683	106	8	is	be	AUX
dpc-5683	106	9	a	a	DET
dpc-5683	106	10	tumorigenic	tumorigenic	ADJ
dpc-5683	106	11	microenvironment	microenvironment	NOUN
dpc-5683	106	12	and	and	CCONJ
dpc-5683	106	13	an	an	DET
dpc-5683	106	14	altered	altered	ADJ
dpc-5683	106	15	immune	immune	ADJ
dpc-5683	106	16	response	response	NOUN
dpc-5683	106	17	that	that	PRON
dpc-5683	106	18	led	lead	VERB
dpc-5683	106	19	to	to	ADP
dpc-5683	106	20	the	the	DET
dpc-5683	106	21	development	development	NOUN
dpc-5683	106	22	of	of	ADP
dpc-5683	106	23	the	the	DET
dpc-5683	106	24	first	first	ADJ
dpc-5683	106	25	neoplasm	neoplasm	NOUN
dpc-5683	106	26	.	.	PUNCT
dpc-5683	107	1	in	in	ADP
dpc-5683	107	2	our	our	PRON
dpc-5683	107	3	study	study	NOUN
dpc-5683	107	4	,	,	PUNCT
dpc-5683	107	5	as	as	ADP
dpc-5683	107	6	in	in	ADP
dpc-5683	107	7	most	most	ADJ
dpc-5683	107	8	previous	previous	ADJ
dpc-5683	107	9	studies	study	NOUN
dpc-5683	107	10	,	,	PUNCT
dpc-5683	107	11	a	a	DET
dpc-5683	107	12	higher	high	ADJ
dpc-5683	107	13	risk	risk	NOUN
dpc-5683	107	14	of	of	ADP
dpc-5683	107	15	developing	develop	VERB
dpc-5683	107	16	a	a	DET
dpc-5683	107	17	second	second	ADJ
dpc-5683	107	18	primary	primary	ADJ
dpc-5683	107	19	neoplasm	neoplasm	NOUN
dpc-5683	107	20	was	be	AUX
dpc-5683	107	21	demonstrated	demonstrate	VERB
dpc-5683	107	22	,	,	PUNCT
dpc-5683	107	23	but	but	CCONJ
dpc-5683	107	24	additional	additional	ADJ
dpc-5683	107	25	tests	test	NOUN
dpc-5683	107	26	for	for	ADP
dpc-5683	107	27	early	early	ADJ
dpc-5683	107	28	detection	detection	NOUN
dpc-5683	107	29	of	of	ADP
dpc-5683	107	30	cancer	cancer	NOUN
dpc-5683	107	31	beyond	beyond	ADP
dpc-5683	107	32	routine	routine	ADJ
dpc-5683	107	33	ageand	ageand	NOUN
dpc-5683	107	34	sex	sex	NOUN
dpc-5683	107	35	-	-	PUNCT
dpc-5683	107	36	appropriate	appropriate	ADJ
dpc-5683	107	37	examinations	examination	NOUN
dpc-5683	107	38	are	be	AUX
dpc-5683	107	39	still	still	ADV
dpc-5683	107	40	not	not	PART
dpc-5683	107	41	part	part	NOUN
dpc-5683	107	42	of	of	ADP
dpc-5683	107	43	the	the	DET
dpc-5683	107	44	guidelines	guideline	NOUN
dpc-5683	107	45	.	.	PUNCT
dpc-5683	108	1	regular	regular	ADJ
dpc-5683	108	2	check	check	NOUN
dpc-5683	108	3	-	-	PUNCT
dpc-5683	108	4	ups	up	NOUN
dpc-5683	108	5	and	and	CCONJ
dpc-5683	108	6	a	a	DET
dpc-5683	108	7	multidisciplinary	multidisciplinary	ADJ
dpc-5683	108	8	approach	approach	NOUN
dpc-5683	108	9	are	be	AUX
dpc-5683	108	10	necessary	necessary	ADJ
dpc-5683	108	11	.	.	PUNCT
dpc-5683	109	1	based	base	VERB
dpc-5683	109	2	on	on	ADP
dpc-5683	109	3	this	this	DET
dpc-5683	109	4	study	study	NOUN
dpc-5683	109	5	,	,	PUNCT
dpc-5683	109	6	we	we	PRON
dpc-5683	109	7	conclude	conclude	VERB
dpc-5683	109	8	that	that	SCONJ
dpc-5683	109	9	patients	patient	NOUN
dpc-5683	109	10	with	with	ADP
dpc-5683	109	11	ctcl	ctcl	NOUN
dpc-5683	109	12	should	should	AUX
dpc-5683	109	13	regularly	regularly	ADV
dpc-5683	109	14	undergo	undergo	VERB
dpc-5683	109	15	preventive	preventive	ADJ
dpc-5683	109	16	examinations	examination	NOUN
dpc-5683	109	17	for	for	ADP
dpc-5683	109	18	the	the	DET
dpc-5683	109	19	purpose	purpose	NOUN
dpc-5683	109	20	of	of	ADP
dpc-5683	109	21	early	early	ADJ
dpc-5683	109	22	detection	detection	NOUN
dpc-5683	109	23	of	of	ADP
dpc-5683	109	24	other	other	ADJ
dpc-5683	109	25	primary	primary	ADJ
dpc-5683	109	26	malignant	malignant	ADJ
dpc-5683	109	27	diseases	disease	NOUN
dpc-5683	109	28	.	.	PUNCT
dpc-5683	110	1	references	reference	NOUN
dpc-5683	110	2	1	1	NUM
dpc-5683	110	3	.	.	PUNCT
dpc-5683	111	1	hodak	hodak	PROPN
dpc-5683	111	2	e	e	NOUN
dpc-5683	111	3	,	,	PUNCT
dpc-5683	111	4	amitay	amitay	ADJ
dpc-5683	111	5	-	-	PUNCT
dpc-5683	111	6	laish	laish	PROPN
dpc-5683	111	7	i.	i.	NOUN
dpc-5683	111	8	mycosis	mycosis	PROPN
dpc-5683	111	9	fungoides	fungoide	VERB
dpc-5683	111	10	:	:	PUNCT
dpc-5683	111	11	a	a	DET
dpc-5683	111	12	great	great	ADJ
dpc-5683	111	13	imitator	imitator	NOUN
dpc-5683	111	14	.	.	PUNCT
dpc-5683	111	15	 	 	SPACE
dpc-5683	112	1	clin	clin	PROPN
dpc-5683	112	2	dermatol	dermatol	NOUN
dpc-5683	112	3	.	.	PUNCT
dpc-5683	112	4	  	  	SPACE
dpc-5683	113	1	2019;37(3):255–267	2019;37(3):255–267	NUM
dpc-5683	113	2	.	.	PUNCT
dpc-5683	113	3	doi:10.1016	doi:10.1016	PROPN
dpc-5683	113	4	/	/	SYM
dpc-5683	113	5	j.clindermatol.2019.01.004	j.clindermatol.2019.01.004	PROPN
dpc-5683	113	6	.	.	PUNCT
dpc-5683	114	1	pmid	pmid	NOUN
dpc-5683	114	2	:	:	PUNCT
dpc-5683	114	3	31178107	31178107	NUM
dpc-5683	114	4	.	.	PUNCT
dpc-5683	115	1	2	2	X
dpc-5683	115	2	.	.	X
dpc-5683	115	3	väkevä	väkevä	NOUN
dpc-5683	115	4	l	l	NOUN
dpc-5683	115	5	,	,	PUNCT
dpc-5683	115	6	pukkala	pukkala	PROPN
dpc-5683	115	7	e	e	NOUN
dpc-5683	115	8	,	,	PUNCT
dpc-5683	115	9	ranki	ranki	PROPN
dpc-5683	115	10	a.	a.	NOUN
dpc-5683	115	11	increased	increase	VERB
dpc-5683	115	12	risk	risk	NOUN
dpc-5683	115	13	of	of	ADP
dpc-5683	115	14	secondary	secondary	ADJ
dpc-5683	115	15	cancers	cancer	NOUN
dpc-5683	115	16	in	in	ADP
dpc-5683	115	17	patients	patient	NOUN
dpc-5683	115	18	with	with	ADP
dpc-5683	115	19	primary	primary	ADJ
dpc-5683	115	20	cutaneous	cutaneous	ADJ
dpc-5683	115	21	t	t	NOUN
dpc-5683	115	22	cell	cell	NOUN
dpc-5683	115	23	lymphoma	lymphoma	NOUN
dpc-5683	115	24	.	.	PUNCT
dpc-5683	115	25	  	  	SPACE
dpc-5683	116	1	j	j	PROPN
dpc-5683	116	2	invest	invest	VERB
dpc-5683	116	3	dermatol	dermatol	NOUN
dpc-5683	116	4	.	.	PUNCT
dpc-5683	116	5	  	  	SPACE
dpc-5683	116	6	2000;115(1):62–65.doi:10.1046	2000;115(1):62–65.doi:10.1046	NUM
dpc-5683	116	7	/	/	SYM
dpc-5683	116	8	j.1523	j.1523	NOUN
dpc-5683	116	9	-1747.2000.00011.x	-1747.2000.00011.x	NOUN
dpc-5683	116	10	.	.	PUNCT
dpc-5683	117	1	pmid	pmid	NOUN
dpc-5683	117	2	:	:	PUNCT
dpc-5683	117	3	10886509	10886509	NUM
dpc-5683	117	4	.	.	PUNCT
dpc-5683	118	1	studies	study	NOUN
dpc-5683	118	2	[	[	X
dpc-5683	118	3	2	2	NUM
dpc-5683	118	4	-	-	PUNCT
dpc-5683	118	5	4,8,10,12	4,8,10,12	NUM
dpc-5683	118	6	-	-	PUNCT
dpc-5683	118	7	14	14	NUM
dpc-5683	118	8	]	]	PUNCT
dpc-5683	118	9	.	.	PUNCT
dpc-5683	119	1	the	the	DET
dpc-5683	119	2	most	most	ADV
dpc-5683	119	3	common	common	ADJ
dpc-5683	119	4	solid	solid	ADJ
dpc-5683	119	5	organ	organ	NOUN
dpc-5683	119	6	cancer	cancer	NOUN
dpc-5683	119	7	was	be	AUX
dpc-5683	119	8	female	female	ADJ
dpc-5683	119	9	breast	breast	NOUN
dpc-5683	119	10	cancer	cancer	NOUN
dpc-5683	119	11	,	,	PUNCT
dpc-5683	119	12	observed	observe	VERB
dpc-5683	119	13	in	in	ADP
dpc-5683	119	14	31.25	31.25	NUM
dpc-5683	119	15	%	%	NOUN
dpc-5683	119	16	(	(	PUNCT
dpc-5683	119	17	n=5	n=5	PROPN
dpc-5683	119	18	)	)	PUNCT
dpc-5683	119	19	of	of	ADP
dpc-5683	119	20	the	the	DET
dpc-5683	119	21	cases	case	NOUN
dpc-5683	119	22	.	.	PUNCT
dpc-5683	120	1	the	the	DET
dpc-5683	120	2	types	type	NOUN
dpc-5683	120	3	of	of	ADP
dpc-5683	120	4	second	second	ADJ
dpc-5683	120	5	primary	primary	ADJ
dpc-5683	120	6	malignancies	malignancy	NOUN
dpc-5683	120	7	varied	vary	VERB
dpc-5683	120	8	across	across	ADP
dpc-5683	120	9	studies	study	NOUN
dpc-5683	120	10	.	.	PUNCT
dpc-5683	121	1	according	accord	VERB
dpc-5683	121	2	to	to	ADP
dpc-5683	121	3	the	the	DET
dpc-5683	121	4	meta	meta	ADJ
dpc-5683	121	5	-	-	PUNCT
dpc-5683	121	6	analysis	analysis	NOUN
dpc-5683	121	7	and	and	CCONJ
dpc-5683	121	8	systematic	systematic	ADJ
dpc-5683	121	9	review	review	NOUN
dpc-5683	121	10	by	by	ADP
dpc-5683	121	11	goyal	goyal	PROPN
dpc-5683	121	12	et	et	PROPN
dpc-5683	121	13	al	al	PROPN
dpc-5683	121	14	.	.	PUNCT
dpc-5683	122	1	[	[	X
dpc-5683	122	2	7	7	X
dpc-5683	122	3	]	]	PUNCT
dpc-5683	122	4	in	in	ADP
dpc-5683	122	5	2021	2021	NUM
dpc-5683	122	6	,	,	PUNCT
dpc-5683	122	7	which	which	PRON
dpc-5683	122	8	included	include	VERB
dpc-5683	122	9	12	12	NUM
dpc-5683	122	10	studies	study	NOUN
dpc-5683	122	11	and	and	CCONJ
dpc-5683	122	12	11,214	11,214	NUM
dpc-5683	122	13	patients	patient	NOUN
dpc-5683	122	14	with	with	ADP
dpc-5683	122	15	mf	mf	NOUN
dpc-5683	122	16	and	and	CCONJ
dpc-5683	122	17	ctcl	ctcl	NOUN
dpc-5683	122	18	,	,	PUNCT
dpc-5683	122	19	8.5	8.5	NUM
dpc-5683	122	20	%	%	NOUN
dpc-5683	122	21	developed	develop	VERB
dpc-5683	122	22	a	a	DET
dpc-5683	122	23	second	second	ADJ
dpc-5683	122	24	primary	primary	ADJ
dpc-5683	122	25	malignant	malignant	ADJ
dpc-5683	122	26	disease	disease	NOUN
dpc-5683	122	27	.	.	PUNCT
dpc-5683	123	1	in	in	ADP
dpc-5683	123	2	that	that	DET
dpc-5683	123	3	cohort	cohort	NOUN
dpc-5683	123	4	,	,	PUNCT
dpc-5683	123	5	the	the	DET
dpc-5683	123	6	most	most	ADV
dpc-5683	123	7	common	common	ADJ
dpc-5683	123	8	second	second	ADJ
dpc-5683	123	9	primary	primary	ADJ
dpc-5683	123	10	malignancies	malignancy	NOUN
dpc-5683	123	11	were	be	AUX
dpc-5683	123	12	non	non	ADJ
dpc-5683	123	13	-	-	ADJ
dpc-5683	123	14	hodgkin	hodgkin	ADJ
dpc-5683	123	15	lymphoma	lymphoma	NOUN
dpc-5683	123	16	(	(	PUNCT
dpc-5683	123	17	nhl	nhl	PROPN
dpc-5683	123	18	)	)	PUNCT
dpc-5683	123	19	20	20	NUM
dpc-5683	123	20	%	%	NOUN
dpc-5683	123	21	,	,	PUNCT
dpc-5683	123	22	hodgkin	hodgkin	PROPN
dpc-5683	123	23	lymphoma	lymphoma	NOUN
dpc-5683	123	24	(	(	PUNCT
dpc-5683	123	25	hl	hl	NOUN
dpc-5683	123	26	)	)	PUNCT
dpc-5683	123	27	17.8	17.8	NUM
dpc-5683	123	28	%	%	NOUN
dpc-5683	123	29	,	,	PUNCT
dpc-5683	123	30	lung	lung	NOUN
dpc-5683	123	31	cancer	cancer	NOUN
dpc-5683	123	32	15.1	15.1	NUM
dpc-5683	123	33	%	%	NOUN
dpc-5683	123	34	,	,	PUNCT
dpc-5683	123	35	bladder	bladder	NOUN
dpc-5683	123	36	cancer	cancer	NOUN
dpc-5683	123	37	8.3	8.3	NUM
dpc-5683	123	38	%	%	NOUN
dpc-5683	123	39	,	,	PUNCT
dpc-5683	123	40	breast	breast	NOUN
dpc-5683	123	41	cancer	cancer	NOUN
dpc-5683	123	42	6.5	6.5	NUM
dpc-5683	123	43	%	%	NOUN
dpc-5683	123	44	,	,	PUNCT
dpc-5683	123	45	melanoma	melanoma	NOUN
dpc-5683	123	46	3.2	3.2	NUM
dpc-5683	123	47	%	%	NOUN
dpc-5683	123	48	,	,	PUNCT
dpc-5683	123	49	and	and	CCONJ
dpc-5683	123	50	kidney	kidney	NOUN
dpc-5683	123	51	cancer	cancer	NOUN
dpc-5683	123	52	2.9	2.9	NUM
dpc-5683	123	53	%	%	NOUN
dpc-5683	123	54	[	[	X
dpc-5683	123	55	7	7	NUM
dpc-5683	123	56	]	]	PUNCT
dpc-5683	123	57	.	.	PUNCT
dpc-5683	124	1	contrary	contrary	ADJ
dpc-5683	124	2	to	to	ADP
dpc-5683	124	3	these	these	DET
dpc-5683	124	4	findings	finding	NOUN
dpc-5683	124	5	,	,	PUNCT
dpc-5683	124	6	brownel	brownel	PROPN
dpc-5683	124	7	et	et	PROPN
dpc-5683	124	8	al	al	PROPN
dpc-5683	124	9	.	.	PROPN
dpc-5683	124	10	did	do	AUX
dpc-5683	124	11	not	not	PART
dpc-5683	124	12	find	find	VERB
dpc-5683	124	13	an	an	DET
dpc-5683	124	14	increased	increase	VERB
dpc-5683	124	15	incidence	incidence	NOUN
dpc-5683	124	16	of	of	ADP
dpc-5683	124	17	lung	lung	NOUN
dpc-5683	124	18	,	,	PUNCT
dpc-5683	124	19	colon	colon	NOUN
dpc-5683	124	20	,	,	PUNCT
dpc-5683	124	21	urinary	urinary	ADJ
dpc-5683	124	22	tract	tract	NOUN
dpc-5683	124	23	,	,	PUNCT
dpc-5683	124	24	melanoma	melanoma	NOUN
dpc-5683	124	25	,	,	PUNCT
dpc-5683	124	26	or	or	CCONJ
dpc-5683	124	27	biliary	biliary	NOUN
dpc-5683	124	28	system	system	NOUN
dpc-5683	124	29	cancer	cancer	NOUN
dpc-5683	124	30	development	development	NOUN
dpc-5683	124	31	[	[	X
dpc-5683	124	32	4	4	NUM
dpc-5683	124	33	]	]	PUNCT
dpc-5683	124	34	.	.	PUNCT
dpc-5683	125	1	the	the	DET
dpc-5683	125	2	type	type	NOUN
dpc-5683	125	3	of	of	ADP
dpc-5683	125	4	second	second	ADJ
dpc-5683	125	5	primary	primary	ADJ
dpc-5683	125	6	malignant	malignant	ADJ
dpc-5683	125	7	disease	disease	NOUN
dpc-5683	125	8	differed	differ	VERB
dpc-5683	125	9	in	in	ADP
dpc-5683	125	10	the	the	DET
dpc-5683	125	11	studied	study	VERB
dpc-5683	125	12	groups	group	NOUN
dpc-5683	125	13	of	of	ADP
dpc-5683	125	14	patients	patient	NOUN
dpc-5683	125	15	,	,	PUNCT
dpc-5683	125	16	and	and	CCONJ
dpc-5683	125	17	some	some	DET
dpc-5683	125	18	study	study	NOUN
dpc-5683	125	19	groups	group	NOUN
dpc-5683	125	20	(	(	PUNCT
dpc-5683	125	21	like	like	ADP
dpc-5683	125	22	ours	ours	ADJ
dpc-5683	125	23	)	)	PUNCT
dpc-5683	125	24	report	report	VERB
dpc-5683	125	25	no	no	DET
dpc-5683	125	26	melanoma	melanoma	NOUN
dpc-5683	125	27	case	case	NOUN
dpc-5683	125	28	[	[	X
dpc-5683	125	29	2,6,8	2,6,8	X
dpc-5683	125	30	]	]	X
dpc-5683	125	31	.	.	PUNCT
dpc-5683	126	1	in	in	ADP
dpc-5683	126	2	contrast	contrast	NOUN
dpc-5683	126	3	,	,	PUNCT
dpc-5683	126	4	there	there	PRON
dpc-5683	126	5	are	be	VERB
dpc-5683	126	6	studies	study	NOUN
dpc-5683	126	7	that	that	PRON
dpc-5683	126	8	identified	identify	VERB
dpc-5683	126	9	melanoma	melanoma	NOUN
dpc-5683	126	10	as	as	ADP
dpc-5683	126	11	a	a	DET
dpc-5683	126	12	frequent	frequent	ADJ
dpc-5683	126	13	secondary	secondary	ADJ
dpc-5683	126	14	malignancy	malignancy	NOUN
dpc-5683	126	15	(	(	PUNCT
dpc-5683	126	16	goyal	goyal	PROPN
dpc-5683	126	17	et	et	PROPN
dpc-5683	126	18	al	al	PROPN
dpc-5683	126	19	.	.	PROPN
dpc-5683	126	20	excluded	exclude	VERB
dpc-5683	126	21	melanoma	melanoma	NOUN
dpc-5683	126	22	in	in	ADP
dpc-5683	126	23	situ	situ	NOUN
dpc-5683	126	24	in	in	ADP
dpc-5683	126	25	their	their	PRON
dpc-5683	126	26	study	study	NOUN
dpc-5683	126	27	)	)	PUNCT
dpc-5683	127	1	[	[	X
dpc-5683	127	2	3,11,15	3,11,15	NUM
dpc-5683	127	3	]	]	X
dpc-5683	127	4	.	.	PUNCT
dpc-5683	128	1	our	our	PRON
dpc-5683	128	2	study	study	NOUN
dpc-5683	128	3	did	do	AUX
dpc-5683	128	4	not	not	PART
dpc-5683	128	5	find	find	VERB
dpc-5683	128	6	any	any	DET
dpc-5683	128	7	sex	sex	NOUN
dpc-5683	128	8	predominance	predominance	NOUN
dpc-5683	128	9	,	,	PUNCT
dpc-5683	128	10	in	in	ADP
dpc-5683	128	11	contrast	contrast	NOUN
dpc-5683	128	12	to	to	ADP
dpc-5683	128	13	previous	previous	ADJ
dpc-5683	128	14	studies	study	NOUN
dpc-5683	128	15	,	,	PUNCT
dpc-5683	128	16	which	which	PRON
dpc-5683	128	17	reported	report	VERB
dpc-5683	128	18	a	a	DET
dpc-5683	128	19	higher	high	ADJ
dpc-5683	128	20	incidence	incidence	NOUN
dpc-5683	128	21	in	in	ADP
dpc-5683	128	22	males	male	NOUN
dpc-5683	128	23	,	,	PUNCT
dpc-5683	128	24	with	with	ADP
dpc-5683	128	25	a	a	DET
dpc-5683	128	26	male	male	NOUN
dpc-5683	128	27	-	-	PUNCT
dpc-5683	128	28	to	to	ADP
dpc-5683	128	29	-	-	PUNCT
dpc-5683	128	30	female	female	ADJ
dpc-5683	128	31	ratio	ratio	NOUN
dpc-5683	128	32	ranging	range	VERB
dpc-5683	128	33	from	from	ADP
dpc-5683	128	34	1.2:1	1.2:1	PROPN
dpc-5683	128	35	to	to	ADP
dpc-5683	128	36	2.9:1	2.9:1	NUM
dpc-5683	128	37	,	,	PUNCT
dpc-5683	128	38	according	accord	VERB
dpc-5683	128	39	to	to	ADP
dpc-5683	128	40	the	the	DET
dpc-5683	128	41	systematic	systematic	ADJ
dpc-5683	128	42	review	review	NOUN
dpc-5683	128	43	and	and	CCONJ
dpc-5683	128	44	meta	meta	NOUN
dpc-5683	128	45	-	-	PUNCT
dpc-5683	128	46	analysis	analysis	NOUN
dpc-5683	128	47	by	by	ADP
dpc-5683	128	48	goyal	goyal	PROPN
dpc-5683	128	49	et	et	PROPN
dpc-5683	128	50	al	al	PROPN
dpc-5683	128	51	.	.	PUNCT
dpc-5683	129	1	[	[	X
dpc-5683	129	2	7	7	NUM
dpc-5683	129	3	]	]	PUNCT
dpc-5683	129	4	.	.	PUNCT
dpc-5683	130	1	the	the	DET
dpc-5683	130	2	average	average	ADJ
dpc-5683	130	3	age	age	NOUN
dpc-5683	130	4	at	at	ADP
dpc-5683	130	5	ctcl	ctcl	ADJ
dpc-5683	130	6	diagnosis	diagnosis	NOUN
dpc-5683	130	7	was	be	AUX
dpc-5683	130	8	between	between	ADP
dpc-5683	130	9	44.6	44.6	NUM
dpc-5683	130	10	and	and	CCONJ
dpc-5683	130	11	68.0	68.0	NUM
dpc-5683	130	12	years	year	NOUN
dpc-5683	130	13	,	,	PUNCT
dpc-5683	130	14	and	and	CCONJ
dpc-5683	130	15	the	the	DET
dpc-5683	130	16	median	median	ADJ
dpc-5683	130	17	age	age	NOUN
dpc-5683	130	18	at	at	ADP
dpc-5683	130	19	diagnosis	diagnosis	NOUN
dpc-5683	130	20	of	of	ADP
dpc-5683	130	21	second	second	ADJ
dpc-5683	130	22	primary	primary	ADJ
dpc-5683	130	23	malignancy	malignancy	NOUN
dpc-5683	130	24	was	be	AUX
dpc-5683	130	25	3.29	3.29	NUM
dpc-5683	130	26	years	year	NOUN
dpc-5683	130	27	after	after	ADP
dpc-5683	130	28	ctcl	ctcl	NOUN
dpc-5683	130	29	diagnosis	diagnosis	NOUN
dpc-5683	130	30	(	(	PUNCT
dpc-5683	130	31	ranging	range	VERB
dpc-5683	130	32	from	from	ADP
dpc-5683	130	33	2.1	2.1	NUM
dpc-5683	130	34	to	to	ADP
dpc-5683	130	35	5.4	5.4	NUM
dpc-5683	130	36	years	year	NOUN
dpc-5683	130	37	)	)	PUNCT
dpc-5683	130	38	.	.	PUNCT
dpc-5683	131	1	in	in	ADP
dpc-5683	131	2	our	our	PRON
dpc-5683	131	3	study	study	NOUN
dpc-5683	131	4	,	,	PUNCT
dpc-5683	131	5	the	the	DET
dpc-5683	131	6	interval	interval	NOUN
dpc-5683	131	7	between	between	ADP
dpc-5683	131	8	ctcl	ctcl	NOUN
dpc-5683	131	9	diagnosis	diagnosis	NOUN
dpc-5683	131	10	and	and	CCONJ
dpc-5683	131	11	second	second	ADJ
dpc-5683	131	12	malignancy	malignancy	NOUN
dpc-5683	131	13	was	be	AUX
dpc-5683	131	14	longer	long	ADJ
dpc-5683	131	15	.	.	PUNCT
dpc-5683	132	1	however	however	ADV
dpc-5683	132	2	,	,	PUNCT
dpc-5683	132	3	unlike	unlike	ADP
dpc-5683	132	4	some	some	DET
dpc-5683	132	5	studies	study	NOUN
dpc-5683	132	6	,	,	PUNCT
dpc-5683	132	7	we	we	PRON
dpc-5683	132	8	did	do	AUX
dpc-5683	132	9	not	not	PART
dpc-5683	132	10	exclude	exclude	VERB
dpc-5683	132	11	patients	patient	NOUN
dpc-5683	132	12	whose	whose	DET
dpc-5683	132	13	second	second	ADJ
dpc-5683	132	14	malignancy	malignancy	NOUN
dpc-5683	132	15	preceded	precede	VERB
dpc-5683	132	16	their	their	PRON
dpc-5683	132	17	ctcl	ctcl	ADJ
dpc-5683	132	18	diagnosis	diagnosis	NOUN
dpc-5683	132	19	.	.	PUNCT
dpc-5683	133	1	the	the	DET
dpc-5683	133	2	age	age	NOUN
dpc-5683	133	3	at	at	ADP
dpc-5683	133	4	onset	onset	NOUN
dpc-5683	133	5	of	of	ADP
dpc-5683	133	6	ctcl	ctcl	NOUN
dpc-5683	133	7	and	and	CCONJ
dpc-5683	133	8	other	other	ADJ
dpc-5683	133	9	primary	primary	ADJ
dpc-5683	133	10	malignant	malignant	ADJ
dpc-5683	133	11	diseases	disease	NOUN
dpc-5683	133	12	has	have	AUX
dpc-5683	133	13	differed	differ	VERB
dpc-5683	133	14	in	in	ADP
dpc-5683	133	15	the	the	DET
dpc-5683	133	16	studies	study	NOUN
dpc-5683	133	17	published	publish	VERB
dpc-5683	133	18	so	so	ADV
dpc-5683	133	19	far	far	ADV
dpc-5683	133	20	.	.	PUNCT
dpc-5683	134	1	the	the	DET
dpc-5683	134	2	median	median	ADJ
dpc-5683	134	3	age	age	NOUN
dpc-5683	134	4	at	at	ADP
dpc-5683	134	5	diagnosis	diagnosis	NOUN
dpc-5683	134	6	of	of	ADP
dpc-5683	134	7	second	second	ADJ
dpc-5683	134	8	primary	primary	ADJ
dpc-5683	134	9	malignant	malignant	ADJ
dpc-5683	134	10	disease	disease	NOUN
dpc-5683	134	11	in	in	ADP
dpc-5683	134	12	our	our	PRON
dpc-5683	134	13	cohort	cohort	NOUN
dpc-5683	134	14	was	be	AUX
dpc-5683	134	15	60.5	60.5	NUM
dpc-5683	134	16	years	year	NOUN
dpc-5683	134	17	,	,	PUNCT
dpc-5683	134	18	and	and	CCONJ
dpc-5683	134	19	the	the	DET
dpc-5683	134	20	average	average	ADJ
dpc-5683	134	21	time	time	NOUN
dpc-5683	134	22	from	from	ADP
dpc-5683	134	23	ctcl	ctcl	ADJ
dpc-5683	134	24	diagnosis	diagnosis	NOUN
dpc-5683	134	25	to	to	ADP
dpc-5683	134	26	the	the	DET
dpc-5683	134	27	development	development	NOUN
dpc-5683	134	28	of	of	ADP
dpc-5683	134	29	another	another	DET
dpc-5683	134	30	primary	primary	ADJ
dpc-5683	134	31	malignancy	malignancy	NOUN
dpc-5683	134	32	was	be	AUX
dpc-5683	134	33	6	6	NUM
dpc-5683	134	34	years	year	NOUN
dpc-5683	134	35	(	(	PUNCT
dpc-5683	134	36	median	median	NOUN
dpc-5683	134	37	:	:	PUNCT
dpc-5683	134	38	54.5	54.5	NUM
dpc-5683	134	39	years	year	NOUN
dpc-5683	134	40	)	)	PUNCT
dpc-5683	134	41	.	.	PUNCT
dpc-5683	135	1	our	our	PRON
dpc-5683	135	2	study	study	NOUN
dpc-5683	135	3	found	find	VERB
dpc-5683	135	4	a	a	DET
dpc-5683	135	5	higher	high	ADJ
dpc-5683	135	6	percentage	percentage	NOUN
dpc-5683	135	7	other	other	ADJ
dpc-5683	135	8	primary	primary	ADJ
dpc-5683	135	9	malignancies	malignancy	NOUN
dpc-5683	135	10	compared	compare	VERB
dpc-5683	135	11	to	to	ADP
dpc-5683	135	12	previously	previously	ADV
dpc-5683	135	13	published	publish	VERB
dpc-5683	135	14	reports	report	NOUN
dpc-5683	135	15	[	[	X
dpc-5683	135	16	2	2	NUM
dpc-5683	135	17	-	-	SYM
dpc-5683	135	18	6,8,11	6,8,11	NUM
dpc-5683	135	19	-	-	SYM
dpc-5683	135	20	15	15	NUM
dpc-5683	135	21	]	]	PUNCT
dpc-5683	135	22	.	.	PUNCT
dpc-5683	136	1	we	we	PRON
dpc-5683	136	2	believe	believe	VERB
dpc-5683	136	3	that	that	SCONJ
dpc-5683	136	4	this	this	PRON
dpc-5683	136	5	may	may	AUX
dpc-5683	136	6	be	be	AUX
dpc-5683	136	7	due	due	ADJ
dpc-5683	136	8	to	to	ADP
dpc-5683	136	9	the	the	DET
dpc-5683	136	10	study	study	NOUN
dpc-5683	136	11	design	design	NOUN
dpc-5683	136	12	.	.	PUNCT
dpc-5683	137	1	some	some	DET
dpc-5683	137	2	studies	study	NOUN
dpc-5683	137	3	excluded	exclude	VERB
dpc-5683	137	4	patients	patient	NOUN
dpc-5683	137	5	who	who	PRON
dpc-5683	137	6	developed	develop	VERB
dpc-5683	137	7	a	a	DET
dpc-5683	137	8	second	second	ADJ
dpc-5683	137	9	malignancy	malignancy	NOUN
dpc-5683	137	10	before	before	ADP
dpc-5683	137	11	or	or	CCONJ
dpc-5683	137	12	within	within	ADP
dpc-5683	137	13	the	the	DET
dpc-5683	137	14	first	first	ADJ
dpc-5683	137	15	year	year	NOUN
dpc-5683	137	16	of	of	ADP
dpc-5683	137	17	ctcl	ctcl	NOUN
dpc-5683	137	18	diagnosis	diagnosis	NOUN
dpc-5683	137	19	,	,	PUNCT
dpc-5683	137	20	likely	likely	ADJ
dpc-5683	137	21	to	to	PART
dpc-5683	137	22	assess	assess	VERB
dpc-5683	137	23	potential	potential	ADJ
dpc-5683	137	24	treatment	treatment	NOUN
dpc-5683	137	25	-	-	PUNCT
dpc-5683	137	26	related	relate	VERB
dpc-5683	137	27	factors	factor	NOUN
dpc-5683	137	28	(	(	PUNCT
dpc-5683	137	29	3,4,8	3,4,8	NOUN
dpc-5683	137	30	)	)	PUNCT
dpc-5683	137	31	.	.	PUNCT
dpc-5683	138	1	however	however	ADV
dpc-5683	138	2	,	,	PUNCT
dpc-5683	138	3	we	we	PRON
dpc-5683	138	4	believe	believe	VERB
dpc-5683	138	5	that	that	SCONJ
dpc-5683	138	6	studies	study	NOUN
dpc-5683	138	7	designed	design	VERB
dpc-5683	138	8	in	in	ADP
dpc-5683	138	9	that	that	DET
dpc-5683	138	10	way	way	NOUN
dpc-5683	138	11	may	may	AUX
dpc-5683	138	12	not	not	PART
dpc-5683	138	13	provide	provide	VERB
dpc-5683	138	14	the	the	DET
dpc-5683	138	15	prevalence	prevalence	NOUN
dpc-5683	138	16	of	of	ADP
dpc-5683	138	17	other	other	ADJ
dpc-5683	138	18	primary	primary	ADJ
dpc-5683	138	19	malignant	malignant	ADJ
dpc-5683	138	20	diseases	disease	NOUN
dpc-5683	138	21	in	in	ADP
dpc-5683	138	22	ctcl	ctcl	NOUN
dpc-5683	138	23	patients	patient	NOUN
dpc-5683	138	24	.	.	PUNCT
dpc-5683	139	1	our	our	PRON
dpc-5683	139	2	result	result	NOUN
dpc-5683	139	3	of	of	ADP
dpc-5683	139	4	19.5	19.5	NUM
dpc-5683	139	5	%	%	NOUN
dpc-5683	139	6	of	of	ADP
dpc-5683	139	7	patients	patient	NOUN
dpc-5683	139	8	with	with	ADP
dpc-5683	139	9	a	a	DET
dpc-5683	139	10	second	second	ADJ
dpc-5683	139	11	primary	primary	ADJ
dpc-5683	139	12	malignancy	malignancy	NOUN
dpc-5683	139	13	is	be	AUX
dpc-5683	139	14	comparable	comparable	ADJ
dpc-5683	139	15	to	to	ADP
dpc-5683	139	16	the	the	DET
dpc-5683	139	17	20.2	20.2	NUM
dpc-5683	139	18	%	%	NOUN
dpc-5683	139	19	reported	report	VERB
dpc-5683	139	20	by	by	ADP
dpc-5683	139	21	macagno	macagno	PROPN
dpc-5683	139	22	et	et	PROPN
dpc-5683	139	23	al	al	PROPN
dpc-5683	139	24	.	.	PUNCT
dpc-5683	140	1	[	[	X
dpc-5683	140	2	11	11	NUM
dpc-5683	140	3	]	]	PUNCT
dpc-5683	140	4	,	,	PUNCT
dpc-5683	140	5	a	a	DET
dpc-5683	140	6	study	study	NOUN
dpc-5683	140	7	that	that	PRON
dpc-5683	140	8	similarly	similarly	ADV
dpc-5683	140	9	did	do	AUX
dpc-5683	140	10	not	not	PART
dpc-5683	140	11	exclude	exclude	VERB
dpc-5683	140	12	cases	case	NOUN
dpc-5683	140	13	in	in	ADP
dpc-5683	140	14	which	which	PRON
dpc-5683	140	15	the	the	DET
dpc-5683	140	16	second	second	ADJ
dpc-5683	140	17	malignancy	malignancy	NOUN
dpc-5683	140	18	preceded	precede	VERB
dpc-5683	140	19	ctcl	ctcl	NOUN
dpc-5683	140	20	.	.	PUNCT
dpc-5683	141	1	according	accord	VERB
dpc-5683	141	2	to	to	ADP
dpc-5683	141	3	that	that	DET
dpc-5683	141	4	study	study	NOUN
dpc-5683	141	5	,	,	PUNCT
dpc-5683	141	6	39.5	39.5	NUM
dpc-5683	141	7	%	%	NOUN
dpc-5683	141	8	of	of	ADP
dpc-5683	141	9	patients	patient	NOUN
dpc-5683	141	10	had	have	VERB
dpc-5683	141	11	nmsc	nmsc	NOUN
dpc-5683	141	12	,	,	PUNCT
dpc-5683	141	13	and	and	CCONJ
dpc-5683	141	14	28.9	28.9	NUM
dpc-5683	141	15	%	%	NOUN
dpc-5683	141	16	had	have	VERB
dpc-5683	141	17	mm	mm	NOUN
dpc-5683	141	18	.	.	PUNCT
dpc-5683	142	1	in	in	ADP
dpc-5683	142	2	contrast	contrast	NOUN
dpc-5683	142	3	,	,	PUNCT
dpc-5683	142	4	in	in	ADP
dpc-5683	142	5	our	our	PRON
dpc-5683	142	6	study	study	NOUN
dpc-5683	142	7	,	,	PUNCT
dpc-5683	142	8	there	there	PRON
dpc-5683	142	9	was	be	VERB
dpc-5683	142	10	no	no	DET
dpc-5683	142	11	case	case	NOUN
dpc-5683	142	12	of	of	ADP
dpc-5683	142	13	melanoma	melanoma	NOUN
dpc-5683	142	14	,	,	PUNCT
dpc-5683	142	15	and	and	CCONJ
dpc-5683	142	16	five	five	NUM
dpc-5683	142	17	cases	case	NOUN
dpc-5683	142	18	of	of	ADP
dpc-5683	142	19	nmsc	nmsc	NOUN
dpc-5683	142	20	(	(	PUNCT
dpc-5683	142	21	5.95	5.95	NUM
dpc-5683	142	22	%	%	NOUN
dpc-5683	142	23	)	)	PUNCT
dpc-5683	142	24	.	.	PUNCT
dpc-5683	143	1	the	the	DET
dpc-5683	143	2	patients	patient	NOUN
dpc-5683	143	3	who	who	PRON
dpc-5683	143	4	developed	develop	VERB
dpc-5683	143	5	nmsc	nmsc	NOUN
dpc-5683	143	6	in	in	ADP
dpc-5683	143	7	our	our	PRON
dpc-5683	143	8	study	study	NOUN
dpc-5683	143	9	were	be	AUX
dpc-5683	143	10	treated	treat	VERB
dpc-5683	143	11	with	with	ADP
dpc-5683	143	12	puva	puva	PROPN
dpc-5683	143	13	6	6	NUM
dpc-5683	143	14	original	original	ADJ
dpc-5683	143	15	article	article	NOUN
dpc-5683	143	16	|	|	ADV
dpc-5683	143	17	dermatol	dermatol	ADJ
dpc-5683	143	18	pract	pract	NOUN
dpc-5683	143	19	concept	concept	NOUN
dpc-5683	143	20	.	.	PUNCT
dpc-5683	144	1	2025;15(4):5683	2025;15(4):5683	NUM
dpc-5683	144	2	11	11	NUM
dpc-5683	144	3	.	.	PUNCT
dpc-5683	145	1	macagno	macagno	PROPN
dpc-5683	145	2	n	n	CCONJ
dpc-5683	145	3	,	,	PUNCT
dpc-5683	145	4	mastorino	mastorino	ADJ
dpc-5683	145	5	l	l	NOUN
dpc-5683	145	6	,	,	PUNCT
dpc-5683	145	7	rubatto	rubatto	NOUN
dpc-5683	145	8	m	m	PROPN
dpc-5683	145	9	,	,	PUNCT
dpc-5683	145	10	et	et	PROPN
dpc-5683	145	11	al	al	PROPN
dpc-5683	145	12	.	.	PROPN
dpc-5683	145	13	primary	primary	ADJ
dpc-5683	145	14	cutaneous	cutaneous	ADJ
dpc-5683	145	15	lymphoma	lymphoma	NOUN
dpc-5683	145	16	patients	patient	NOUN
dpc-5683	145	17	seen	see	VERB
dpc-5683	145	18	at	at	ADP
dpc-5683	145	19	a	a	DET
dpc-5683	145	20	referral	referral	ADJ
dpc-5683	145	21	dermatological	dermatological	ADJ
dpc-5683	145	22	centre	centre	NOUN
dpc-5683	145	23	in	in	ADP
dpc-5683	145	24	1	1	NUM
dpc-5683	145	25	  	  	SPACE
dpc-5683	145	26	year	year	NOUN
dpc-5683	145	27	:	:	PUNCT
dpc-5683	145	28	a	a	DET
dpc-5683	145	29	single	single	ADJ
dpc-5683	145	30	-	-	PUNCT
dpc-5683	145	31	centre	centre	NOUN
dpc-5683	145	32	observational	observational	ADJ
dpc-5683	145	33	retrospective	retrospective	ADJ
dpc-5683	145	34	cohort	cohort	NOUN
dpc-5683	145	35	study	study	NOUN
dpc-5683	145	36	of	of	ADP
dpc-5683	145	37	the	the	DET
dpc-5683	145	38	diagnoses	diagnosis	NOUN
dpc-5683	145	39	and	and	CCONJ
dpc-5683	145	40	staging	staging	NOUN
dpc-5683	145	41	,	,	PUNCT
dpc-5683	145	42	comorbidities	comorbiditie	NOUN
dpc-5683	145	43	and	and	CCONJ
dpc-5683	145	44	associated	associated	ADJ
dpc-5683	145	45	symptoms	symptom	NOUN
dpc-5683	145	46	,	,	PUNCT
dpc-5683	145	47	treatment	treatment	NOUN
dpc-5683	145	48	performed	perform	VERB
dpc-5683	145	49	and	and	CCONJ
dpc-5683	145	50	clinical	clinical	ADJ
dpc-5683	145	51	course	course	NOUN
dpc-5683	145	52	.	.	PUNCT
dpc-5683	145	53	  	  	SPACE
dpc-5683	146	1	j	j	PROPN
dpc-5683	146	2	eur	eur	PROPN
dpc-5683	146	3	acad	acad	PROPN
dpc-5683	146	4	dermatol	dermatol	NOUN
dpc-5683	146	5	venereol	venereol	NOUN
dpc-5683	146	6	.	.	PUNCT
dpc-5683	147	1	2022;36(12):2388	2022;36(12):2388	NUM
dpc-5683	147	2	-	-	SYM
dpc-5683	147	3	2392	2392	NUM
dpc-5683	147	4	.	.	PUNCT
dpc-5683	148	1	doi:10.1111	doi:10.1111	NOUN
dpc-5683	148	2	/	/	SYM
dpc-5683	148	3	jdv.18469	jdv.18469	SYM
dpc-5683	148	4	12	12	NUM
dpc-5683	148	5	.	.	PUNCT
dpc-5683	148	6	barzilai	barzilai	NOUN
dpc-5683	148	7	a	a	PROPN
dpc-5683	148	8	,	,	PUNCT
dpc-5683	148	9	trau	trau	PROPN
dpc-5683	148	10	h	h	NOUN
dpc-5683	148	11	,	,	PUNCT
dpc-5683	148	12	david	david	PROPN
dpc-5683	148	13	m	m	PROPN
dpc-5683	148	14	,	,	PUNCT
dpc-5683	148	15	et	et	PROPN
dpc-5683	148	16	al	al	PROPN
dpc-5683	148	17	.	.	PROPN
dpc-5683	148	18	mycosis	mycosis	NOUN
dpc-5683	148	19	fungoides	fungoide	NOUN
dpc-5683	148	20	associated	associate	VERB
dpc-5683	148	21	with	with	ADP
dpc-5683	148	22	b	b	NOUN
dpc-5683	148	23	-	-	PUNCT
dpc-5683	148	24	cell	cell	NOUN
dpc-5683	148	25	malignancies	malignancy	NOUN
dpc-5683	148	26	.	.	PUNCT
dpc-5683	148	27	 	 	SPACE
dpc-5683	149	1	br	br	PROPN
dpc-5683	149	2	j	j	PROPN
dpc-5683	149	3	dermatol	dermatol	NOUN
dpc-5683	149	4	.	.	PUNCT
dpc-5683	150	1	2006;155(2):379	2006;155(2):379	NUM
dpc-5683	150	2	-	-	SYM
dpc-5683	150	3	386	386	NUM
dpc-5683	150	4	.	.	PUNCT
dpc-5683	151	1	doi:10.1111	doi:10.1111	ADJ
dpc-5683	151	2	/	/	SYM
dpc-5683	151	3	j.1365	j.1365	NOUN
dpc-5683	151	4	-	-	PUNCT
dpc-5683	151	5	2133.2006.07346.x	2133.2006.07346.x	NUM
dpc-5683	151	6	.	.	PUNCT
dpc-5683	152	1	pmid	pmid	NOUN
dpc-5683	152	2	:	:	PUNCT
dpc-5683	152	3	16882178	16882178	NUM
dpc-5683	152	4	.	.	PUNCT
dpc-5683	153	1	13	13	NUM
dpc-5683	153	2	.	.	X
dpc-5683	153	3	hallermann	hallermann	PROPN
dpc-5683	153	4	c	c	PROPN
dpc-5683	153	5	,	,	PUNCT
dpc-5683	153	6	kaune	kaune	PROPN
dpc-5683	153	7	mk	mk	PROPN
dpc-5683	153	8	,	,	PUNCT
dpc-5683	153	9	tiemann	tiemann	PROPN
dpc-5683	153	10	m	m	PROPN
dpc-5683	153	11	,	,	PUNCT
dpc-5683	153	12	et	et	PROPN
dpc-5683	153	13	al	al	PROPN
dpc-5683	153	14	.	.	PROPN
dpc-5683	153	15	high	high	ADJ
dpc-5683	153	16	frequency	frequency	NOUN
dpc-5683	153	17	of	of	ADP
dpc-5683	153	18	primary	primary	ADJ
dpc-5683	153	19	cutaneous	cutaneous	ADJ
dpc-5683	153	20	lymphomas	lymphoma	NOUN
dpc-5683	153	21	associated	associate	VERB
dpc-5683	153	22	with	with	ADP
dpc-5683	153	23	lymphoproliferative	lymphoproliferative	ADJ
dpc-5683	153	24	disorders	disorder	NOUN
dpc-5683	153	25	of	of	ADP
dpc-5683	153	26	different	different	ADJ
dpc-5683	153	27	lineage	lineage	NOUN
dpc-5683	153	28	.	.	PUNCT
dpc-5683	153	29	  	  	SPACE
dpc-5683	154	1	ann	ann	PROPN
dpc-5683	154	2	hematol	hematol	NOUN
dpc-5683	154	3	.	.	PUNCT
dpc-5683	154	4	  	  	SPACE
dpc-5683	155	1	2007;86(7):509–515.doi:10.1007	2007;86(7):509–515.doi:10.1007	NUM
dpc-5683	155	2	/	/	SYM
dpc-5683	155	3	s00277	s00277	NOUN
dpc-5683	155	4	-	-	PUNCT
dpc-5683	155	5	007	007	NUM
dpc-5683	155	6	-	-	PUNCT
dpc-5683	155	7	0304	0304	NUM
dpc-5683	155	8	-2	-2	NOUN
dpc-5683	155	9	.	.	PUNCT
dpc-5683	156	1	pmid	pmid	NOUN
dpc-5683	156	2	:	:	PUNCT
dpc-5683	156	3	17403369	17403369	NUM
dpc-5683	156	4	.	.	PUNCT
dpc-5683	157	1	14	14	NUM
dpc-5683	157	2	.	.	PUNCT
dpc-5683	158	1	lindahl	lindahl	PROPN
dpc-5683	158	2	lm	lm	PROPN
dpc-5683	158	3	,	,	PUNCT
dpc-5683	158	4	fenger	fenger	ADV
dpc-5683	158	5	-	-	PUNCT
dpc-5683	158	6	grøn	grøn	PROPN
dpc-5683	158	7	m	m	NOUN
dpc-5683	158	8	,	,	PUNCT
dpc-5683	158	9	iversen	iversen	PROPN
dpc-5683	158	10	l.	l.	PROPN
dpc-5683	158	11	subsequent	subsequent	ADJ
dpc-5683	158	12	cancers	cancer	NOUN
dpc-5683	158	13	,	,	PUNCT
dpc-5683	158	14	mortality	mortality	NOUN
dpc-5683	158	15	,	,	PUNCT
dpc-5683	158	16	and	and	CCONJ
dpc-5683	158	17	causes	cause	NOUN
dpc-5683	158	18	of	of	ADP
dpc-5683	158	19	death	death	NOUN
dpc-5683	158	20	in	in	ADP
dpc-5683	158	21	patients	patient	NOUN
dpc-5683	158	22	with	with	ADP
dpc-5683	158	23	mycosis	mycosis	NOUN
dpc-5683	158	24	fungoides	fungoide	NOUN
dpc-5683	158	25	and	and	CCONJ
dpc-5683	158	26	parapsoriasis	parapsoriasis	NOUN
dpc-5683	158	27	:	:	PUNCT
dpc-5683	158	28	a	a	DET
dpc-5683	158	29	danish	danish	ADJ
dpc-5683	158	30	nationwide	nationwide	ADJ
dpc-5683	158	31	,	,	PUNCT
dpc-5683	158	32	population	population	NOUN
dpc-5683	158	33	-	-	PUNCT
dpc-5683	158	34	based	base	VERB
dpc-5683	158	35	cohort	cohort	NOUN
dpc-5683	158	36	study	study	NOUN
dpc-5683	158	37	.	.	PUNCT
dpc-5683	158	38	  	  	SPACE
dpc-5683	159	1	j	j	PROPN
dpc-5683	159	2	am	be	AUX
dpc-5683	159	3	acad	acad	PROPN
dpc-5683	159	4	dermatol.2014;71(3):529–535	dermatol.2014;71(3):529–535	NOUN
dpc-5683	159	5	.	.	PUNCT
dpc-5683	160	1	doi:10.1016	doi:10.1016	PROPN
dpc-5683	160	2	/	/	SYM
dpc-5683	160	3	j.jaad.2014.03.044	j.jaad.2014.03.044	PROPN
dpc-5683	160	4	.	.	PUNCT
dpc-5683	161	1	pmid	pmid	NOUN
dpc-5683	161	2	:	:	PUNCT
dpc-5683	161	3	24931734	24931734	NUM
dpc-5683	161	4	.	.	PUNCT
dpc-5683	162	1	15	15	NUM
dpc-5683	162	2	.	.	PUNCT
dpc-5683	162	3	goyal	goyal	PROPN
dpc-5683	162	4	a	a	PRON
dpc-5683	162	5	,	,	PUNCT
dpc-5683	162	6	o’leary	o’leary	PROPN
dpc-5683	162	7	d	d	PROPN
dpc-5683	162	8	,	,	PUNCT
dpc-5683	162	9	goyal	goyal	PROPN
dpc-5683	162	10	k	k	PROPN
dpc-5683	162	11	,	,	PUNCT
dpc-5683	162	12	et	et	PROPN
dpc-5683	162	13	al	al	PROPN
dpc-5683	162	14	.	.	PUNCT
dpc-5683	163	1	screening	screen	VERB
dpc-5683	163	2	for	for	ADP
dpc-5683	163	3	second	second	ADJ
dpc-5683	163	4	malignancies	malignancy	NOUN
dpc-5683	163	5	in	in	ADP
dpc-5683	163	6	mycosis	mycosis	NOUN
dpc-5683	163	7	fungoides	fungoide	NOUN
dpc-5683	163	8	:	:	PUNCT
dpc-5683	163	9	non	non	ADJ
dpc-5683	163	10	-	-	ADJ
dpc-5683	163	11	hodgkin	hodgkin	ADJ
dpc-5683	163	12	lymphoma	lymphoma	NOUN
dpc-5683	163	13	,	,	PUNCT
dpc-5683	163	14	hodgkin	hodgkin	NOUN
dpc-5683	163	15	lymphoma	lymphoma	NOUN
dpc-5683	163	16	,	,	PUNCT
dpc-5683	163	17	lung	lung	NOUN
dpc-5683	163	18	cancer	cancer	NOUN
dpc-5683	163	19	,	,	PUNCT
dpc-5683	163	20	bladder	bladder	NOUN
dpc-5683	163	21	cancer	cancer	NOUN
dpc-5683	163	22	and	and	CCONJ
dpc-5683	163	23	melanoma	melanoma	NOUN
dpc-5683	163	24	.	.	PUNCT
dpc-5683	163	25	  	  	SPACE
dpc-5683	164	1	j	j	PROPN
dpc-5683	164	2	eur	eur	PROPN
dpc-5683	164	3	acad	acad	PROPN
dpc-5683	164	4	dermatol	dermatol	NOUN
dpc-5683	164	5	venereol.2021;35(9):1821–1829	venereol.2021;35(9):1821–1829	NOUN
dpc-5683	164	6	.	.	PUNCT
dpc-5683	165	1	doi:10.1111	doi:10.1111	PROPN
dpc-5683	165	2	/	/	SYM
dpc-5683	165	3	jdv.17384	jdv.17384	PROPN
dpc-5683	165	4	.	.	PUNCT
dpc-5683	166	1	pmid	pmid	NOUN
dpc-5683	166	2	:	:	PUNCT
dpc-5683	166	3	34013554	34013554	NUM
dpc-5683	166	4	.	.	PUNCT
dpc-5683	167	1	16	16	NUM
dpc-5683	167	2	.	.	X
dpc-5683	167	3	agar	agar	NOUN
dpc-5683	167	4	ns	ns	ADJ
dpc-5683	167	5	,	,	PUNCT
dpc-5683	167	6	wedgeworth	wedgeworth	NOUN
dpc-5683	167	7	e	e	NOUN
dpc-5683	167	8	,	,	PUNCT
dpc-5683	167	9	crichton	crichton	PROPN
dpc-5683	167	10	s	s	PROPN
dpc-5683	167	11	,	,	PUNCT
dpc-5683	167	12	et	et	PROPN
dpc-5683	167	13	al	al	PROPN
dpc-5683	167	14	.	.	PROPN
dpc-5683	168	1	survival	survival	PROPN
dpc-5683	168	2	outcomes	outcome	NOUN
dpc-5683	168	3	and	and	CCONJ
dpc-5683	168	4	prognostic	prognostic	ADJ
dpc-5683	168	5	factors	factor	NOUN
dpc-5683	168	6	in	in	ADP
dpc-5683	168	7	mycosis	mycosis	NOUN
dpc-5683	168	8	fungoides	fungoide	NOUN
dpc-5683	168	9	/	/	SYM
dpc-5683	168	10	sézary	sézary	ADJ
dpc-5683	168	11	syndrome	syndrome	NOUN
dpc-5683	168	12	:	:	PUNCT
dpc-5683	168	13	validation	validation	NOUN
dpc-5683	168	14	of	of	ADP
dpc-5683	168	15	the	the	DET
dpc-5683	168	16	revised	revise	VERB
dpc-5683	168	17	iscl	iscl	PROPN
dpc-5683	168	18	/	/	SYM
dpc-5683	168	19	eortc	eortc	VERB
dpc-5683	168	20	staging	staging	NOUN
dpc-5683	168	21	proposal	proposal	NOUN
dpc-5683	168	22	.	.	PUNCT
dpc-5683	168	23	  	  	SPACE
dpc-5683	169	1	j	j	PROPN
dpc-5683	169	2	clin	clin	PROPN
dpc-5683	169	3	oncol	oncol	PROPN
dpc-5683	169	4	.	.	PUNCT
dpc-5683	169	5	  	  	SPACE
dpc-5683	170	1	2010;28(31):4730–4739	2010;28(31):4730–4739	NUM
dpc-5683	170	2	.	.	PUNCT
dpc-5683	171	1	doi:10.1200	doi:10.1200	X
dpc-5683	171	2	/jco.2010.28.31.4730	/jco.2010.28.31.4730	PUNCT
dpc-5683	171	3	.	.	PUNCT
dpc-5683	172	1	pmid	pmid	NOUN
dpc-5683	172	2	:	:	PUNCT
dpc-5683	172	3	21098385	21098385	NUM
dpc-5683	172	4	.	.	PUNCT
dpc-5683	173	1	3	3	X
dpc-5683	173	2	.	.	X
dpc-5683	173	3	huang	huang	PROPN
dpc-5683	173	4	kp	kp	PROPN
dpc-5683	173	5	,	,	PUNCT
dpc-5683	173	6	weinstock	weinstock	PROPN
dpc-5683	173	7	ma	ma	PROPN
dpc-5683	173	8	,	,	PUNCT
dpc-5683	173	9	clarke	clarke	PROPN
dpc-5683	173	10	ca	ca	PROPN
dpc-5683	173	11	,	,	PUNCT
dpc-5683	173	12	et	et	PROPN
dpc-5683	173	13	al	al	PROPN
dpc-5683	173	14	.	.	PROPN
dpc-5683	173	15	second	second	ADJ
dpc-5683	173	16	lymphomas	lymphoma	NOUN
dpc-5683	173	17	and	and	CCONJ
dpc-5683	173	18	other	other	ADJ
dpc-5683	173	19	malignant	malignant	ADJ
dpc-5683	173	20	neoplasms	neoplasm	NOUN
dpc-5683	173	21	in	in	ADP
dpc-5683	173	22	patients	patient	NOUN
dpc-5683	173	23	with	with	ADP
dpc-5683	173	24	mycosis	mycosis	NOUN
dpc-5683	173	25	fungoides	fungoide	NOUN
dpc-5683	173	26	and	and	CCONJ
dpc-5683	173	27	sézary	sézary	ADJ
dpc-5683	173	28	syndrome	syndrome	NOUN
dpc-5683	173	29	:	:	PUNCT
dpc-5683	173	30	evidence	evidence	NOUN
dpc-5683	173	31	from	from	ADP
dpc-5683	173	32	population	population	NOUN
dpc-5683	173	33	-	-	PUNCT
dpc-5683	173	34	based	base	VERB
dpc-5683	173	35	and	and	CCONJ
dpc-5683	173	36	clinical	clinical	ADJ
dpc-5683	173	37	cohorts	cohort	NOUN
dpc-5683	173	38	.	.	PUNCT
dpc-5683	173	39	  	  	SPACE
dpc-5683	173	40	arch	arch	ADJ
dpc-5683	173	41	dermatol.2007;143(1):45–50	dermatol.2007;143(1):45–50	NOUN
dpc-5683	173	42	.	.	PUNCT
dpc-5683	174	1	doi:10.1001	doi:10.1001	PROPN
dpc-5683	174	2	/	/	SYM
dpc-5683	174	3	archderm.143.1.45	archderm.143.1.45	NOUN
dpc-5683	174	4	.	.	PUNCT
dpc-5683	175	1	pmid	pmid	NOUN
dpc-5683	175	2	:	:	PUNCT
dpc-5683	175	3	17224541	17224541	NUM
dpc-5683	175	4	.	.	PUNCT
dpc-5683	176	1	4	4	X
dpc-5683	176	2	.	.	X
dpc-5683	177	1	brownell	brownell	PROPN
dpc-5683	177	2	i	i	PRON
dpc-5683	177	3	,	,	PUNCT
dpc-5683	177	4	etzel	etzel	PROPN
dpc-5683	177	5	cj	cj	PROPN
dpc-5683	177	6	,	,	PUNCT
dpc-5683	177	7	yang	yang	PROPN
dpc-5683	177	8	dj	dj	PROPN
dpc-5683	177	9	,	,	PUNCT
dpc-5683	177	10	et	et	PROPN
dpc-5683	177	11	al	al	PROPN
dpc-5683	177	12	.	.	PROPN
dpc-5683	177	13	increased	increase	VERB
dpc-5683	177	14	malignancy	malignancy	NOUN
dpc-5683	177	15	risk	risk	NOUN
dpc-5683	177	16	in	in	ADP
dpc-5683	177	17	the	the	DET
dpc-5683	177	18	cutaneous	cutaneous	ADJ
dpc-5683	177	19	t	t	PROPN
dpc-5683	177	20	-	-	PUNCT
dpc-5683	177	21	cell	cell	NOUN
dpc-5683	177	22	lymphoma	lymphoma	NOUN
dpc-5683	177	23	patient	patient	ADJ
dpc-5683	177	24	population	population	NOUN
dpc-5683	177	25	.	.	PUNCT
dpc-5683	177	26	 	 	SPACE
dpc-5683	178	1	clin	clin	PROPN
dpc-5683	178	2	lymphoma	lymphoma	NOUN
dpc-5683	178	3	myeloma	myeloma	PROPN
dpc-5683	178	4	.	.	PUNCT
dpc-5683	178	5	 	 	SPACE
dpc-5683	179	1	2008;8(2):100–105	2008;8(2):100–105	NUM
dpc-5683	179	2	.	.	PUNCT
dpc-5683	180	1	doi:10.3816	doi:10.3816	NOUN
dpc-5683	180	2	/	/	SYM
dpc-5683	180	3	clm.2008.n.011	clm.2008.n.011	PROPN
dpc-5683	180	4	.	.	NOUN
dpc-5683	180	5	5	5	NUM
dpc-5683	180	6	.	.	X
dpc-5683	180	7	olsen	olsen	PROPN
dpc-5683	180	8	ea	ea	PROPN
dpc-5683	180	9	,	,	PUNCT
dpc-5683	180	10	delzell	delzell	NOUN
dpc-5683	180	11	e	e	PROPN
dpc-5683	180	12	,	,	PUNCT
dpc-5683	180	13	jegasothy	jegasothy	ADJ
dpc-5683	180	14	bv	bv	PROPN
dpc-5683	180	15	.	.	PROPN
dpc-5683	180	16	second	second	ADJ
dpc-5683	180	17	malignancies	malignancy	NOUN
dpc-5683	180	18	in	in	ADP
dpc-5683	180	19	cutaneous	cutaneous	ADJ
dpc-5683	180	20	t	t	NOUN
dpc-5683	180	21	cell	cell	NOUN
dpc-5683	180	22	lymphoma	lymphoma	NOUN
dpc-5683	180	23	.	.	PUNCT
dpc-5683	180	24	 	 	SPACE
dpc-5683	181	1	j	j	PROPN
dpc-5683	181	2	am	be	AUX
dpc-5683	181	3	acad	acad	PROPN
dpc-5683	181	4	dermatol.1984;10(2):197–204	dermatol.1984;10(2):197–204	NOUN
dpc-5683	181	5	.	.	PUNCT
dpc-5683	182	1	doi:10.1016	doi:10.1016	PROPN
dpc-5683	182	2	/	/	SYM
dpc-5683	182	3	s0190	s0190	PROPN
dpc-5683	182	4	-	-	PUNCT
dpc-5683	182	5	9622(84)70023	9622(84)70023	NUM
dpc-5683	182	6	-	-	SYM
dpc-5683	182	7	5	5	NUM
dpc-5683	182	8	.	.	NOUN
dpc-5683	182	9	6	6	NUM
dpc-5683	182	10	.	.	PUNCT
dpc-5683	183	1	kim	kim	PROPN
dpc-5683	183	2	yj	yj	PROPN
dpc-5683	183	3	,	,	PUNCT
dpc-5683	183	4	shin	shin	PROPN
dpc-5683	183	5	hj	hj	PROPN
dpc-5683	183	6	,	,	PUNCT
dpc-5683	183	7	won	win	VERB
dpc-5683	183	8	ch	ch	NOUN
dpc-5683	183	9	,	,	PUNCT
dpc-5683	183	10	et	et	PROPN
dpc-5683	183	11	al	al	PROPN
dpc-5683	183	12	.	.	PUNCT
dpc-5683	184	1	the	the	DET
dpc-5683	184	2	incidence	incidence	NOUN
dpc-5683	184	3	of	of	ADP
dpc-5683	184	4	other	other	ADJ
dpc-5683	184	5	primary	primary	ADJ
dpc-5683	184	6	cancers	cancer	NOUN
dpc-5683	184	7	in	in	ADP
dpc-5683	184	8	patients	patient	NOUN
dpc-5683	184	9	with	with	ADP
dpc-5683	184	10	cutaneous	cutaneous	ADJ
dpc-5683	184	11	lymphoma	lymphoma	NOUN
dpc-5683	184	12	.	.	PUNCT
dpc-5683	184	13	  	  	SPACE
dpc-5683	184	14	ann	ann	PROPN
dpc-5683	184	15	dermatol	dermatol	NOUN
dpc-5683	184	16	.	.	PUNCT
dpc-5683	184	17	 	 	SPACE
dpc-5683	184	18	2018;30(3):335–341	2018;30(3):335–341	NUM
dpc-5683	184	19	.	.	PUNCT
dpc-5683	184	20	doi:10.5021	doi:10.5021	PROPN
dpc-5683	184	21	/	/	SYM
dpc-5683	184	22	ad.2018.30.3.335	ad.2018.30.3.335	PROPN
dpc-5683	184	23	.	.	PROPN
dpc-5683	185	1	7	7	X
dpc-5683	185	2	.	.	X
dpc-5683	185	3	goyal	goyal	PROPN
dpc-5683	185	4	a	a	PRON
dpc-5683	185	5	,	,	PUNCT
dpc-5683	185	6	o’leary	o’leary	PROPN
dpc-5683	185	7	d	d	PROPN
dpc-5683	185	8	,	,	PUNCT
dpc-5683	185	9	goyal	goyal	PROPN
dpc-5683	185	10	k	k	PROPN
dpc-5683	185	11	,	,	PUNCT
dpc-5683	185	12	et	et	PROPN
dpc-5683	185	13	al	al	PROPN
dpc-5683	185	14	.	.	PROPN
dpc-5683	186	1	cutaneous	cutaneous	ADJ
dpc-5683	186	2	t	t	PROPN
dpc-5683	186	3	-	-	PUNCT
dpc-5683	186	4	cell	cell	NOUN
dpc-5683	186	5	lymphoma	lymphoma	NOUN
dpc-5683	186	6	is	be	AUX
dpc-5683	186	7	associated	associate	VERB
dpc-5683	186	8	with	with	ADP
dpc-5683	186	9	increased	increase	VERB
dpc-5683	186	10	risk	risk	NOUN
dpc-5683	186	11	of	of	ADP
dpc-5683	186	12	lymphoma	lymphoma	NOUN
dpc-5683	186	13	,	,	PUNCT
dpc-5683	186	14	melanoma	melanoma	NOUN
dpc-5683	186	15	,	,	PUNCT
dpc-5683	186	16	lung	lung	NOUN
dpc-5683	186	17	cancer	cancer	NOUN
dpc-5683	186	18	,	,	PUNCT
dpc-5683	186	19	and	and	CCONJ
dpc-5683	186	20	bladder	bladder	NOUN
dpc-5683	186	21	cancer	cancer	NOUN
dpc-5683	186	22	.	.	PUNCT
dpc-5683	186	23	 	 	SPACE
dpc-5683	187	1	j	j	PROPN
dpc-5683	187	2	am	be	AUX
dpc-5683	187	3	acad	acad	ADJ
dpc-5683	187	4	dermatol	dermatol	NOUN
dpc-5683	187	5	.	.	PUNCT
dpc-5683	187	6	 	 	SPACE
dpc-5683	187	7	2021;85(6):1418–1428	2021;85(6):1418–1428	NUM
dpc-5683	187	8	.	.	PUNCT
dpc-5683	188	1	doi:10.1016	doi:10.1016	PROPN
dpc-5683	188	2	/	/	SYM
dpc-5683	189	1	j.jaad.2020.06.1033	j.jaad.2020.06.1033	PROPN
dpc-5683	189	2	.	.	PUNCT
dpc-5683	190	1	pmid	pmid	NOUN
dpc-5683	190	2	:	:	PUNCT
dpc-5683	190	3	32822803	32822803	NUM
dpc-5683	190	4	.	.	PUNCT
dpc-5683	191	1	8	8	NUM
dpc-5683	191	2	.	.	PUNCT
dpc-5683	192	1	kantor	kantor	PROPN
dpc-5683	192	2	af	af	PROPN
dpc-5683	192	3	,	,	PUNCT
dpc-5683	192	4	curtis	curtis	PROPN
dpc-5683	192	5	re	re	PROPN
dpc-5683	192	6	,	,	PUNCT
dpc-5683	192	7	vonderheid	vonderheid	PROPN
dpc-5683	192	8	ec	ec	PROPN
dpc-5683	192	9	,	,	PUNCT
dpc-5683	192	10	et	et	PROPN
dpc-5683	192	11	al	al	PROPN
dpc-5683	192	12	.	.	PROPN
dpc-5683	192	13	risk	risk	NOUN
dpc-5683	192	14	of	of	ADP
dpc-5683	192	15	second	second	ADJ
dpc-5683	192	16	malignancy	malignancy	NOUN
dpc-5683	192	17	after	after	ADP
dpc-5683	192	18	cutaneous	cutaneous	ADJ
dpc-5683	192	19	t	t	PROPN
dpc-5683	192	20	-	-	PUNCT
dpc-5683	192	21	cell	cell	NOUN
dpc-5683	192	22	lymphoma	lymphoma	NOUN
dpc-5683	192	23	.	.	PUNCT
dpc-5683	193	1	cancer	cancer	NOUN
dpc-5683	193	2	.	.	PUNCT
dpc-5683	194	1	1989;63(8	1989;63(8	NUM
dpc-5683	194	2	):	):	PUNCT
dpc-5683	194	3	1612–1615	1612–1615	NUM
dpc-5683	194	4	.	.	PUNCT
dpc-5683	195	1	doi:10.1002/1097	doi:10.1002/1097	NOUN
dpc-5683	195	2	-	-	PUNCT
dpc-5683	195	3	0142(19890415)63:8<1612	0142(19890415)63:8<1612	NUM
dpc-5683	195	4	:	:	PUNCT
dpc-5683	195	5	:	:	PUNCT
dpc-5683	196	1	aid	aid	NOUN
dpc-5683	196	2	-	-	PUNCT
dpc-5683	196	3	cncr2820630828>3.0.co;2	cncr2820630828>3.0.co;2	NOUN
dpc-5683	196	4	-	-	PUNCT
dpc-5683	196	5	c.	c.	NOUN
dpc-5683	196	6	9	9	NUM
dpc-5683	196	7	.	.	PUNCT
dpc-5683	196	8	olsen	olsen	NOUN
dpc-5683	196	9	e	e	PROPN
dpc-5683	196	10	,	,	PUNCT
dpc-5683	196	11	vonderheid	vonderheid	NOUN
dpc-5683	196	12	e	e	PROPN
dpc-5683	196	13	,	,	PUNCT
dpc-5683	196	14	pimpinelli	pimpinelli	PROPN
dpc-5683	196	15	n	n	CCONJ
dpc-5683	196	16	,	,	PUNCT
dpc-5683	196	17	et	et	PROPN
dpc-5683	196	18	al	al	PROPN
dpc-5683	196	19	.	.	PUNCT
dpc-5683	197	1	revisions	revision	NOUN
dpc-5683	197	2	to	to	ADP
dpc-5683	197	3	the	the	DET
dpc-5683	197	4	staging	staging	NOUN
dpc-5683	197	5	and	and	CCONJ
dpc-5683	197	6	classification	classification	NOUN
dpc-5683	197	7	of	of	ADP
dpc-5683	197	8	mycosis	mycosis	NOUN
dpc-5683	197	9	fungoides	fungoide	NOUN
dpc-5683	197	10	and	and	CCONJ
dpc-5683	197	11	sézary	sézary	ADJ
dpc-5683	197	12	syndrome	syndrome	NOUN
dpc-5683	197	13	:	:	PUNCT
dpc-5683	197	14	a	a	DET
dpc-5683	197	15	proposal	proposal	NOUN
dpc-5683	197	16	of	of	ADP
dpc-5683	197	17	the	the	DET
dpc-5683	197	18	iscl	iscl	NOUN
dpc-5683	197	19	and	and	CCONJ
dpc-5683	197	20	the	the	DET
dpc-5683	197	21	eortc	eortc	ADJ
dpc-5683	197	22	cutaneous	cutaneous	ADJ
dpc-5683	197	23	lymphoma	lymphoma	NOUN
dpc-5683	197	24	task	task	NOUN
dpc-5683	197	25	force	force	NOUN
dpc-5683	197	26	.	.	PUNCT
dpc-5683	197	27	  	  	SPACE
dpc-5683	197	28	blood.2007;110(6):1713–1722	blood.2007;110(6):1713–1722	PROPN
dpc-5683	197	29	.	.	PUNCT
dpc-5683	198	1	doi:10.1182	doi:10.1182	NOUN
dpc-5683	198	2	/	/	SYM
dpc-5683	198	3	blood-2007	blood-2007	ADJ
dpc-5683	198	4	-	-	PUNCT
dpc-5683	198	5	03	03	NUM
dpc-5683	198	6	-	-	PUNCT
dpc-5683	198	7	055749	055749	NUM
dpc-5683	198	8	.	.	PUNCT
dpc-5683	199	1	pmid	pmid	NOUN
dpc-5683	199	2	:	:	PUNCT
dpc-5683	199	3	17540844	17540844	NUM
dpc-5683	199	4	.	.	PUNCT
dpc-5683	200	1	10	10	NUM
dpc-5683	200	2	.	.	PUNCT
dpc-5683	201	1	petković	petković	PROPN
dpc-5683	201	2	m	m	PROPN
dpc-5683	201	3	,	,	PUNCT
dpc-5683	201	4	ilić	ilić	PROPN
dpc-5683	201	5	i	i	PRON
dpc-5683	201	6	,	,	PUNCT
dpc-5683	201	7	tončić	tončić	PROPN
dpc-5683	201	8	rj	rj	PROPN
dpc-5683	201	9	,	,	PUNCT
dpc-5683	201	10	et	et	PROPN
dpc-5683	201	11	al	al	PROPN
dpc-5683	201	12	.	.	PROPN
dpc-5683	201	13	mycosis	mycosis	NOUN
dpc-5683	201	14	fungoides	fungoide	NOUN
dpc-5683	201	15	with	with	ADP
dpc-5683	201	16	large	large	ADJ
dpc-5683	201	17	cell	cell	NOUN
dpc-5683	201	18	transformation	transformation	NOUN
dpc-5683	201	19	(	(	PUNCT
dpc-5683	201	20	cd30	cd30	PROPN
dpc-5683	201	21	+	+	NOUN
dpc-5683	201	22	)	)	PUNCT
dpc-5683	201	23	and	and	CCONJ
dpc-5683	201	24	b	b	X
dpc-5683	201	25	-	-	PUNCT
dpc-5683	201	26	cell	cell	NOUN
dpc-5683	201	27	chronic	chronic	ADJ
dpc-5683	201	28	lymphocytic	lymphocytic	ADJ
dpc-5683	201	29	leukemia	leukemia	NOUN
dpc-5683	201	30	.	.	PUNCT
dpc-5683	201	31	 	 	SPACE
dpc-5683	202	1	acta	acta	PROPN
dpc-5683	202	2	dermatovenerol	dermatovenerol	PROPN
dpc-5683	202	3	croat	croat	PROPN
dpc-5683	202	4	.	.	PUNCT
dpc-5683	202	5	 	 	SPACE
dpc-5683	203	1	2023;31(4):223–224	2023;31(4):223–224	NUM
dpc-5683	203	2	.	.	PUNCT